Education. Evidence. Regrowth.
Prioritize knowledge. Make better choices.
Sort good studies from the bad.
Get bigger hair gains.
PhD's, resarchers, & consumer advocates.
Founder, researcher, & consumer advocate
Our team of PhD’s, researchers, & more
Discover how we conduct our research.
Have questions? Contact us.
Our library of before-after photos.
I have attached my before and afters of my progress since joining this group...
I’m convinced I’ve recovered to probably the hairline I had 3 years ago. Super stoked…
My friends actually told me, “Your hairline improved. Your hair looks thicker...
I also feel my hair has a different texture to it now…
Firstly thank you for your work in this field. I am immensely grateful that...
I just wanted to thank you for all your research, for introducing me to this method...
To be honest I am having fun with all this and I still don’t know how much...
I see a massive amount of regrowth that is all less than about 8 cm long...
150+ member experiences.
Scroll DownPopular treatments. But do they work?
Top-selling ingredients, quantified.
The truth about hair loss "best sellers".
Xyon Health
Strut Health
Happy Head
DS Laboratories
Advanced Trichology
Fully Vital
Xyon Health
DrFormulas
Revivogen MD
Standardized rubrics to evaluate all treatments.
Is this treatment well studied?
How much regrowth can you expect?
Is this treatment safe & sustainable?
Apps, tools, guides, freebies, & more.
100+ free articles.
Our team’s peer-reviewed studies.
Education. Evidence. Regrowth.
PhD's, resarchers, & consumer advocates.
Discover how we conduct our research.
Have questions? Contact us.
Our library of before-after photos.
Read the experiences of members
Finasteride is among the most effective drugs for androgenic alopecia. And while side effects are often overstated, it can lead to reduced libido or lowered sperm counts in some men. For this reason, many choose topical versus oral finasteride, hoping to limit the drug’s DHT-reducing effects to the scalp. But at certain doses, even topical finasteride can become systemic. So, to minimize side effects, which finasteride dosage, formula and application is best?
In this article, we’ll review
Low-dose & full-strength finasteride available, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
Finasteride, also known under the brand name Propecia or Proscar, is a prescription medication approved by the FDA for the treatment of androgenic alopecia (AGA). The anti-androgen works by reducing the production of Dihydrotestosterone (DHT), a hormone linked to pattern hair loss. In use since 1992, Finasteride is among the most powerful and well-studied drugs for hair loss.
Oral finasteride stops AGA progression in 80-90% of men and, on average, leads to a 10% increase in hair count over two years.[1]https://www.sciencedirect.com/science/article/pii/S0022202X15529357 For men wanting a “hands-off” approach to hair maintenance, oral finasteride can be an excellent option. With a once-daily pill, it’s expected that hair loss will stop at approximately 6 months, and thereafter, improve.
However, oral finasteride isn’t for everyone. While the risk of side effects are often overstated online, the drug appears to reduce libido in a certain percentage of men. Oral finasteride can also temporarily lower sperm counts, which might make conception more difficult during its first six months of use. In some men, the use of finasteride appears to increase anxiety and/or depression. While the true incidence and magnitude of these reports are hard to discern, it’s understandable that many are weary of taking this once daily pill.
Fortunately, recent improvements in finasteride’s delivery may mean we no longer need to throw the proverbial baby out with the bathwater.
The biggest reason people seek out topical finasteride (instead of oral finasteride) is because they want to minimize systemic exposure to the drug, and in doing so, localize finasteride’s effects to the scalp.
While research is still in the early stages, evidence suggests that topical finasteride can produce similar levels of hair regrowth compared to oral finasteride, with a significantly reduced incidence of side effects.
Topical finasteride works identically to its oral counterpart: by inhibiting the type II 5-alpha reductase enzyme to reduce DHT. It is designed to target scalp DHT instead of systemic DHT levels.
However, limiting finasteride’s reach to scalp, not serum, DHT is harder than perhaps anticipated. To understand why, let’s take a closer look at scalp versus serum DHT.
There’s a lot of evidence that the hormone DHT is directly implicated in androgenic alopecia. In fact, research directly links DHT to all three of AGA’s defining characteristics:
There are a wide variety of DHT reducers available, including prescription drugs, over-the-counter products, intradermal injections, and even herbal supplements. Finasteride reduces DHT in two ways.
However, it’s far easier than most realize for topical finasteride to go systemic. And when it does, it potentially reduces DHT everywhere – leading to the very side effects it’s meant to prevent.
Why? When it comes to lowering DHT (the goal of the drug), finasteride has a highly-sensitive, dose-dependent response curve. This means that while 0.01 mg of finasteride barely reduces any DHT at all, 0.1 mg reduces almost as much DHT as 5 mg, a much larger dose.
This implies that when applying topical finasteride, only a tiny fraction of it needs to go systemic in order to produce the same DHT-lowering effects as oral finasteride. If this happens, the purpose of using the topical formulation is completely defeated.
Research suggests a 1% topical finasteride formulation, applied twice daily, is ‘non-inferior,’ meaning equivalent, to 1 mg oral finasteride tablets.[2]https://www.ncbi.nlm.nih.gov/pubmed/19172031 And while that’s a positive in terms of hair growth, using this amount topically twice daily pretty much guarantees systemic absorption. In other words, if 1% topical is the equivalent of 1 mg oral, we can expect it to reduce serum DHT levels by 71%.
So what if we choose a formula with even lower percentages of the active drug? A study on 0.25% topical finasteride showed just a 35% reduction in serum DHT levels versus 55% for the oral medication, and yet similar outcomes for hair regrowth in both oral and topical groups.[3]https://onlinelibrary.wiley.com/doi/10.1111/jdv.17738
So what if we go even lower? A study on 0.005% alcohol-based topical finasteride instructed participants to use the formulation twice daily, with 1 mL applied per session.[4]https://dx.doi.org/10.3109%2F09546639709160517 This led to no appreciable changes in serum DHT levels… meaning that for this ultra-low topical formulation, there was little-to-no systemic absorption (and presumably, few-to-no side effects). The good news? This group still experienced great hair growth outcomes.
It’s tempting from the above to infer we’ve reached the end of our story. As long as we reach for the lowest percentage of topical finasteride, we can be free from worries about the drug’s systemic effects. But, reality is a bit more complicated than that.
Systemic absorption isn’t just about dilution percentages. Topical finasteride’s systemic absorption actually depends on (at least) for variables:
For an example, see this figure from a 2014 study measuring how one versus two applications of 1 mL of 0.25% topical finasteride affected serum DHT levels.[5]https://www.ncbi.nlm.nih.gov/pubmed/25074865

Caserini, M., Radicioni, M., Leuratti, C., Annoni, O., & Palmieri, R. (2014). A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. International journal of clinical pharmacology and therapeutics, 52(10), 842–849.
Over a 24-hour period, what were the findings?
As such, we need to factor in these variables if we plan on sticking with topical finasteride for the long-term. Otherwise, we risk lowering our DHT levels to the same degree as 1 mg of oral finasteride, which would defeat the purpose of using the topical in the first place.
Let’s take a closer look at some of the studies mentioned above. In addition to the percentage of active drug in the formula, there are a few more variables to understand. How much of the topical was applied, and which carrier agents were used?
The table below shows how even a .25% formula, for example, can reduce DHT in the serum by 24-70%
Based on this table, our total mg of daily finasteride exposure is probably the biggest factor in determining systemic leakage. And our total daily exposure (in mg) is a function of topical finasteride dilution (%) and the amount (mL) applied daily.
Knowing this, we can turn this table into a chart and sort it by mg of daily exposure. In doing so, we see a clear trend:
The good news? At both extremes of this chart – 0.091 mg and 2.275 mg daily – topical finasteride was shown to produce clinical results in improving hair parameters. Based on this, if we’re going for topical finasteride, we probably want to be prescribed topical finasteride solutions that net us daily exposure volumes of 0.228 mg and lower. After all, at 0.091 mg of topical finasteride daily, no systemic effects on DHT were observed.[6]https://www.tandfonline.com/doi/abs/10.3109/09546639709160517
In other words, low dilutions (i.e., 1-2 mL of 0.005% to 0.02% of topical finasteride) confer significant benefits but at reduced risks of side effects due to lower systemic absorption – provided that guidelines for daily amounts (in mL) are also followed.
Our analyses from member-submitted lab tests and the clinical data suggest that 10-15% of topical finasteride will enter the bloodstream, at least when it’s formulated with alcohol and/or propylene glycol as carrier ingredients (as most compounding pharmacies do). So, if we apply 1-2 mL of 0.005% to 0.02% topical finasteride, this might equate to just 0.01-0.03 mg of systemic drug exposure.
For the overwhelming majority of people, that’s not enough systemic leakage to significantly lower DHT levels in the body. But it is enough to produce great hair loss outcomes.

Our partial analysis estimating systemic leakage of topical finasteride from the study: Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial (2021)
Join our Membership Program to get the full analysis.
Long-story short: stick to 1-2 mL of 0.005% to 0.02% topical finasteride solutions. This equates to roughly 0.1-0.2mg of daily finasteride exposure to the scalp. Any more than that, and there’s risk of significant systemic leakage, which defeats the purpose of using topical finasteride altogether.
Maximizing gains while minimizing the side effects of finasteride can be done, but it’s not a perfect science. We’ve outlined several tips below that we think might help. Due to individual variance, the most important step is to always start with testing.
The goal with topical finasteride is to reduce the risk of side effects. To do this, we must minimize the amount of finasteride that leaks into the bloodstream. The best way to do this isn’t to rely on estimated metrics from clinical studies, but to collect personal data.
Get a serum DHT test before using the topical to establish a baseline. Then, DHT levels should be retested at one month to gauge just how much is going systemic. Testing is easier than most expect, and in our experience, the expenses are worth the peace of mind.
If future lab tests deviate from baseline, it’s an indication of just how much topical finasteride is going systemic. According to the clinical data, 30 days of application is more than enough time for finasteride to saturate at its maximum levels in the scalp and serum.
As such, measuring DHT levels after one month of finasteride use offers a great reference point to see if topical finasteride is impacting serum DHT levels. If needed, changes can be made to the application or use frequency depending on any changes to your blood levels of DHT.
Keep in mind, some fluctuation in DHT levels is normal. DHT levels fluctuate throughout the day and across seasons. As such, 15-20% differences across tests are normal and expected. Anything beyond 20% suggests that topical finasteride might be having slight systemic effects.
Because of this fluctuation, however, it’s important to get blood draws done at the same time of day – preferably in the morning and while in a fasted state. Also, try not to make drastic changes to diet, lifestyle, or environment prior to testing. Heavy drinking, deviations from a typical daily diet, the introduction of creatine powders, and/or sleep deprivation can all influence DHT levels and muddy test results. In the 3-5 days prior to the second test, try to keep things as they were when you first went in for testing.
Maintaining systemic DHT levels, while maximizing the effects of finasteride, isn’t just about the drug. There are other activities that could potentially affect DHT levels. Supplementing with quercetin and/or creatine is one common mistake that could impact results.
Studies on mice suggest that quercetin can inhibit the DHT-reducing effects of finasteride.[7]https://joe.bioscientifica.com/view/journals/joe/181/3/493.xmlWhile the translatability to humans has not yet been studied, the dosages used in these mouse models were comparable to what humans typically consume from quercetin supplements. As such, it may be best for those using finasteride to avoid this supplement.
When it comes to creatine, one study found that in training athletes, creatine supplementation increased serum DHT levels by over 70%.[8]https://pubmed.ncbi.nlm.nih.gov/19741313/ While the study was small, we have to reconcile these findings with the reality that for the overwhelming majority of training athletes, creatine is unnecessary. Bodybuilders can still look great without using it, and so can the every-day gym goer. Competitive bodybuilders are, however, a different story.
Finasteride is the best-studied intervention for androgenic alopecia. In order to appreciate its full effects, consider the following:
Following the tips above allows for the best possible shot at measurable hair growth results, while minimizing the potential effects of systemic DHT reduction.
Oral finasteride works great for male pattern hair loss, but by significantly reducing serum DHT, it can cause unwanted side effects.
Topical finasteride was developed as a solution, with a goal to reduce DHT in the scalp only. But when applied in high percentages or large amounts, it too, can go systemic and reduce serum DHT levels.
To minimize the side effects of finasteride without missing out on the benefits, stick to 1-2 mL of 0.005% to 0.02% topical finasteride solutions. This equates to roughly 0.1-0.2mg of daily finasteride exposure to the scalp.
The best way to ensure a reduced risk for side effects is to track serum DHT levels. Establish a baseline by taking one test before using finasteride, then test again one month later.
References[+]
| ↑1 | https://www.sciencedirect.com/science/article/pii/S0022202X15529357 |
|---|---|
| ↑2 | https://www.ncbi.nlm.nih.gov/pubmed/19172031 |
| ↑3 | https://onlinelibrary.wiley.com/doi/10.1111/jdv.17738 |
| ↑4 | https://dx.doi.org/10.3109%2F09546639709160517 |
| ↑5 | https://www.ncbi.nlm.nih.gov/pubmed/25074865 |
| ↑6 | https://www.tandfonline.com/doi/abs/10.3109/09546639709160517 |
| ↑7 | https://joe.bioscientifica.com/view/journals/joe/181/3/493.xml |
| ↑8 | https://pubmed.ncbi.nlm.nih.gov/19741313/ |
Men’s hair loss is a booming multi-billion-dollar industry, yet the vast majority of over-the-counter products fall short when measured against rigorous clinical evidence. This landscape is cluttered with quick-fix promises, leaving consumers sifting through marketing claims with little scientific support. Among all topical hair regrowth options, minoxidil is one of the most extensively studied. It is also one of two FDA-approved treatments for male pattern hair loss (in its topical form).
In this comprehensive guide, we rank our top minoxidil picks of 2025 across Best Overall, Best Value, and other categories to help you navigate the crowded hair loss market with more clarity and confidence.
| Product | Strength | Format | Customization | Price | Best: |
| Ulo | 7% | Solution | High | $41.65 | Overall |
| Kirkland Minoxidil | 5% | Solution | None | $17.99 | Value |
| Rogaine | 5% | Solution/Foam | None | $49.97 | Sensitive Scalp |
| Keeps | 5% | Solution/Foam/Spray | Low | $16.67 | Subscription Convenience |
| Happy Head | 5-8% | Solution/Gel | High | $59 | Strength |
Minoxidil was originally developed to treat high blood pressure and is now widely used in both topical and oral forms as a first-line therapy for androgenic alopecia (AGA).
Minoxidil was first introduced in the 1970s as a powerful oral vasodilator for resistant hypertension. Clinicians soon noticed a frequent side effect, generalized increased hair growth (hypertrichosis).[1]Gupta, A.K., Talukder, M., Venkataraman, M., Bamimore, M.A. (2021). Minoxidil: a comprehensive review. Journal of Dermatological Treatment. 33(4). 1896-1906. Available at: … Continue reading This led to the development of topical formulations specifically for AGA. Today, 2-5% topical minoxidil is FDA-approved for both male and female pattern hair loss and is used off-label for other alopecias.
Minoxidil is a potassium-channel opener that causes vasodilation and improves microcirculation around hair follicles.[2]Hussein, R.S., Dayel, S.B., Abahussein, O., El-Sherbiny, A.A. (2024). Applications and efficacy of minoxidil in dermatology. Skin Health and Disease. 4(6). E472. Available at: … Continue reading It also acts as a prodrug; sulfotransferase converts it to minoxidil sulfate, which prolongs the anagen (growth) phase and shortens the telogen (resting) phase, shifting more hair follicles into active growth.[3]Pietrauszka, K., Bergler-Czop, B. (2020). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a … Continue reading Additional data suggests that induction of key growth factors like vascular endothelial growth factor (VEGF) and activation of Wnt/ꞵ-catenin signaling further support hair regrowth.[4]Gupta, A.K., Talukder, M., Shemer, A., Piraccini, B.M., Tosti, A. (2023). Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders. 9(6). 423-437. Available at: … Continue reading
Although minoxidil doesn’t target dihydrotestosterone, it can improve the effectiveness of other treatments by targeting multiple other targets. When combined with anti-DHT drugs like finasteride, which reduce the hormonal trigger of AGA, minoxidil provides a complementary, non-hormonal pathway. The two treatments have been shown to provide synergistic improvement in hair density in men.[5]Asad, N., Naseer, M., Ghafoor, R. (2024). Efficacy of Topical Finasteride 0.25% with Minoxidil 5% versus Topical Minoxidil 5% Alone in Treatment of Male Pattern Androgenic Alopecia. Journal of Drugs … Continue reading
Over-the-counter (OTC) minoxidil solutions (2% and 5%) can be effective for many men, but absorption and vehicle limits mean “stronger” drug percentages above 5% often add irritation rather than results unless the entire formulation is engineered and supervised medically.
Early minoxidil development work showed a clear dose-response between low strengths (1-2%) and mid-strength (5%) solutions, with 5% yielding larger gains in hair counts and shaft diameter in AGA.[6]Olsen, E.A., Dunlap, F.E., Funicella, T., Koperski, J.A., Swinehart, J.M., Tschen, E.H., Trancik, R.J. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and … Continue reading
Other companies offer concentrations of 10% or over; however, recent head-to-head studies have shown that 5% topical minoxidil is moderately superior to the higher concentration.[7]Ghonemy, S., Alarawi, A., Bessar, H. (2021). Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic … Continue reading Additionally, the 10% minoxidil was associated with more marked irritation.
So, with that in mind, let’s take a look at some of our top minoxidil picks of 2025.
| Pros: | Cons: |
| ✓ Clinically-backed combinations | ✗Prescription products are only available in the USA |
| ✓ Ongoing medical monitoring and a user-friendly platform | |
| ✓ Quality-tested ingredients free of irritants |
Ulo’s Minoxidil Rx takes the top spot for men who want a data-driven, medically supervised approach rather than a one-size-fits-all bottle. Custom strengths and evidence-based optional add-ons allow precise targeting for hair regrowth.
Their high-strength concentration can be combined with tretinoin 0.01% to enhance absorption and efficacy, as well as cetirizine 1%, melatonin 0.01% for antioxidant protection, and caffeine 0.2% to boost circulation, which further improves the product’s effectiveness.
This treatment begins at $49 per month, increasing to $54 if you choose to have all of the add-ons.
Bottom Line: Ulo’s customizable, science-driven minoxidil prescription offers one of the most advanced, value-conscious options for men who are serious about long-term hair regrowth.
| Pros: | Cons: |
| ✓ Lowest cost we could find for 6 months’ worth. | ✗Contains propylene glycol, which can cause irritation or dryness in some users. |
| ✓ Same core 5% minoxidil strength. | ✗ No customization possible for strength or add-on ingredients. |
| ✓ Widely available at multiple stores, including Amazon, Costco, etc. | ✗ No medical consultation or tailoring of treatment included. |
| ✓ Simple formula. |
Kirkland Signature Minoxidil 5% is the classic value choice for me who want an over-the-counter treatment without paying for branding or bundled medical services. You get a standard 5% solution similar in strength to more expensive competitors, making it ideal for cost-conscious users who are happy to follow a simple twice-daily routine and do not need personalized compounding.
Bottom line: If you want the most affordable entry point into 5% minoxidil, Kirkland’s no-frills formula is hard to beat for sheer value per effective dose.
| Pros: | Cons: |
| ✓ Clinically proven 5% minoxidil strength | ✗On the higher end in terms of price. |
| ✓ Foam vehicle is propylene glycol-free, so it is usually better tolerated on sensitive or irritated scalps. | ✗ Fixed strength for men with no customization or add-on actives. |
| ✓ Quick drying, less greasy texture | ✗ No medical consultation or tailoring of treatment included. |
| ✓ Widely available OTC |
Rogaine 5% is a strong pick for men who need minoxidil but find traditional liquid formulas too irritating or cosmetically heavy. The foam format avoids common irritants found in many solutions and tends to be more comfortable for daily use, which can improve adherence and long-term outcomes.
Bottom Line: For sensitive scalps that still need full-strength 5% minoxidil, Rogaine Foam provides a gentler, easy-to-use option that balances proven efficacy with better tolerability.
| Pros: | Cons: |
| ✓ Automatic subscription refills so you rarely run out or miss doses. | ✗More expensive than buying generic minoxidil in bulk. |
| ✓ Offers both 5% foam and 5% solution to suit different scalp and styling preferences. | ✗ Limited to preset strengths and formulas with no true custom compounding. |
| ✓ Option to bundle with finasteride and other treatments for a complete regimen. | |
| ✓ Online prescribing and follow-up. |
Keeps Minoxidil is designed for men who value a set-and-forget routine, trading a price increase ($16.67 for 3 months compared to Kirkland’s $17.99 for 6 months) for automatic deliveries and integrated telehealth support. The ability to pair minoxidil with finasteride and keep everything managed through a single platform could make adherence simpler for busy users.
Bottom Line: If you want 5% minoxidil with minimal hassle, Keeps’ subscription model is a strong fit for convenience-focused men who prefer not to manage refills and prescriptions on their own.
| Pros: | Cons: |
| ✓ Offers high-strength minoxidil concentrations beyond standard 5%. | ✗Higher strengths may carry a greater risk of irritation or systemic absorption. |
| ✓ Can be combined with topical finasteride and other actives in a single solution. | ✗ More expensive than generic 5% minoxidil and some standard telehealth offerings. |
| ✓ Telehealth model with online consultation and prescription management. | ✗Corticosteroids used to offset irritation from propylene glycol. |
| ✓ Multiple formula options aimed at men who have plateaued on basic OTC products. |
Happy Head is built for men who want to move past entry-level minoxidil and explore higher-strength, prescription-only blends under medical oversight. By pairing elevated minoxidil concentrations (8%) with agents like tretinoin and topical finasteride, Happy Head targets users seeking a more comprehensive protocol. With that said, some ingredients included, like the carrier agent propylene glycol, which is used in their base formula, can cause irritation. To offset this, Happy Head uses corticosteroids; however, this may cause skin thinning long-term.
You can read more about corticosteroid usage in hair loss treatments here.
Bottom Line: Happy Head delivers a good jump in strength for minoxidil users who need to increase efficacy.
It’s important that realistic expectations are set for regrowth when starting out on your minoxidil usage journey.
| Timeframe | What to Expect | Clinical Evidence |
| Months 0-3 | This is the initial shedding phase, which usually resolves in the first 4-8 weeks. | [8]Nohria, A., Desai, D., Sikora, M., Mandal, S., Shapiro, J., Lo Sicco, K. (2024). Combating “dread shed”: The impact of overlapping topical and oral minoxidil on temporary hair shedding during … Continue reading |
| Months 3-6 | Early visible improvements, like the appearance of new hairs, can be expected. | [9]Amit, K., Mansukh, G., Satyaprakash, M., Dhiraj, D., Hanmant, B. (2023). Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal … Continue reading |
| Months 6-12 | Cosmetic changes peak, with stronger hair, increased density, and most coverage is seen. | [10]Katz, H.I., Hien, N.T., Prawer, S.E., Goldman, S.J. (1987). Long-term efficacy of topical minoxidil in male pattern baldness. Journal of the American Academy of Dermatology. 16(3). 711-718. Available … Continue reading |
| Months 12+ | Further gains plateau, continued use needed to maintain improvements. | [11]Katz, H.I., Hien, N.T., Prawer, S.E., Goldman, S.J. (1987). Long-term efficacy of topical minoxidil in male pattern baldness. Journal of the American Academy of Dermatology. 16(3). 711-718. Available … Continue reading |
Minoxidil works by prolonging the anagen phase and shortening the telogen phase. Regular dosing maintains these effects at the follicle level; repeatedly missing applications reduces the cumulative time that hair follicles spend in a pro-growth, anagen-biased state.[12]Messenger, A.G., Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology. 2(1). 186-194. Available at: … Continue reading
Because human scalp follicles cycle slowly (anagen can last years), many follicles need months of uninterrupted exposure before visible density gains can be seen.[13]Hoover E, Alhajj M, Flores JL. Physiology, Hair. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: … Continue reading This is why most guidance recommends at least 6 months of continuous use before judging the response.
Minoxidil is not disease-modifying for AGA, meaning that it does not correct androgen-driven miniaturization but counteracts it while present by improving hair cycle dynamics and follicle size. When treatment is stopped, these pharmacologic effects wane, and follicles gradually revert toward their genetically determined, androgen-sensitive pattern.
Clinical and patient information sources consistently note that any gain from minoxidil is maintained only while therapy continues. After discontinuation, increased shedding and loss of density over months are typical, ultimately leading to a reversal of gains to the original starting point.
You can buy minoxidil in several different vehicles that differ mainly in tolerability, practicality, and how well they fit a given scalp and routine. Choosing the “best” format is less about raw efficacy and more about matching the base to skin sensitivity and your preference of application.
Minoxidil is generally well tolerated, but like any active drug, it can cause local irritation, a transient shedding phase, and very rare systemic effects, especially in people with underlying skin or cardiovascular issues.
Common local side effects include:
Systemic and heart-related side effects are very rare with correctly used topical minoxidil, but case reports and product information advise seeking medical help if symptoms like chest pain, palpitations, dizziness, or unexplained swelling occur, as these could reflect systemic absorption or accidental ingestion. Risk is higher with oral minoxidil or overdose, where hypotension, tachycardia, and even heart failure have been documented.[15]Tripathee, S., Benyovszky, A., Devbhandari, R., Quiza, K., Boris, J. (2024). A Very Bad Hair Day: Minoxidil Ingestion Causing Shock and Heart Failure. Cureus. 16(8). E66039. Available at: … Continue reading
To minimize problems, many clinicians suggest starting once daily and titrating up, choosing foam or gentler vehicles to reduce dermatitis, and using custom compounded formulas (for example, lower alcohol, lower strength, or liposomal bases) in those with sensitive or disease-prone scalps.
People with chronic inflammatory scalp conditions such as active psoriasis, eczema, or severe seborrheic dermatitis are typically advised to get the primary condition under control before adding topical minoxidil or other actives, as applying them to an inflamed barrier increases irritation, may worsen the disease, and can unpredictably alter absorption.[16]Junge, A., Jic-Hoesli, S.R., Bossart, S., Simon, D., de Viragh, P., Hunger, R.E., Heidemeye, K., Seyed Jafari, S.M. (2025). Contact Dermatitis Caused by Topical Minoxidil: Allergy or Just Irritation. … Continue reading
In 2025, several minoxidil-based options stand out for different priorities, from cost to customization. All of them rely on the same core ingredient, but vehicle, strength, and add-ons make a real-world difference in adherence and results.
Whichever route you choose, there is strong evidence that consistent minoxidil use can stabilize loss and improve density for many men, and modern platforms make it easier than ever to find a formulation that fits your scalp, schedule, and risk tolerance.
References[+]
| ↑1 | Gupta, A.K., Talukder, M., Venkataraman, M., Bamimore, M.A. (2021). Minoxidil: a comprehensive review. Journal of Dermatological Treatment. 33(4). 1896-1906. Available at: https://doi.org/10.1080/09546634.2021.1945527 |
|---|---|
| ↑2 | Hussein, R.S., Dayel, S.B., Abahussein, O., El-Sherbiny, A.A. (2024). Applications and efficacy of minoxidil in dermatology. Skin Health and Disease. 4(6). E472. Available at: https://doi.org/10.1002/ski2.472 |
| ↑3 | Pietrauszka, K., Bergler-Czop, B. (2020). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review. Advances in Dermatology and Allergology. 39(3). 472-478. Available at: https://doi.org/10.5114/ada.2020.99947 |
| ↑4 | Gupta, A.K., Talukder, M., Shemer, A., Piraccini, B.M., Tosti, A. (2023). Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders. 9(6). 423-437. Available at: https://doi.org/10.1159/0000531890 |
| ↑5 | Asad, N., Naseer, M., Ghafoor, R. (2024). Efficacy of Topical Finasteride 0.25% with Minoxidil 5% versus Topical Minoxidil 5% Alone in Treatment of Male Pattern Androgenic Alopecia. Journal of Drugs in Dermatology. 23(11). 1003-1008. Available at: https://doi.org/10.36849/JDD.7826 |
| ↑6 | Olsen, E.A., Dunlap, F.E., Funicella, T., Koperski, J.A., Swinehart, J.M., Tschen, E.H., Trancik, R.J. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology. 47(3). 377-385. Available at: https://doi.org/10.1067/mjd.2002.124088 |
| ↑7 | Ghonemy, S., Alarawi, A., Bessar, H. (2021). Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. Journal of Dermatological Treatment. 32(2). 236-241. Available at: https://doi.org/10.1080/09546634.2019.1654070 |
| ↑8 | Nohria, A., Desai, D., Sikora, M., Mandal, S., Shapiro, J., Lo Sicco, K. (2024). Combating “dread shed”: The impact of overlapping topical and oral minoxidil on temporary hair shedding during oral minoxidil initiation. JAAD International. 15. 220-224. Available at: https://doi.org/10.1016/j.jdin.2024.03.005 |
| ↑9 | Amit, K., Mansukh, G., Satyaprakash, M., Dhiraj, D., Hanmant, B. (2023). Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal Minoxidil 5% With Finasteride 0.1% in the Management of Androgenetic Alopecia (Inbilt Study). Cureus. 15(7). E41681. Available at: https://doi.org/10.7759/cureus.41681 |
| ↑10, ↑11 | Katz, H.I., Hien, N.T., Prawer, S.E., Goldman, S.J. (1987). Long-term efficacy of topical minoxidil in male pattern baldness. Journal of the American Academy of Dermatology. 16(3). 711-718. Available at: https://doi.org/10.1016/s0190-9622(87)70092-9 |
| ↑12 | Messenger, A.G., Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology. 2(1). 186-194. Available at: https://doi.org/https://doi.org/10.1111/j.1365-2133.2004.05785.x |
| ↑13 | Hoover E, Alhajj M, Flores JL. Physiology, Hair. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499948/ (Accessed: November 2025) |
| ↑14 | Purnak, T., Senel, E., Sahin, C. (2011). Liquid formulation of minoxidil versus its foam formulation. Indian Journal of Dermatology. 56(4). 462. Available at: https://doi.org/10.4103/0019-5154.84714 |
| ↑15 | Tripathee, S., Benyovszky, A., Devbhandari, R., Quiza, K., Boris, J. (2024). A Very Bad Hair Day: Minoxidil Ingestion Causing Shock and Heart Failure. Cureus. 16(8). E66039. Available at: https://doi.org/10.7759/cureus.66039 |
| ↑16 | Junge, A., Jic-Hoesli, S.R., Bossart, S., Simon, D., de Viragh, P., Hunger, R.E., Heidemeye, K., Seyed Jafari, S.M. (2025). Contact Dermatitis Caused by Topical Minoxidil: Allergy or Just Irritation. Acta Dermato-Venereologica. 105. 42401. Available at: https://doi.org/10.2340/actadv.v105.42401 |
Dihydrotestosterone (DHT) is a potent androgen hormone that can significantly impact hair loss. Its activity, however, isn’t just restricted to the scalp. What’s more, hair loss is a multifactorial condition, with a wide range of causes. As such, the solution to hair loss is much more complicated than simply eliminating DHT.
Many natural or pharmaceutical therapies seek to reduce, or rather, rebalance DHT levels. While lowering DHT can slow or even reverse hair loss, the hormone itself plays vital roles in sexual function, mood regulation, and overall well-being. Therefore, the goal should not be total suppression, but rather modulation that considers the balance between hair health and systemic androgen levels.
In this article, we will rank both natural and pharmaceutical DHT blockers from weakest to strongest, based on research, effectiveness, and risk of side effects.
The top natural ingredients for hair growth, all in one serum.
Take the next step in your hair growth journey with a world-class natural serum. Ingredients, doses, & concentrations built by science.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
DHT is derived from testosterone through the enzyme 5-alpha-reductase. Once formed, DHT binds to androgen receptors and plays a major role in androgenic alopecia (AGA). In hair follicles genetically sensitive to DHT, such as those on the crown and frontal scalp, the hormone acts as a signal for miniaturization. Over time, the follicle shrinks, producing thinner, shorter hairs until it eventually becomes dormant.[1]York, K., Meah, N., Bhoyrul, B., & Sinclair, R. (2020). A review of the treatment of male pattern hair loss. Expert Opinion on Pharmacotherapy. 21(5). 603-612. Available at: … Continue reading

Figure 1. 5α-reductase converts testosterone into dihydrotestosterone. Finasteride is a 5α-reductase inhibitor, meaning it prevents or reduces this activity. Image adapted from Figure 1.[2]Azizi, A., Mumin, N. H., & Shafqat, N. (2021). Phytochemicals with anti-5-alpha-reductase activity: A prospective for prostate cancer treatment. F1000Research. 10. 221. Available at: … Continue reading Image used under Creative Commons License.
By reducing DHT levels or blocking its receptor binding, therapies can interrupt this miniaturization cascade. The goal is to prevent DHT from triggering the cellular changes that cause follicles to shrink and enter a premature resting (telogen) phase. AGA is influenced not just by DHT levels but also by individual receptor sensitivity, local inflammation, and oxidative stress.
However, because of DHT’s wide-reaching activity, side effects of its reduction can include sexual dysfunction, decreased motivation, and mood changes, especially in individuals who are more hormonally sensitive. As such, careful consideration of different therapies and their potential impacts is essential if you choose to use a DHT-blocking treatment.[3]Traish, A. M., Melcangi, R. C., Bortolato, M., Garcia-Segura, L. M., & Zitzmann, M. (2015). Adverse effects of 5α-reductase inhibitors: what do we know, don’t know, and need to know?. Reviews … Continue reading
We’ll rank DHT blockers based on their potency, as well as on the quality of evidence supporting their use for hair loss. You can learn more about our treatment metrics, including evidence quality, in our article.
Natural treatments, typically based on oils and herbs, are generally more gentle than pharmaceutical options. They tend to be less potent, but have far fewer side effects and are not typically subject to the same stringent regulation as pharmaceuticals.
Epigallocatechin gallate (EGCG), a catechin compound found in green tea, is another naturally derived compound that has attracted interest for its potential to influence hair follicle biology. As a potent antioxidant and anti-inflammatory molecule, EGCG helps protect follicular cells from oxidative stress and inflammation, both of which are exacerbated by androgen activity.

Figure 2: Molecular structure of EGCG. Adapted from:[4]Wikipedia. (no date). Epigallocatechin gallate. Available at: https://en.wikipedia.org/wiki/Epigallocatechin_gallate (Accessed: November 2025) Image used under Creative Commons License
EGCG appears to enhance cell-survival pathways such as Akt and Erk, supporting follicular cell proliferation while suppressing apoptotic signals that can trigger hair follicle regression.[5]Kwon, O. S., Han, J. H., Yoo, H. G., Chung, J. H., Cho, K. H., Eun, H. C., & Kim, K. H. (2007). Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG). … Continue reading
Laboratory studies also indicate that EGCG can partially inhibit 5AR, reducing the local generation of DHT.[6]Hiipakka, R. A., Zhang, H. Z., Dai, W., Dai, Q., & Liao, S. (2002). Structure–activity relationships for inhibition of human 5α-reductases by polyphenols. Biochemical Pharmacology. 63(6). … Continue reading However, while this study showed that EGCG can inhibit 5AR in cell-free experiments, it did not have the same impact in cells. This suggests that it may not be able to enter cells and would have reduced impacts in humans.
This seems to be the case, and clinical evidence for EGCG in the treatment of hair loss remains limited. A small pilot study of topical EGCG found no visible changes in hair, although this research was conducted in people with no hair loss disorders.[7]Kwon, O. S., Han, J. H., Yoo, H. G., Chung, J. H., Cho, K. H., Eun, H. C., & Kim, K. H. (2007). Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG). … Continue reading Despite the lack of large-scale human trials, molecular findings do suggest EGCG contributes meaningfully to the cellular environment that supports hair growth and protection.
Catechins from green tea infusions are generally well tolerated. However, supplements should be used cautiously at high doses, particularly above 800 mg per day, as they have been linked to liver enzyme elevations in sensitive individuals.[8]EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS), Younes, M., Aggett, P., Aguilar, F., Crebelli, R., Dusemund, B., Filipič, M., Frutos, M. J., Galtier, P., Gott, D., … Continue reading
You can read more about the evidence for using EGCG for hair loss in our article here.
Pumpkin seed oil (PSO) is one of the most extensively studied non-pharmaceutical treatments for hair loss. In general, it is mild and well-tolerated. Its effects appear to arise from its profile of phytosterols and essential fatty acids, such as linoleic and oleic acid. These compounds have been shown to exhibit mild 5AR inhibitory activity in laboratory studies, potentially reducing local DHT formation in scalp tissues.[9]Azizi, A., Mumin, N. H., & Shafqat, N. (2021). Phytochemicals with anti 5-alpha-reductase activity: a prospective for prostate cancer treatment. F1000Research. 10. 221. Available at: … Continue reading,[10]Liang, T., & Liao, S. (1992). Inhibition of steroid 5α-reductase by specific aliphatic unsaturated fatty acids. Biochemical Journal. 285(2). 557-562. Available at: … Continue reading
Beyond hormonal modulation, pumpkin seed oil provides antioxidant and anti-inflammatory support, which can help protect hair follicles from oxidative damage and microinflammation – two key contributors to progressive miniaturization.[11]Fahim, A. T., Abd-El Fattah, A. A., Agha, A. M., & Gad, M. Z. (1995). Effect of pumpkin-seed oil on the level of free radical scavengers induced during adjuvant-arthritis in rats. Pharmacological … Continue reading
A clinical trial carried out in Korea made waves in 2014 when it reported a 40% increase in hair count after 24 weeks. However, the formulation, Octa-Sabal Plus, included multiple additional herbal compounds, alongside pumpkin seed powder, not oil. This means we can’t attribute the growth reported to pumpkin seed oil.[12]Cho, Y. H., Lee, S. Y., Jeong, D. W., Choi, E. J., Kim, Y. J., Lee, J. G., & Cha, H. S. (2014). Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia: a randomized, … Continue reading
You can read more about the controversial PSO study here.
Cold-pressed pumpkin seed oil is typically taken orally at doses ranging from 400 to 1000 mg daily, with results accumulating gradually over several months. The compound is generally well tolerated, with gastrointestinal discomfort being rare and mild.[13]Hong, H., Kim, C. S., & Maeng, S. (2009). Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutrition Research and Practice. 3(4). … Continue reading Although PSO alone is unlikely to reverse established AGA, it may serve as a gentle adjunct for individuals seeking natural or preventive strategies to support long-term scalp and hair health.
Saw palmetto (Serenoa repens) is one of the most widely studied natural 5AR inhibitors and is sometimes called “nature’s finasteride.” It appears to reduce DHT by inhibiting Type II 5AR, reducing the binding of DHT to androgen receptor sites and increasing the conversion of DHT to a weaker metabolite called androstanediol.[14]Suzuki, M., Ito, Y., Fujino, T., Abe, M., Umegaki, K., Onoue, S., Noguchi, H., & Yamada, S. (2009). Pharmacological effects of saw palmetto extract in the lower urinary tract. *Acta … Continue reading
Importantly, saw palmetto appears to reduce DHT selectively, with research showing decreases in DHT in the prostate but not in the blood. As such, it may cause fewer side effects than systemic DHT reducers.[15]Fagelman, E., & Lowe, F. C. (2001). Saw palmetto berry as a treatment for BPH. Reviews in Urology. 3(3). 134-138. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1476047/
Clinical studies have shown modest impacts of saw palmetto on hair loss. In one study, participants using oral extracts over several months showed reductions in hair shedding, increases in hair density, and subjective improvements in scalp coverage and hair quality.{ Importantly, however, this was an open-label study, where participants and researchers both knew what product they were receiving, so is not as strong a form of evidence as a randomzied controlled trial (RCT).[16]Rossi, A., Mari, E., Scarno, M., Garelli, V., Maxia, C., Scali, E., Iorio, A., & Carlesimo, M. (2012). Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a … Continue reading
In a recent RCT, a standardized, proprietary saw palmetto extract was given as either a 400mg oral capsule or 5 ml of topical formulation and compared to relevant controls. The study found a significant reduction in hair shedding in both oral and topical groups compared to their controls, alongside an increase in hair density of 5% and 7.5% respectively. However, this study also had significant drawbacks. For example, measurements of hair density were not well defined and may therefore include vellus hairs, which do not contribute to visible hair. Despite this, the study does provide some support for the use of saw palmetto in decreasing hair shedding and increasing hair thickness.[17]Sudeep, H. V., Rashmi, S., Jestin, T. V., Richards, A., Gouthamchandra, K., & Shyamprasad, K. (2023). Oral and topical administration of a standardized saw palmetto oil reduces hair fall and … Continue reading
Evidence from benign prostatic hyperplasia suggests that an oral dose of 320 mg per day is optimal, with increases in dose above that resulting in no further improvements. For topical use, concentrations around 0.5 – 1% applied once or twice daily are common. Both routes are well tolerated, with infrequent reports of mild gastrointestinal discomfort or skin irritation.
You can read about the differences between saw palmetto and finasteride in our article here.
Over-the-Counter Pharmaceutical Options bridge the gap between gentle natural therapies and prescription-strength DHT blockers, potentially offering clinically supported benefits with relatively low systemic risk.
Originally developed as an antifungal agent, ketoconazole helps normalize the scalp environment by reducing inflammation, fungal overgrowth, and excess sebum, all of which can worsen AGA. Beyond its antifungal activity, laboratory and clinical research suggest that ketoconazole exerts mild local antiandrogenic effects, likely through partial inhibition of 5AR and modulation of DHT activity within the scalp.
Clinical evidence for men is stronger than for women. One 21-month study using 2% ketoconazole shampoo showed progressive improvement in hair shaft diameter and percentage of hairs in the growth (anagen) phase, reversing the slow decline seen in untreated AGA.[18]Piérard-Franchimont, C., De Doncker, P., Cauwenbergh, G., & Piérard, G. E. (1998). Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 196(4). 474-477. Available … Continue reading
Another study, which compared Ketoconazole with other shampoos, found that 1% ketoconazole reduced hair shedding by 17%, improved anagen hair by 4.9%, and lowered scalp sebum levels.[19]Piérard-Franchimont, C., Goffin, V., Henry, F., Uhoda, I., Braham, C., & Piérard, G. E. (2002). Nudging hair shedding by antidandruff shampoos: A comparison of 1% ketoconazole, 1% piroctone … Continue reading Studies also show that ketoconazole performs well as an adjunct therapy, with synergistic effects when combined with finasteride.[20]Perez, B. S. H. (2004). Ketoconazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Medical Hypotheses. 62(1). 112-115. Available at: … Continue reading
Evidence in women is limited, with only one published study investigating ketoconazole solution, rather than shampoo. They compared 2% ketoconazole to 2% minoxidil and reported meaningful regrowth in both groups, with ketoconazole producing improvements by the six-month mark and causing far fewer side effects.[21]El-Garf, A., Mohie, M., & Salah, E. (2019). Trichogenic effect of topical ketoconazole versus minoxidil 2% in female pattern hair loss: a clinical and trichoscopic evaluation. Biomedical … Continue reading
Ketoconazole is generally well tolerated. Mild irritation, dryness, or temporary scalp tightness may occur, especially with 2% formulations or frequent use. Most regimens recommend applying it 2–3 times per week, leaving the shampoo on the scalp for 3–5 minutes before rinsing.
You can read our breakdown of the research into ketoconazole shampoos here.
You can also read about why 2% ketoconazole might be a better choice than 1% here.
Prescription Pharmaceutical DHT Blockers represent the most potent and clinically validated options, offering stronger and more predictable suppression of DHT than natural therapies but with a greater need for careful monitoring of side effects.
Topical finasteride represents a new, more targeted approach to DHT inhibition, delivering the drug directly to the scalp while aiming to minimize systemic exposure. Like its oral counterpart, it blocks the Type II 5-alpha reductase enzyme. However, by focusing this activity locally within the hair follicle, topical formulations can achieve substantial reductions in scalp DHT while maintaining serum levels that are a fraction of those seen with oral dosing. This distinction is clinically important for individuals concerned about systemic side effects such as decreased libido or hormonal shifts.
Clinical research has consistently shown that topical finasteride can achieve similar improvements in hair density and regrowth as oral therapy. One 24-week study showed a 34.5% decrease in DHT, compared to 55.6% for oral finasteride. However, plasma concentrations were 100 times lower, indicating that systemic exposure is greatly reduced.[22]Piraccini, B. M., Blume-Peytavi, U., Scarci, F., Jansat, J. M., Falqués, M., Otero, R., Tamarit, M. L., Galván, J., Tebbs, V., Massana, È., on behalf of the Topical Finasteride Study Group. … Continue reading
Topical finasteride is particularly appealing to men who respond well to oral therapy but wish to lower the risk of systemic adverse effects. When applied once daily at concentrations between 0.1% and 0.25%, it can stabilize shedding within four to six months, with visible improvements generally continuing over the course of a year.[23]Mazzarella, G. F., Loconsole, G. F., Cammisa, G. A., Mastrolonardo, G. M., & Vena, G. A. (1997). Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a … Continue reading For optimal results, it can be combined with topical minoxidil to stimulate regrowth through complementary pathways.[24]Wang, H., Chen, B., & Hong, X. (2020). The efficacy and safety of finasteride combined with topical minoxidil for androgenetic alopecia: A systematic review and meta-analysis. *Journal of … Continue reading
Our members can find the ultimate guide to finasteride here.
Dutasteride is the most potent 5AR inhibitor currently available, targeting both Type I and Type II isoenzymes. This dual inhibition results in serum DHT reductions of up to 90 – 95%, creating a profoundly anti-androgenic environment within scalp follicles.[25]Roehrborn, C. G., Marks, L. S., Fenter, T., Freedman, S., Tuttle, J., Gittleman, M., Morrill, B., & Wolford, E. T. (2004). Efficacy and safety of dutasteride in the four-year treatment of men … Continue reading Clinically, this translates into faster and often more pronounced regrowth compared to finasteride, particularly in individuals with advanced hair thinning.
Because dutasteride suppresses DHT more comprehensively, it may pose a slightly higher risk of hormonal side effects such as gynecomastia or reduced libido. However, head-to-head studies have suggested superior efficacy for dutasteride in both short-term and long-term endpoints.
A meta-analysis, which combines results from multiple studies, indicated that dutasteride showed better efficacy in treating AGA.[26]Zhou, Z., Song, S., Gao, Z., Wu, J., Ma, J., & Cui, Y. (2019). The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and … Continue reading These results suggest that dutasteride is ~3 times more potent than finasteride in blocking Type II 5α-reductase and up to 100 times more potent against Type I. This dual inhibition reduces scalp DHT levels by over 50%, compared to approximately 41% with finasteride, leading to greater prevention of follicular miniaturization and enhanced regrowth response with similar levels of adverse effects.
Dutasteride has a relatively low evidence quality score compared to finasteride, though this is largely due to there being fewer studies. The studies that do investigate dutasteride have shown higher potency and effectiveness.
Topical dutasteride formulations are now under active investigation. Concentrations ranging from 0.01% to 0.05% have produced significant gains in target-area hair counts, with studies suggesting that improvements associated with oral formulations can be achieved without drops in serum DHT.[27]Panuganti, V. K., Madala, P. K., Grandhi, V. R., Alluri, C. V., Mohammad, J., KSSVV, S. R., & Dundigalla, M. R. (2025). A randomized, double-blind, placebo and active controlled Phase II study to … Continue reading

Figure 3. Topical Dutasteride supports hair regrowth. Adapted from Figure 2.[28]Panuganti, V. K., Madala, P. K., Grandhi, V. R., Alluri, C. V., Mohammad, J., KSSVV, S. R., & Dundigalla, M. R. (2025). A randomized, double-blind, placebo and active controlled Phase II study to … Continue reading Image used under Creative Commons License
A 2018 randomized clinical study further demonstrated that topical dutasteride (0.02%) combined with microneedling significantly improved hair shaft thickness and patient satisfaction compared with microneedling alone, without notable systemic absorption or hormonal side effects. These findings suggest that localized delivery of dutasteride may enhance follicular response while minimizing systemic exposure and related adverse effects.[29]Nada, E.A., El Sharkawy, R.E.E.D., Abd El-Maged, W. M., & Abo Elmagd, M. A. (2018). Topical dutasteride with microneedling in treatment of male androgenetic alopecia. Sohag Medical Journal. … Continue reading
Similarly, research published in 2024 looked into the impact of microneedling. However, in this study, topical dutasteride was combined with minoxidil. They found similar improvements in hair density and hair width in participants who had topical dutasteride and minoxidil treatment to those in patients who had oral dutasteride and topical minoxidil.[30]Abu Obeid, M. N., Abdel Fattah, N. S., Elfangary, M. M., & Al Husseni, R. M. (2024). Comparison between Topical Minoxidil 5% Alone versus Combined with Dutasteride (Topical 0.02% through … Continue reading These results suggest that, in combination with other therapies (minoxidil or microneedling), topical dutasteride may be able to produce similar results to oral formulations but with a significantly lower chance of side effects.
A newly published Phase II trial has also drawn significant attention because it is the first study to test topical dutasteride alone, without microneedling. The results appear impressive: all topical doses improved hair parameters versus placebo, showed minimal impact on serum DHT (suggesting good scalp localization), and 1 ml daily of 0.05% topical dutasteride reportedly outperformed oral finasteride in key regrowth metrics.[31]Panuganti, V. K., Madala, P. K., Grandhi, V. R., Alluri, C. V., Mohammad, J., Kssvv, S. R., & Dundigalla, M. R. (2025). A randomized, double-blind, placebo- and active-controlled phase II study … Continue reading
However, the study reports unusually high baseline hair counts, as well as inconsistencies in the placement and size of the 1 cm² target areas used for serial hair counts. These issues can dramatically skew results, creating the illusion of improvement even when none exists. Real-world data from users of low-dose topical dutasteride (0.01–0.02% applied daily or near-daily) also paint a more modest picture: good localization and serum DHT stability, but primarily maintenance rather than regrowth exceeding oral finasteride
As you can see from our evidence quality score, oral finasteride remains the most clinically validated pharmacological treatment for AGA. It acts as a selective inhibitor of the Type II 5AR enzyme, reducing systemic and scalp DHT levels by approximately 60–70%.[32]Drake, L., Hordinsky, M., Fiedler, V., Swinehart, J., Unger, W. P., Cotterill, P. C., Thiboutot, D. M., Lowe, N., Jacobson, C., Whiting, D., Stieglitz, S., Kraus, S. J., Griffin, E. I., Weiss, D., … Continue reading This substantial suppression slows or halts follicular miniaturization, prolongs the growth (anagen) phase, and enables partial regrowth in many users. The standard 1 mg daily dose for AGA has been extensively studied and represents the optimal balance between efficacy and safety for most men.
Clinical trials have consistently confirmed the effectiveness of finasteride in both the short and long term. A 4-year, randomized study found that 1 mg of finasteride led to increased hair weight (46% vs placebo) and hair count (20% vs. placebo).[33]Price, V. H., Menefee, E., Sanchez, M., & Kaufman, K. D. (2006). Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. … Continue reading
You can find an in-depth overview of the clinical studies on finasteride here.
While highly effective, oral finasteride is not without potential drawbacks. A small percentage of users report side effects related to sexual function, including reduced libido, erectile difficulty, and diminished ejaculate volume. Most of these effects are mild and resolve upon discontinuation, although persistent symptoms have been reported in rare cases. Some users also report changes in mood or motivation, likely reflecting individual hormonal sensitivity. For those wishing to minimize systemic exposure, transitioning to topical finasteride or titrating to a lower dose (e.g., 0.25-0.5 mg daily) may be a suitable option.[34]Gupta, A. K., Venkataraman, M., Talukder, M., & Bamimore, M. A. (2022). Finasteride for hair loss: a review. Journal of Dermatological Treatment. 33(4). 1938-1946. Available at: … Continue reading
There have also been reports of a condition that’s been named ‘post-finasteride syndrome’. While not widely accepted by the medical community, similar symptoms have been reported in a number of individuals who are taking finasteride. These symptoms can include sexual dysfunction, such as loss of libido and erectile dysfunction, neuropsychiatric symptoms like depression and anxiety, and physical changes like muscle atrophy and fatigue. Importantly, there have been cases where these symptoms have persisted after users have stopped taking the drug.
While the authors who published the original article on post-finasteride syndrome do highlight the lack of consistent evidence for persistent side effects found in clinical trials, they suggest that finasteride may act to worsen symptoms associated with sexual dysfunction and psychiatric conditions for some users who already have these issues.[35]Pereira, A. F. J. R., & Coelho, T. O. A. (2020). Post-finasteride syndrome. Anais Brasileiros de Dermatologia. 95(3). 271-277. Available at: https://doi.org/10.1016/j.abd.2020.02.001
Overall, oral finasteride remains the gold standard for DHT suppression, providing robust and predictable results when used consistently. It’s also important to consider the potential side effects when choosing to take finasteride, and consult with your doctor if symptoms arise.
Pyrilutamide takes a different approach to androgen modulation. Rather than reducing DHT production, it acts as a topical androgen receptor antagonist, blocking DHT and testosterone from binding to their receptors in the follicle. By interfering with receptor activation, pyrilutamide aims to suppress the downstream gene expression that leads to follicular miniaturization.[36]Koralewicz, M. M., & Szatkowska, O. A. (2024, July). Topical solutions for androgenetic alopecia: evaluating efficacy and safety. Forum Dermatologicum. 10(3). 61-70. Available at: … Continue reading
Clinical data show encouraging signals. Trials conducted in China and the United States suggest that topical formulations applied once or twice daily can produce measurable increases in hair counts over several months. Reported side effects are primarily mild local dermatitis, and systemic exposure appears very low. However, many of these results remain unpublished in peer-reviewed journals and have failed to demonstrate statistical superiority over placebo for some measurements.[37]Kintor Pharmaceuticals. (2022). Developing Novel Drugs and Commercialization Platform. Available at: … Continue reading,[38]Kintor Pharmaceutical Limited. (2023, March 28). Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial for KX-826 for Treatment of Male Androgenetic Alopecia in China. … Continue reading Because these reports have not been published in peer-reviewed journals, they can only currently be considered pre-releases, rather than academic papers. The absence of published, peer-reviewed, blinded, controlled data means that we can’t draw firm conclusions on pyrilutamide, even in the wake of the many press releases that Kintor has published.
For now, pyrilutamide should be viewed as an experimental therapy. Its mechanism is compelling and localized, offering a theoretical advantage over systemic antiandrogens. Still, robust, peer-reviewed clinical trials confirming efficacy and long-term safety are needed before it can be considered a mainstream treatment. Those interested in exploring it should do so only under medical supervision or within the context of formal clinical research.
DHT blockers span a broad spectrum, ranging from gentle, naturally derived modulators like pumpkin seed oil and EGCG to powerful prescription therapies such as finasteride and dutasteride. Natural options may improve scalp health and have a modest influence on hormonal activity, but their effects are typically gradual and limited. In contrast, pharmacological inhibitors act directly on the enzymatic pathways responsible for DHT synthesis, offering stronger and more predictable outcomes. Topical finasteride has emerged as a compelling middle ground, delivering scalp-level efficacy with minimal systemic impact, while dutasteride represents the upper limit of potency for those requiring more aggressive intervention.
Ultimately, the “best” DHT blocker depends on individual tolerance, goals, and the stage of hair loss. A well-balanced regimen typically combines a DHT inhibitor with a growth stimulant, such as minoxidil, alongside scalp care and lifestyle modifications. With consistent use and proper medical guidance, these approaches can collectively slow, halt, or even reverse the progression of AGA, helping individuals maintain fuller, healthier hair over time.
References[+]
| ↑1 | York, K., Meah, N., Bhoyrul, B., & Sinclair, R. (2020). A review of the treatment of male pattern hair loss. Expert Opinion on Pharmacotherapy. 21(5). 603-612. Available at: https://doi.org/10.1080/14656566.2020.1721463 |
|---|---|
| ↑2 | Azizi, A., Mumin, N. H., & Shafqat, N. (2021). Phytochemicals with anti-5-alpha-reductase activity: A prospective for prostate cancer treatment. F1000Research. 10. 221. Available at: https://doi.org/10.12688/f1000research.51066.3 |
| ↑3 | Traish, A. M., Melcangi, R. C., Bortolato, M., Garcia-Segura, L. M., & Zitzmann, M. (2015). Adverse effects of 5α-reductase inhibitors: what do we know, don’t know, and need to know?. Reviews in Endocrine and Metabolic Disorders. 16(3). 177-198. Available at: https://doi.org/10.1007/s11154-015-9319-y |
| ↑4 | Wikipedia. (no date). Epigallocatechin gallate. Available at: https://en.wikipedia.org/wiki/Epigallocatechin_gallate (Accessed: November 2025) |
| ↑5, ↑7 | Kwon, O. S., Han, J. H., Yoo, H. G., Chung, J. H., Cho, K. H., Eun, H. C., & Kim, K. H. (2007). Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG). Phytomedicine. 14(7-8). 551-555. Available at: https://doi.org/10.1016/j.phymed.2006.11.003 |
| ↑6 | Hiipakka, R. A., Zhang, H. Z., Dai, W., Dai, Q., & Liao, S. (2002). Structure–activity relationships for inhibition of human 5α-reductases by polyphenols. Biochemical Pharmacology. 63(6). 1165-1176. Available at: https://doi.org/10.1016/S0006-2952(02)00848-1 |
| ↑8 | EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS), Younes, M., Aggett, P., Aguilar, F., Crebelli, R., Dusemund, B., Filipič, M., Frutos, M. J., Galtier, P., Gott, D., Gundert-Remy, U., Kuhnle, G. G., Lambré, C., Leblanc, J.-C., Lillegaard, I. T., Moldeus, P., Mortensen, A., Oskarsson, A., Stankovic, I., Waalkens-Berendsen, I., Woutersen, R. A., Andrade, R. J., Fortes, C., Mosesso, P., Restani, P., Arcella, D., Pizzo, F., Smeraldi, C., & Wright, M. (2018). Scientific opinion on the safety of green tea catechins. *EFSA Journal.* 16(4). e05239. Available at: https://doi.org/10.2903/j.efsa.2018.5239 |
| ↑9 | Azizi, A., Mumin, N. H., & Shafqat, N. (2021). Phytochemicals with anti 5-alpha-reductase activity: a prospective for prostate cancer treatment. F1000Research. 10. 221. Available at: https://doi.org/10.12688/f1000research.51066.3 |
| ↑10 | Liang, T., & Liao, S. (1992). Inhibition of steroid 5α-reductase by specific aliphatic unsaturated fatty acids. Biochemical Journal. 285(2). 557-562. Available at: https://doi.org/10.1042/bj2850557 |
| ↑11 | Fahim, A. T., Abd-El Fattah, A. A., Agha, A. M., & Gad, M. Z. (1995). Effect of pumpkin-seed oil on the level of free radical scavengers induced during adjuvant-arthritis in rats. Pharmacological Research. 31(1). 73-79. Available at: https://doi.org/10.1016/1043-6618(95)80051-4 |
| ↑12 | Cho, Y. H., Lee, S. Y., Jeong, D. W., Choi, E. J., Kim, Y. J., Lee, J. G., & Cha, H. S. (2014). Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia: a randomized, double-blind, placebo-controlled trial. *Evidence-Based Complementary and Alternative Medicine.* 2014(1). 549721. Available at: https://doi.org/10.1155/2014/549721 |
| ↑13 | Hong, H., Kim, C. S., & Maeng, S. (2009). Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutrition Research and Practice. 3(4). 323-327. Available at: https://doi.org/10.4162/nrp.2009.3.4.323 |
| ↑14 | Suzuki, M., Ito, Y., Fujino, T., Abe, M., Umegaki, K., Onoue, S., Noguchi, H., & Yamada, S. (2009). Pharmacological effects of saw palmetto extract in the lower urinary tract. *Acta Pharmacologica Sinica.* 30(3). 271-281. Available at: https://doi.org/10.1038/aps.2009.1 |
| ↑15 | Fagelman, E., & Lowe, F. C. (2001). Saw palmetto berry as a treatment for BPH. Reviews in Urology. 3(3). 134-138. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1476047/ |
| ↑16 | Rossi, A., Mari, E., Scarno, M., Garelli, V., Maxia, C., Scali, E., Iorio, A., & Carlesimo, M. (2012). Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. International Journal of Immunopathology and Pharmacology. 25(4). 1167-1173. Available at: https://doi.org/10.1177/039463201202500435 |
| ↑17 | Sudeep, H. V., Rashmi, S., Jestin, T. V., Richards, A., Gouthamchandra, K., & Shyamprasad, K. (2023). Oral and topical administration of a standardized saw palmetto oil reduces hair fall and improves hair growth in androgenetic alopecia subjects – a 16-week randomized, placebo-controlled study. Clinical, Cosmetic and Investigational Dermatology. 16. 3251-3266. Available at: https://doi.org/10.2147/CCID.S380214 |
| ↑18 | Piérard-Franchimont, C., De Doncker, P., Cauwenbergh, G., & Piérard, G. E. (1998). Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 196(4). 474-477. Available at: https://doi.org/10.1159/000017954 |
| ↑19 | Piérard-Franchimont, C., Goffin, V., Henry, F., Uhoda, I., Braham, C., & Piérard, G. E. (2002). Nudging hair shedding by antidandruff shampoos: A comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations. International Journal of Cosmetic Science. 24(5). 249-256. Available at: https://doi.org/10.1046/j.1467-2494.2002.00145.x |
| ↑20 | Perez, B. S. H. (2004). Ketoconazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Medical Hypotheses. 62(1). 112-115. Available at: https://doi.org/10.1016/S0306-9877(03)00264-0 |
| ↑21 | El-Garf, A., Mohie, M., & Salah, E. (2019). Trichogenic effect of topical ketoconazole versus minoxidil 2% in female pattern hair loss: a clinical and trichoscopic evaluation. Biomedical Dermatology. 3(1). 1-8. Available at: https://doi.org/10.1186/s41702-019-0046-y |
| ↑22 | Piraccini, B. M., Blume-Peytavi, U., Scarci, F., Jansat, J. M., Falqués, M., Otero, R., Tamarit, M. L., Galván, J., Tebbs, V., Massana, È., on behalf of the Topical Finasteride Study Group. (2022). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology. 36(2). 286-294. Available at: https://doi.org/10.1111/jdv.17738 |
| ↑23 | Mazzarella, G. F., Loconsole, G. F., Cammisa, G. A., Mastrolonardo, G. M., & Vena, G. A. (1997). Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. Journal of Dermatological Treatment. 8(3). 189-192. Available at: https://doi.org/10.3109/09546639709160517 |
| ↑24 | Wang, H., Chen, B., & Hong, X. (2020). The efficacy and safety of finasteride combined with topical minoxidil for androgenetic alopecia: A systematic review and meta-analysis. *Journal of Dermatological Treatment.* Available at: https://doi.org/10.1007/s00403-020-02100-6 |
| ↑25 | Roehrborn, C. G., Marks, L. S., Fenter, T., Freedman, S., Tuttle, J., Gittleman, M., Morrill, B., & Wolford, E. T. (2004). Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology. 63(4). 709-715. Available at: https://doi.org/10.1016/j.urology.2004.01.001 |
| ↑26 | Zhou, Z., Song, S., Gao, Z., Wu, J., Ma, J., & Cui, Y. (2019). The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clinical Interventions in Aging. 14. 399-406. Available at: https://doi.org/10.2147/CIA.S192435 |
| ↑27 | Panuganti, V. K., Madala, P. K., Grandhi, V. R., Alluri, C. V., Mohammad, J., KSSVV, S. R., & Dundigalla, M. R. (2025). A randomized, double-blind, placebo and active controlled Phase II study to evaluate the safety and efficacy of novel dutasteride topical solution (0.01%, 0.02%, and 0.05% w/v) in male subjects with androgenetic alopecia. Cureus. 17(8). e89309. Available at: https://doi.org/10.7759/cureus.89309 |
| ↑28 | Panuganti, V. K., Madala, P. K., Grandhi, V. R., Alluri, C. V., Mohammad, J., KSSVV, S. R., & Dundigalla, M. R. (2025). A randomized, double-blind, placebo and active controlled Phase II study to evaluate the safety and efficacy of novel dutasteride topical solution (0.01%, 0.02%, and 0.05% w/v) in male subjects with androgenetic alopecia. Cureus. 17(8). e89309. Available at: https://doi.org/10.7759/cureus.89309 |
| ↑29 | Nada, E.A., El Sharkawy, R.E.E.D., Abd El-Maged, W. M., & Abo Elmagd, M. A. (2018). Topical dutasteride with microneedling in treatment of male androgenetic alopecia. Sohag Medical Journal. 22(1). 387-400. Available at: https://doi.org/10.21608/smj.2018.42083 |
| ↑30 | Abu Obeid, M. N., Abdel Fattah, N. S., Elfangary, M. M., & Al Husseni, R. M. (2024). Comparison between Topical Minoxidil 5% Alone versus Combined with Dutasteride (Topical 0.02% through Microneedling or Oral 0.5 mg) in Treatment of Androgenetic Alopecia. QJM: An International Journal of Medicine. 117(Supplement_2). hcae175-207. Available at: https://doi.org/10.1093/qjmed/hcae175.207 |
| ↑31 | Panuganti, V. K., Madala, P. K., Grandhi, V. R., Alluri, C. V., Mohammad, J., Kssvv, S. R., & Dundigalla, M. R. (2025). A randomized, double-blind, placebo- and active-controlled phase II study to evaluate the safety and efficacy of novel dutasteride topical solution (0.01%, 0.02%, and 0.05% w/v) in male subjects with androgenetic alopecia. *Cureus.* 17(8). e89309. Available at: https://doi.org/10.7759/cureus.89309 |
| ↑32 | Drake, L., Hordinsky, M., Fiedler, V., Swinehart, J., Unger, W. P., Cotterill, P. C., Thiboutot, D. M., Lowe, N., Jacobson, C., Whiting, D., Stieglitz, S., Kraus, S. J., Griffin, E. I., Weiss, D., Carrington, P., Gencheff, C., Cole, G. W., Pariser, D. M., Epstein, E. S., Tanaka, W. K., Dallob, A. L., Vandormael, K., Geissler, L. A., & Waldstreicher, J. (1999). The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. *Journal of the American Academy of Dermatology.* 41(4). 550-554. Available at: https://doi.org/10.1016/S0190-9622(99)80051-6 |
| ↑33 | Price, V. H., Menefee, E., Sanchez, M., & Kaufman, K. D. (2006). Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. Journal of the American Academy of Dermatology. 55(1). 71-74. Available at: https://doi.org/10.1016/j.jaad.2005.07.001 |
| ↑34 | Gupta, A. K., Venkataraman, M., Talukder, M., & Bamimore, M. A. (2022). Finasteride for hair loss: a review. Journal of Dermatological Treatment. 33(4). 1938-1946. Available at: https://doi.org/10.1080/09546634.2021.1959506 |
| ↑35 | Pereira, A. F. J. R., & Coelho, T. O. A. (2020). Post-finasteride syndrome. Anais Brasileiros de Dermatologia. 95(3). 271-277. Available at: https://doi.org/10.1016/j.abd.2020.02.001 |
| ↑36 | Koralewicz, M. M., & Szatkowska, O. A. (2024, July). Topical solutions for androgenetic alopecia: evaluating efficacy and safety. Forum Dermatologicum. 10(3). 61-70. Available at: https://doi.org/10.5603/fd.101208 |
| ↑37 | Kintor Pharmaceuticals. (2022). Developing Novel Drugs and Commercialization Platform. Available at: https://docs.publicnow.com/viewDoc?hash_primary=BFD6444A4669BD4BE0683A8BCC8B5E80F3D7E430
(Accessed: October 2025) |
| ↑38 | Kintor Pharmaceutical Limited. (2023, March 28). Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial for KX-826 for Treatment of Male Androgenetic Alopecia in China. Available at: https://www.prnewswire.com/news-releases/kintor-pharma-announced-the-primary-endpoint-of-phase-ii-clinical-study-for-kx-826s-treatment-of-female-androgenetic-alopecia-in-china-was-met-301691321.html
(Accessed: November 2025) |
Oral finasteride is one of the most widely prescribed treatments for androgenic alopecia (AGA). The drug is a type II 5a-reductase inhibitor, which means it helps reduce dihydrotestosterone (DHT) – the major hormone implicated in pattern hair loss.
At the same time, finasteride isn’t the most powerful DHT-reducing drug available. In fact, there’s a drug that can reduce up to 50% more DHT than finasteride. It’s called dutasteride – and for those who are interested in unlocking another level of hair regrowth, it might be the right choice for them.
So, how much hair regrowth can we expect from dutasteride? Does dutasteride outperform finasteride? How does this drug stack up in terms of side effects? And is there anything else we should know before making the “leap” to a more powerful DHT reducer?
This ultimate guide uncovers the answers.
Interestingly, despite dutasteride’s stronger DHT-reducing effects, this drug doesn’t seem to come with an increased risk of cognitive or sexual side effects – at least when compared to finasteride. In fact, some research indicates that dutasteride might be a better option altogether.
Oral Dutasteride Hair gains bigger than finasteride? Dutasteride makes this possible, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
Dutasteride is a drug used most commonly in the treatment of benign prostate hyperplasia. But it’s also used off-label as a treatment for male pattern hair loss.
Dutasteride is a dual 5α-reductase inhibitor, meaning that the drug inhibits both the type I and type II isoforms of the 5α-reductase enzyme. This makes it unique from finasteride, a drug that only inhibits type II 5-alpha reductase. And since dutasteride inhibits more 5-alpha reductase, it can reduce DHT levels much more effectively than finasteride. Specifically, dutasteride appears to reduce systemic DHT levels by 92-96% and scalp DHT levels by 51-79%; whereas finasteride reduces systemic DHT by 60-70% and scalp DHT by 50-60%.
When it comes to hair regrowth, short-term studies suggest that dutasteride is anywhere from 2-5 times more effective than finasteride (depending on the dose). However, the studies comparing dutasteride and finasteride are generally over six-month periods. This may not make for a fair comparison, as finasteride tends to take two years to achieve its full effect.
Despite being more effective, dutasteride doesn’t seem to come with an increased risk of side effects relative to finasteride. In fact, in some instances, dutasteride’s risk of side effects is actually lower than that of finasteride… despite a more substantial decrease in systemic DHT. While it’s debated why this is the case, one explanation might involve dutasteride’s molecular weight, which is much heavier than finasteride, so much so that the drug cannot likely cross the blood-brain barrier.
If you opt for dutasteride, research suggests that for treating pattern hair loss, a dosage of 0.5 mg daily is best. At this dose, dutasteride seems to outperform finasteride and not result in long-term DHT suppression after stopping the medication. At higher dosages (i.e., 2.5 mg daily), DHT can remain suppressed for 6+ even after stopping treatment.
Dutasteride is a drug used to treat a variety of androgen-related problems in men. It’s branded as Avodart®, and it’s most commonly prescribed for the treatment of benign prostate hyperplasia (BPH). But since it’s such a powerful DHT-reducing drug, many doctors will prescribe it “off-label” to treat male pattern hair loss, or androgenic alopecia (AGA).
There are dozens of ways to reduce DHT levels – from lowering overall testosterone to inhibiting enzymes to blocking androgen receptors to increasing DHT metabolism (to name just a few). Some of these methods are safe; some of them are dangerous; some of them aren’t studied well enough in humans to consider trying.
The good news? Dutasteride reduces DHT through one of the better studied (and safer) ways… and similarly to finasteride. It inhibits the enzyme that converts testosterone into DHT: the 5-alpha reductase enzyme.
Dutasteride differs from finasteride in one key way: it reduces more DHT than finasteride. This is because dutasteride inhibits both type I and type II 5-alpha reductase, whereas finasteride inhibits only the type II 5-alpha reductase enzyme.
Both isoforms of 5-alpha reductase – type I and type II – help convert free testosterone into DHT. However, both function at different pH levels, and both are found in different tissue locations throughout the body:[1]Gerst, C., Dalko, M., Pichaud, P., Galey, J.B., Buan, B., Bernard, B.A. (2002). Type-1 steroid 5 alpha-reductase is functionally active in the hair follicle as evidenced by new selective inhibitors … Continue reading
When it comes to skin tissues near and within hair follicles, the type I isoform dominates… at least in terms of the quantity of enzymes present. But interestingly, it’s the type II isoform that tends to get all of the attention when it comes to male pattern hair loss (AGA).
This is because type II 5-alpha reductase activity in the scalp seems to be a prerequisite for male AGA. This was confirmed back in the 1970s, when studies showed that men born without the genes that make type II 5-alpha reductase also never lose their hair to AGA later in life.[2]Imperato-McGinley, J., Miller, M., Wilson, J.D., Peterson, R.E., Shackleton, C., Gajdusek, D.C. (1991). A cluster of male pseudohermaphrodites with 5-alpha-reductase deficiency in Papua New Guinea. … Continue reading
In fact, these studies were what built the basis for finasteride – a drug that is now the most popular (and most studied) FDA-approved treatment for AGA. After all, finasteride is a type II 5a-reductase inhibitor, and it’s this specific enzyme that seems directly implicated in DHT-related hair follicle miniaturization.
Dutasteride does the exact same thing as finasteride – except it also inhibits both the type I and type II isoforms of 5-alpha reductase. And, since the body’s total DHT levels are closely linked to the sum of type I and type II isoform activity, dutasteride can technically reduce more DHT than finasteride – around 50% more (depending on the tissue being measured).
Maybe.
Several studies have demonstrated that dutasteride reduces DHT levels more than finasteride– at least in tests done on serum (i.e., blood) levels of DHT.[3]Bramson, H.M., Hermann, D., Batchelor, K.W., Lee, F.W., James, M.K., Frye, S.V. (1997). Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. The Journal of pharmacology and … Continue reading In fact, a study found that while finasteride reduces serum DHT levels by ~70%, dutasteride reduces them by ~90% (depending on the dose):[4]Clark, R.V., Hermann, D.J., Cunningham, G.R., Wilson, T.H., Morrill, B.B., Hobbs, S. (2004). Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual … Continue reading

Figure 1: Change in DHT from baseline. Dutasteride vs. finasteride.[5]Clark, R.V., Hermann, D.J., Cunningham, G.R., Wilson, T.H., Morrill, B.B., Hobbs, S. (2004). Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual … Continue reading
But do these results also hold for scalp DHT – the region where DHT reduction matters most?
At least so far, the data suggests yes. Scalp biopsy studies on men taking dutasteride versus finasteride show that at certain dosages, dutasteride reduces much more DHT.[6]Olsen, E.A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M.L., Wilson, T., Rittmaster, R.S., Dutasteride Alopecia Research Team. (2006). The importance of dual 5alpha-reductase … Continue reading
Again, this makes logical sense. After all, type I and type II 5-alpha reductase are found inside and surrounding our hair follicles. And since dutasteride reduces both of these enzymes, this drug should technically reduce more scalp DHT than finasteride.
Thus, it’s totally rational to presume that since:
Then all else equal, dutasteride should be a more effective hair loss drug.
But is this what the clinical research suggests? In order to answer this question, we’ll need to evaluate dutasteride’s hair-regrowing abilities against its risk profile: its reports of side effects, and how this does (or doesn’t) differ from finasteride.
While there have been a handful of studies that have researched dutasteride, there are only four studies that provide data relevant to this question. We’ve compiled these studies as well as their methodologies, results, and conclusions into the chart below.
|
Studies Comparing the Effectiveness of Dutasteride and Finasteride |
|||||||
|
High quality study? |
Daily dosages used | Length of study | Average hair count changes with dutasteride (%) | Average hair count changes with finasteride (%) | Any other notable results? |
Superior treatment? |
|
| Study #1.[7]Olsen, E.A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M.L., Wilson, T., Rittmaster, R.S., Dutasteride Alopecia Research Team. (2006). The importance of dual 5alpha-reductase … Continue reading |
Yes, randomized, placebo-controlled |
Dutasteride:
0.1 mg, 0.5 mg, 2.5 mg Finasteride: 5 mg |
24 weeks | 0.1 mg: 8.6%
0.5 mg: 10.1% 2.5 mg: 11.3% |
8.3% | The amount of patients who achieved at least 10% increase in hair count increases with dutasteride dose. In other words, as dose increased, so did the amount of patients who achieved at least 10% increase in density |
Dutasteride 0.5 mg and 2.5 mg |
| Study #2.[8]Shanshanwal, S.J.S., Dhurat, R.S. (2017). Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled … Continue reading |
Yes, randomized controlled trial |
Dutasteride: 0.5 mg
Finasteride: 1 mg |
24 weeks | 11% | 2% | 24% increase in the number of thick, terminal hairs with dutasteride vs. 4% with finasteride |
Dutasteride |
| Study #3.[9]Harcha, W.G., Martinez, B.J., Tsai, T-F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., Chetty, D. (2014). A randomized, active- and placebo-controlled study of the efficacy … Continue reading |
Yes, randomized, placebo-controlled trial |
Dutasteride: 0.02 mg
0.1 mg 0.5 mg Finasteride: 1 mg |
24 weeks | 0.02 mg: 2.3%
0.1 mg: 8% 0.5 mg: 11.7% |
7.5% | 0.5 mg dosage of dutasteride was superior to 1mg finasteride in increasing hair thickness. |
Dutasteride at 0.5 mg |
| Study #4.[10]Choi, G-S., Sim, W-Y., Kang, H., Huh, C.H., Lee, Y.W., Shantakumar, S., Ho, Y-F., Oh, E-J., Duh, M.S., Cheng, W.Y., Bobbili, P., Thompson-Leduc, P., Ong, G. (2022). Long-Term Effectiveness and Safety … Continue reading |
Yes, multicenter long-term retrospective study |
Dutasteride: 0.5 mg/day
Finasteride: 1 mg/day |
≥3 years (mean 3.4 years) | Hair count data not reported (too sparse; BASP classification used instead) | N/A | Dutasteride is significantly superior across BASP basic, basic M, and V types. |
Dutasteride |
Here’s what these results tell us about dutasteride:
The most interesting finding, though? Despite the fact that 2.5 mg of dutasteride reduces scalp DHT by almost 30% more than 0.5 mg, this doesn’t necessarily translate to more hair regrowth. In fact, the difference in efficacy between the two doses doesn’t even reach statistical significance.
This suggests that even when we reduce DHT to a greater degree and where it’s most important (the scalp), we don’t necessarily see evidence that this increases efficacy. In other words, maybe reductions to scalp DHT don’t always correlate to increased hair regrowth. Maybe there is a degree of pattern hair loss that stems directly from serum DHT, not just scalp DHT. Dr. George Cotsarelis (of PGD2 fame) has mentioned this before in interviews. Hopefully, with more research, we’ll have a clearer answer.
Nonetheless, these trials still tell us that dutasteride, at various doses, is more effective than finasteride – and anywhere between 2- and 5-fold more effective (depending on the doses).
The one caveat to all but one of these comparative studies is that they were conducted over a 24-week period. This makes it difficult to discern just how effective dutasteride versus finasteride is… mainly because finasteride is notoriously slow at regrowing hair.
For instance, studies show that men taking finasteride generally just start to see improvements around the 3-6 month mark.[11]Price, V.H., Menefee, E., Sanchez, M., Ruane, P., Kaufman, K.D. (2002). Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. Journal … Continue reading These studies also show that finasteride takes 2+ years to take full effect on our hair, with scalp hair counts increasing an average of 10% over this two-year period before plateauing.
That’s 96 weeks for finasteride to demonstrate full efficacy, not 24 weeks – the length of time for all studies comparing dutasteride to finasteride. If, for unforeseen reasons, dutasteride efficacy plateaus after six months, then maybe finasteride catches up in the long run. If dutasteride continues its trajectory at the same pace as finasteride, then maybe it’s actually 2- to 5-times more effective than finasteride… and we just don’t know it yet.
In any case, we can surmise that:
Regardless, there’s still one piece to the puzzle we haven’t examined yet: the incidence of side effects.
After all, if dutasteride is 200%-500% more effective than finasteride, but it also comes with a 200-500% increase in side effects… that may defeat the point of using it. After all, for those dealing with hair loss, we’re always trying to find treatments that strike the right balance between effectiveness versus the risk of side effects.
This begs the question: given that dutasteride reduces more DHT and seems much more effective than finasteride, does it also come with an increased risk of side effects?
The answers might surprise you.
We already know that dutasteride reduces serum DHT by larger amounts than finasteride. So, does this come with a higher risk of sexual side effects?
Several studies have attempted to answer this question. Here’s what they have to say:
|
Incidence of Side Effects |
|||||||
| Average incidence of total side effects among dutasteride group vs. finasteride group | Decreased libido (%) | Ejaculation disorders (%) | Erectile dysfunction (%) | Breast enlargement (%) | Breast tenderness (%) | Total serum DHT reduction | |
|
Study #1 |
4.6% vs. 2.6% | Dutasteride
0.1 mg: 3% 0.5 mg: 1% 2.5 mg: 13% Finasteride 5 mg: 4% |
Dutasteride
0.1 mg: 4% 0.5 mg: 1% 2.5 mg: 1% Finasteride 5 mg: 3% |
Dutasteride
0.1 mg: 0% 0.5 mg: 0% 2.5 mg: 0% Finasteride 5 mg: 1% |
N/A | N/A | Dutasteride
0.1 mg: 69.8% 0.5 mg: 92% 2.5 mg: 96.4% Finasteride 5 mg: 73% |
| Study #2 |
10% vs 10% |
N/A |
N/A | N/A | N/A | N/A |
N/A |
| Study #3 |
11.5% vs. 13.4% |
Dutasteride 0.02 mg: 8.1% 0.1 mg: 6.9% 0.5 mg: 4.9% Finasteride 1 mg: 6.7% |
Dutasteride
0.02 mg: 2.2% 0.1 mg: 4.8% 0.5 mg: 3.3% Finasteride 1 mg: 3.9% |
Dutasteride
0.02 mg: 4.3% 0.1 mg: 3.7% 0.5 mg: 5.4% Finasteride 1 mg: 5.6% |
Dutasteride
0.02 mg: 0% 0.1 mg: 0.5% 0.5 mg: 0.5% Finasteride 1 mg: 0.6% |
Dutasteride
0.02 mg: 0.5% 0.1 mg: 0.5% 0.5 mg: 0% Finasteride 1 mg: 0% |
N/A |
| Study #4 | 7.6% vs. 10.5% | Dutasteride: 1.2%
Finasteride: 0.7% |
N/A | Dutasteride: 0.4%
Finasteride 0% |
N/A | N/A |
N/A |
When we examine this data, here’s what we find:
Moreover, here are some other findings from these studies that are not reported within that table:
Again, these side effects are only derived from clinical trials conducted over the course of 6 months. So, these studies alone don’t really tell us what might happen over longer periods of use. And considering that, much like finasteride, dutasteride likely has to be taken for a lifetime to sustain its effectiveness – this really matters.
So, is there any insight as to what the incidence of side effects might be after 6 months?
Well, when we examine the research, we find that the incidence of side effects actually decrease over time with dutasteride use. For example, one four-year trial employing a daily 0.5 mg dose demonstrated that the incidence of side effects decreased from 6% in year one to a marginal 0.4% by year four.
We could argue that this shift is simply a consequence of our olfactory wiring + change blindness – whereby we have a tendency to only notice changes (i.e., new smells) when they first arrive, and whereby if changes occur too slowly, we generally won’t notice them at all.
At the same time, we could also argue that with long-term use of dutasteride, our bodies simply rewire and find ways for testosterone (and other hormones) to replace the roles previously fulfilled by DHT. This is generally how the body works – there are dozens of “fallback” mechanisms in case a vitamin, mineral, or hormone is missing. In other words, we’re more durable than we think.
It’s puzzling that dutasteride seems to come with an equivalent (or lower) risk of side effects… and that over time, these side effects seem to decrease more than with finasteride. This is in spite of dutasteride reducing much more DHT than finasteride. What could explain these paradoxical findings?
Well, one could argue that maybe DHT reduction isn’t necessarily as great of a predictor of side effects as we think. But, there is one additional explanation for these findings, and one that’s much more interesting to explore…
It’s the actual structure of the dutasteride molecule itself… and the fact that the size of this molecule might greatly reduce the drug’s accessibility to certain organs within our body. Specifically, the brain.
The blood is the ultimate transporter for nutrition. It’s also the transporter for oral drugs.
During circulation, the blood will deposit various compounds into cells, where they then elicit their specific effects. However, in the brain, it isn’t quite as simple. This is because of a membrane called the blood-brain barrier (BBB).
This membrane is comprised of cells that maintain tight cellular junctions. In other words, these cells are packed in close together with minimal space between each cell. As such, only very small compounds or compounds that can bind to specific entry receptors on the BBB can pass through the membrane into the brain.
In terms of molecular size, a given compound has to be smaller than 400 daltons (a measurement of mass) to traverse past this membrane. If any larger? The compounds cannot theoretically enter the brain through blood transportation. Therefore, these molecules may not be able to elicit their specific effects on the brain.
So, what does this have to do with dutasteride and finasteride? And why might this explain the difference in the incidence of side effects?
Interestingly, while both finasteride and dutasteride act similarly with respect to DHT reduction, they are actually quite different on a molecular level – particularly regarding their molecular weight.
While finasteride is only 372 daltons, dutasteride is 528 daltons.
The biggest difference here? Finasteride is small enough to pass through the tight junctions of the blood-brain barrier (BBB). Dutasteride isn’t.
As such, finasteride may elicit effects on the brain itself, which may precipitate major effects on sexual and mental side effects. In contrast, dutasteride may have less of a direct effect on the brain… or a reduced capacity to effect androgen metabolism in the brain relative to finasteride.
Again, this is all hypothetical, and the science is still very much debated. For instance, this study on mice found that dutasteride does influence androgen metabolism in the brain (although that study also found that dutasteride had neuroprotective effects on mice, helping to stave off Parkinsons).[12]Litim, N., Morissette, M., Caruso, D., Melcangi, R.C., Di Paolo, T. (2017). Effect of the 5α-reductase enzyme inhibitor dutasteride in the brain of intact and Parkinsonian mice. The Journal of … Continue reading
At the same time, with dutasteride use, some reduction in brain androgen activity is technically to be expected… even if dutasteride doesn’t technically enter the brain. Why? Because 5-alpha reductase can be transported via the blood (where dutasteride does elicit an effect). And if blood entering the brain has less 5-alpha reductase activity, then this would also change androgen activity in the tissues where that blood eventually gets transported (i.e., the brain).
In any case, our suggestion here is that dutasteride itself has a harder time entering into brain tissues, and that this is why it may confer to a lower risk of side effects (despite more DHT reduction) than finasteride.
So, despite the fact that dutasteride has a more powerful effect on both systemic DHT than finasteride, the lower or on-par incidence of side effects may simply be due to dutasteride’s molecular weight… and how this dampens the drug’s ability to enter brain tissue.
Thus, it appears we can derive faster, more substantial hair regrowth in AGA… all with the same or even lower risk of side effects. Moreover, we can even leverage dosages to both maximize regrowth and minimize the risk of side effects.
It goes without saying that dutasteride is a drug that is appropriate only for one specific kind of hair loss: androgenic alopecia (pattern hair loss). It also goes without saying that this drug is studied almost exclusively on men. Therefore, men with pattern hair loss are the best candidates.
So, for men with pattern hair loss, what’s the best dose?
Well, revisiting data from the three studies comparing dutasteride to finasteride, we see that larger doses of dutasteride are generally no more effective than a dosage of 0.5 mg. And based on the safety data, this appears to be one of the safest doses, too.
Specifically, the studies show that 0.5 mg can increase hair counts by anywhere between 10 and 11.5% in 6 months, with just a 1.3% overall risk of sexual side effects. In contrast, finasteride’s risk of side effects ranges from 2-13% with regrowth rates only around 7-8%.
So, a daily dose of 0.5 mg of dutasteride orally seems to both maximize hair regrowth and minimize the risk of side effects. Moreover, it does so in a safer and more effective manner than both 1 mg and 5 mg doses of finasteride.
Finally, a 0.5 mg daily dose is also a dose that allows for our DHT levels to bounce back within six months after stopping the drug. Because of dutasteride’s longer half-life, it tends to exert a longer effect in the body. At higher dosages, it seems as though DHT levels remain suppressed for the majority of users, at least for six months of quitting. A 0.5 mg daily dose prevents this from happening, allowing DHT to return to 80% of baseline levels after six months of cessation, and likely 100% baseline levels a few months thereafter.
If you’d like an example of a long-term dutasteride user, look no further than Ashton Kutcher.[13]Team Coco. (2018). Ashton Kutcher’s Hair Is Starting To Go | CONAN on TBS. Available at: https://www.youtube.com/watch?v=Wv9gu1zJdRo (Accessed: November 2025)
During his 2018 interview with Konan, he revealed that he had used the drug for years, only hopping off to father his children (born in 2014 and 2016). It seems to have worked wonderfully for him. Just look at his hairline in 1998 versus today. While there’s no information about whether he has returned to using dutasteride, it also doesn’t seem like his hairline has changed much over the past several years anyway.
Finasteride is one of the most powerful and frequently used therapies for AGA. However, emerging research indicates that dutasteride may have a clear advantage over finasteride, at least in terms of (1) scalp DHT reduction, (2) hair regrowth, and (3) side effects.
Specifically, a 0.5 mg daily dose appears to increase hair density by anywhere between 10 and 11.5% over the course of 6 months, which happens to be the hair count increase expected from 2+ years of finasteride use. Moreover, dutasteride seems to achieve this without greatly increasing someone’s risk of cognitive or sexual side effects. In fact, the incidence of side effects with dutasteride seems to decrease over time, with one study demonstrating just a 0.4% incidence of side effects with four years of use.
While higher doses (up to 2.5 mg) do increase the response rate to the treatment, they don’t appear to increase the average amount of hair someone regrows. Moreover, they also increase the likelihood of long-term DHT suppression post-treatment. As such, a 0.5 mg daily dose seems like the best approach when utilizing this drug for hair regrowth.
Considering these overall advantages, cost-effectiveness, and accessibility, dutasteride shows considerable promise for men with AGA.
If you’re interested in taking dutasteride or swapping out your oral finasteride, talk with your doctor about the research. If you’re a good candidate for the drug, ask them to prescribe you a 0.5 mg daily dose, and please keep us posted with your results!
References[+]
| ↑1 | Gerst, C., Dalko, M., Pichaud, P., Galey, J.B., Buan, B., Bernard, B.A. (2002). Type-1 steroid 5 alpha-reductase is functionally active in the hair follicle as evidenced by new selective inhibitors of either type-1 or type-2 human steroid 5 alpha-reductase. Experimental Dermatology. 11(1). 52-58. Available at: https://doi.org/10.1034/j.1600-0625.2002.110106.x. |
|---|---|
| ↑2 | Imperato-McGinley, J., Miller, M., Wilson, J.D., Peterson, R.E., Shackleton, C., Gajdusek, D.C. (1991). A cluster of male pseudohermaphrodites with 5-alpha-reductase deficiency in Papua New Guinea. Clinical Endocrinology. 34(4). 293-298. Available at: https://doi.org/10.1111/j.1365-2265.1991.tb03769.x. |
| ↑3 | Bramson, H.M., Hermann, D., Batchelor, K.W., Lee, F.W., James, M.K., Frye, S.V. (1997). Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. The Journal of pharmacology and experimental therapeutics. 282(3). 1496-1502. Available at: PMID 9316864 |
| ↑4, ↑5 | Clark, R.V., Hermann, D.J., Cunningham, G.R., Wilson, T.H., Morrill, B.B., Hobbs, S. (2004). Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor. The Journal of Clinical Endocrinology & Metabolism. 89(5). 2179-2184. Available at: https://doi.org/10.1210/jc.2003-030330 |
| ↑6, ↑7 | Olsen, E.A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M.L., Wilson, T., Rittmaster, R.S., Dutasteride Alopecia Research Team. (2006). The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. Journal of the American Academy of Dermatology. 55(6). 1014-1023. Available at: https://doi.org/10.1016/j.jaad.2006.05.007 |
| ↑8 | Shanshanwal, S.J.S., Dhurat, R.S. (2017). Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian Journal of Dermatology, Venereology and Leprology. 83(1). 47-54. Available at: https://doi.org/10.4103/0378-6323.188652 |
| ↑9 | Harcha, W.G., Martinez, B.J., Tsai, T-F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., Chetty, D. (2014). A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. Journal of the American Academy of Dermatology. 70(3). 489-498. Available at: https://doi.org/10.1016/j.jaad.2013.10.049 |
| ↑10 | Choi, G-S., Sim, W-Y., Kang, H., Huh, C.H., Lee, Y.W., Shantakumar, S., Ho, Y-F., Oh, E-J., Duh, M.S., Cheng, W.Y., Bobbili, P., Thompson-Leduc, P., Ong, G. (2022). Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study. 34(5). 349-359. Available at: https://doi.org/10.5021/ad.22.027 |
| ↑11 | Price, V.H., Menefee, E., Sanchez, M., Ruane, P., Kaufman, K.D. (2002). Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. Journal of the American Academy of Dermatology. 46(4). 517-523. Available at: https://doi.org/10.1067/mjd.2002.120537 |
| ↑12 | Litim, N., Morissette, M., Caruso, D., Melcangi, R.C., Di Paolo, T. (2017). Effect of the 5α-reductase enzyme inhibitor dutasteride in the brain of intact and Parkinsonian mice. The Journal of Steroid Biochemistry and Molecular Biology. 174. 242-256. Available at: https://doi.org/10.1016/j.jsbmb.2017.09.021 |
| ↑13 | Team Coco. (2018). Ashton Kutcher’s Hair Is Starting To Go | CONAN on TBS. Available at: https://www.youtube.com/watch?v=Wv9gu1zJdRo (Accessed: November 2025) |
Dutasteride is one of the strongest off-label treatments for androgenic alopecia. In this guide, we’ll explore the evidence supporting two delivery methods for dutasteride: topical dutasteride and mesotherapy dutasteride. We’ll also provide clear step-by-step instructions for anyone looking to try these therapies at home or find clinicians willing to do the procedures.
Hair gains bigger than finasteride? Dutasteride makes this possible, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
Topical dutasteride and mesotherapy dutasteride are probably most appropriate for people who:
If trying topical dutasteride:
If trying mesotherapy dutasteride:
It’s not easy, but it can be done.
Step #1: Build a list of practitioners offering mesotherapy in your locale
Run a google search for dermatologists and/or medical spas in your area. When checking out their websites, make sure they offer mesotherapy. It’s okay if the mesotherapy they offer is not related to hair loss. All that matters is that they offer mesotherapy, because that means they will have a mesotherapy gun in their office.
Track down their names and contact information via contact forms and emails listed on their sites. Try to build a list of 5-10 clinicians within travel distance.
Step #2: Send each practitioner this personalized email
Here’s an email script that has given us some success. Please personalize as necessary:
Dear [CLINICIAN],
My name is [YOUR NAME]. I’m reaching out because I’m interested in trying mesotherapy dutasteride for the treatment of androgenic alopecia. The procedures are typically done once monthly for 6+ months. I wanted to see if your offices would be willing to provide the therapy to me.
I’ve been encouraged by the results of this mini-review, suggesting that repeated mesotherapy dutasteride may improve hair loss outcomes for men with androgenic alopecia, and without significantly altering serum DHT levels.[1]Herz-Ruelas, M.E., Alvarez-Villalobos, N.A., Millan-Alanis, J.M., de Leon-Gutierrez, H., Ocampo-Garza, S.S., Grimalt, R. (2020). Efficacy of Intralesional and Oral Dutasteride in the Treatment of … Continue reading I’m planning on tracking serum DHT before/during treatment, and I’d be happy to share the blood work with you (especially as interest in this therapy is growing, it might be nice to have the data).
I’m happy to source the mesotherapy dutasteride serum. All I need is a clinician trained in mesotherapy to administer the procedure. Are you interested? If so, I can come to offices as soon as next week.
All my best,
[YOUR NAME]
[PHONE NUMBER]
Step #3: Secure a practitioner
Typically, for every 5-10 clinicians who receive the above email, one will respond to say that they’re interested. Meet with these clinicians, print out and share with them the studies, and show them the methodologies (below) to standardize the procedure, thus making it as easy as possible for the doctor to administer.[2]Herz-Ruelas, M.E., Alvarez-Villalobos, N.A., Millan-Alanis, J.M., de Leon-Gutierrez, H., Ocampo-Garza, S.S., Grimalt, R. (2020). Efficacy of Intralesional and Oral Dutasteride in the Treatment of … Continue reading
Methods For Mesotherapy Dutasteride (With A Clinician):
To be clear, we DO NOT recommend taking a DIY approach to mesotherapy. If you cannot find a provider, we recommend trying topical dutasteride + microneedling. Topical dutasteride is far more accessible, and it’s also easily administered at home. It’s also likely that the combination produces similar results to mesotherapy dutasteride.
Under the circumstances that you decide not to heed our warnings, here are DIY instructions for mesotherapy dutasteride.
Methods for Mesotherapy Dutasteride (At-Home):
Below is a scientific deep-dive on topical / mesotherapy dutasteride.
Topical dutasteride is topical version of the oral drug, dutasteride. Whereas oral dutasteride tends to have hormonal effects all throughout the body, topical dutasteride is designed to selectively target just the scalp skin – allowing people to reap all the hair-growing benefits of dutasteride, and without the risk of systemic side effects.
At least, that’s the hope.
Specifically, dutasteride lowers the hormone dihydrotestosterone (DHT), which is causally linked to androgenic alopecia. It does so by inhibiting the enzyme that converts testosterone into DHT: 5-alpha reductase.
Dutasteride is one of the most powerful 5-alpha reductase inhibitors available. Whereas hair loss drugs like finasteride inhibit 5-alpha reductase and lower DHT levels by ~70%, dutasteride can lower DHT levels by 95%.
This is because there are three known isoforms of 5-alpha reductase: type I, II, and III. Compared to finasteride, dutasteride is more effective at inhibiting them. In fact, dutasteride is able to target the type I isoform 100x better than finasteride, and the type II isoform 3x better than finasteride.[3]Zhou, Z., Song, S., Gao, Z., Wu, J., Ma, J., Cui, Y. (2019). The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and … Continue reading
Dutasteride’s larger effects on DHT reduction also confer better hair regrowth outcomes.
A 2019 meta-analysis by Zhou et al. found that oral dutasteride regrew more hair than oral finasteride – even at dosage ranges lower than 0.5 mg daily.[4]Zhou, Z., Song, S., Gao, Z., Wu, J., Ma, J., Cui, Y. (2019). The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and … Continue reading And while the studies in this review were relatively short (i.e., 6 months) and had sample sizes of less than 500 participants, it’s hard to ignore the preliminary evidence suggesting that oral dutasteride packs a big punch for hair regrowth – even at dosages as low as 0.1mg daily.

Figure 1: The studies cited maintain a low risk of bias, but because of the low sample size, it’s difficult to say with confidence that dutasteride is superior to finasteride.[5]Zhou, Z., Song, S., Gao, Z., Wu, J., Ma, J., Cui, Y. (2019). The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and … Continue reading
Despite reducing more DHT and regrowing more hair, both finasteride and dutasteride appear to carry the same risk of side effects.

Figure 2: Forest plots showing changes in (A) altered libido, (B) erectile dysfunction, and (C) ejaculation disorders.
Abbreviation: M–H, Mantel–Haenszel.[6]Zhou, Z., Song, S., Gao, Z., Wu, J., Ma, J., Cui, Y. (2019). The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and … Continue reading
Why is this? Wouldn’t we expect dutasteride to carry a higher risk of side effects, since it reduces DHT levels more?
Generally, yes. But that’s not currently reflected in the data. Regarding why, there are many hypotheses:
Even still, there remains no consensus among clinicians for why this is the case.
Pharmacokinetics is a term used to describe the behavior of drugs once they enter the body: how quickly they are transported to tissues, how quickly they are metabolized (i.e., their half-life), and more.
Dutasteride and finasteride, despite being structurally similar, differ dramatically in their half-lives. For instance, finasteride has a half-life of 5-8 hours. That means that after ingesting finasteride, it takes 5-8 hours before 50% of that finasteride leaves our bloodstream.
Dutasteride, on the other hand, has a half-life that can last 5+ weeks. In fact, dutasteride’s half-life depends on a lot of factors: age, genetics, and, most importantly, the amount of dutasteride given to an individual at one time.
This was investigated by Gislekog et al. (1998) by giving a dose of dutasteride ranging from 0.01mg to 40mg to 32 healthy males. The findings showed a number of distinctions:
This is presented in the following table:
| Dose | Serum Concentration Duration (up to 1ng mL-1) |
| 0.1mg | Approximately one day. |
| 1.0mg | Averaging around seven days, but can be up to 14 days. |
| 2.5mg | Averaging approximately 14-21 days, but can be as long as 28 days. |
| 5.0mg | Approximately 21-28 days. |
| 10.0mg | Greater than 28 days. |
| 20.0mg | Greater than 28 days. |
| 40.0mg | Greater than 28 days. |

Concentration of dutasteride in serum is dependent on how large a dose is used. This means that beyond half-life, the general concentration of the drug can last for quite a while when using greater than 2.5mg doses.[10]Gisleskog, P.O., Hermann, D., Hammarlund-Udenaes, M., Karlsson, M.O. (1999). The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. … Continue reading
This is not only possible, but plausible… provided that we play with the dosages of dutasteride and the frequencies of application.
Since dutasteride rapidly distributes across tissues and has a dose-dependent half-life, the key is to find an exposure volume of topical dutasteride that…
Encouragingly, we have some data to suggest there are pharmacokinetic “sweet spots” to achieving this.
A recent analysis measured how much of a 1 mL solution of 0.025% dutasteride (i.e., 0.25mg) applied to the scalp (1) stayed on the skin, (2) penetrated into the dermis, and (3) travelled systemically into the bloodstream.
Across 12 hours of study, here’s what the investigators discovered:

Figure 4: Effect of topical dutasteride on skin absorption and circulation entry.
If the above chart feels overwhelming, don’t worry. For now, just know that 12 hours after applying topical dutasteride:
This is actually good news. Why? Because 12 hours after applying 1 mL of 0.025% topical dutasteride, 0.06 mg of that dutasteride permeated into balding tissues, while only 0.016 mg entered into the bloodstream.
In balding skin tissue, 0.06 mg of dutasteride is probably:
Simultaneously, with the amount of dutasteride reaching the bloodstream, 0.016 mg of dutasteride is probably:
In other words, one application of 1 mL of 0.025% topical dutasteride might lead to impressive reductions to scalp DHT, while having minimal impact on serum DHT (and thereby DHT levels elsewhere in the body).
We wish it were that simple.
The problem is that the above analysis only measures the effects from one application of topical dutasteride. If we apply this dosage daily, dutasteride levels in the scalp skin will accumulate, as will the amount of dutasteride entering the bloodstream.
Additionally, after that 12-hour mark, a portion of the ~25% of dutasteride already absorbed into the skin will continue to leak into the bloodstream. The above study does not capture these effects. So, while the analysis is insightful, it unfortunately does not run long enough to reveal the full extent of systemic absorption from a single 1 mL dose of 0.025% topical dutasteride. That means total bloodstream exposure from 1 mL of 0.025% topical dutasteride is probably a bit higher than the 0.016 mg suggested by the study.
Finally, as blood levels of dutasteride increase, so too will the drug’s half-life. Remember: the more dutasteride present, the longer the half-life. So, after a few weeks of daily application, it’s not unreasonable to expect serum drug exposure to accumulate and thereby serum DHT levels to substantially decrease. This is exactly what most people trying topical dutasteride want to avoid!
Fortunately, we don’t have to rely exclusively on mathematical modeling to figure this out. There are clinical studies testing topical dutasteride for the treatment of androgenic alopecia – some of which measured not only hair growth, but also changes to serum DHT levels before and after treatment.
In a 2018 clinical study, researchers sought to determine how topical dutasteride + microneedling fared versus microneedling alone.[11]Nada, E.A., El-Dawla, R.E., El-Maged, W.M.A., Elmagd, M.A.A. (2018). Topical dutasteride with microneedling in treatment of male androgenetic alopecia. Sohag Medical Journal. 22(1). 387-401. … Continue reading
So, they recruited 30 males with androgenic alopecia, randomized them into two groups, and tracked hair parameter changes of a six-month period.
Using a Dermapen with a 12-gauge needle cartridge and a 1.5mm needle length, both groups received 13 microneedling sessions over six months, and using the following schedule:
However, during each microneedling session, the topical dutasteride group also received up to 2 mL of 0.02% topical dutasteride (i.e., 0.4mg) applied to the scalp.
After six months, the topical dutasteride + microneedling group saw greater improvements in hair density versus the microneedling-only group. This equated to a 12% increase in hair density.

Figure 5: Changes of hair density in the study groups before and after treatment.[12]Nada, E.A., El-Dawla, R.E., El-Maged, W.M.A., Elmagd, M.A.A. (2018). Topical dutasteride with microneedling in treatment of male androgenetic alopecia. Sohag Medical Journal. 22(1). 387-401. … Continue reading
Additionally, the topical dutasteride + microneedling group also saw hair thickness improve by nearly 100%.

Figure 6: Changes in hair caliber width in the study groups before and after treatment.[13]Nada, E.A., El-Dawla, R.E., El-Maged, W.M.A., Elmagd, M.A.A. (2018). Topical dutasteride with microneedling in treatment of male androgenetic alopecia. Sohag Medical Journal. 22(1). 387-401. … Continue reading
Finally, hormonal testing revealed that the topical dutasteride + microneedling group did experience a 5.3% reduction in serum levels of DHT. However, this level of DHT reduction is considered biologically insignificant. Keep in mind that serum DHT levels can fluctuate as much as 20-40% daily, depending on if the measurements were taken during the morning or night. So a ~5% change in DHT isn’t very concerning.

Figure 7: Hormone levels before and after treatment.[14]Nada, E.A., El-Dawla, R.E., El-Maged, W.M.A., Elmagd, M.A.A. (2018). Topical dutasteride with microneedling in treatment of male androgenetic alopecia. Sohag Medical Journal. 22(1). 387-401. … Continue reading
While these results are encouraging, they’re also problematic. Specifically, the results are obfuscated by a methodological concern: staggered microneedling + topical dutasteride sessions, and no measurements for serum DHT during shorter durations between dutasteride applications.
Throughout the study, time gaps between topical dutasteride applications grew. For the first 8 weeks, topical dutasteride was applied once weekly. But for the last 12 weeks, it was applied once monthly. The investigators only reported changes to serum DHT before/after the study concluded. Specifically, they recorded serum DHT before the study began, and one week after their final dutasteride application. So, are these results really representative of serum DHT levels throughout the study… or were serum DHT levels much lower in the first few months when application frequency was 4x higher?
Unfortunately, the investigators do not give us enough information to know the answers to these questions. We’re reaching out and hope to have answers for you soon.
In the interim, we’ve had several members emulate the methodologies of this study, test serum DHT levels before/during treatment, and adhere to a once-weekly topical dutasteride application rate (at up to 2 mL of 0.025% dutasteride, that’s up to 0.4mg of weekly dutasteride exposure).
The good news is that all of these members reported only 10-15% decreases in serum DHT. While those decreases are likely partly due to serum dutasteride, they’re still within the realm of biologically insignificant. And encouragingly, our members’ results not only align with the ballpark results of this study, but also the previous dosing analysis – at least in terms of expectations for systemic leakage.
In our eyes, these are all positive signs. They’re preliminary signals (validated by some members) that at weekly dosages of up to 2 mL x 0.02% topical dutasteride (i.e., 0.4 mg per week), we can mostly preserve serum DHT levels – even when adding in microneedling.
Encouragingly, a 2022 study also validated this approach – at least in terms of efficacy.
In 2022, investigators conducted another study on topical dutasteride + microneedling, albeit without serum DHT and with slightly different methodologies.[15]Sanchez-Meza, E., Ocampo-Candiani, J., Gomez-Flores, M., Herz-Ruelas, M.E., Ocampo-Garza, J., Orizaga-y-Quiroga, T.L., Martinez-Moreno, A., Ocampo-Garza, S.S. (2022). Microneedling plus topical … Continue reading
These investigators randomized 34 men into two groups. One received microneedling + 1 mL of 0.01% topical dutasteride (i.e., 0.1 mg). The other received microneedling + 1 mL of saline solution (i.e., water).
Both groups were treated once every four weeks for a total of three sessions. In both groups, the investigators used a Dr. Pen A6 Ultimate microneedling device and set the needle depth to 2.5mm.
Hair parameters were assessed 4-8 weeks later, thus bringing the study duration to 20 weeks (despite each group only having received three microneedling + topical treatments).
Encouragingly, over 50% of people in the microneedling + topical dutasteride group observed “marked improvement” in their hair loss. Hair thickness, hair density, and the ratio of vellus:terminal hairs also improved versus the microneedling-only group.

Figure 8: Results from a 2022 study on microneedling + dutasteride (left column) versus microneedling alone (right column).[16]Sanchez-Meza, E., Ocampo-Candiani, J., Gomez-Flores, M., Herz-Ruelas, M.E., Ocampo-Garza, J., Orizaga-y-Quiroga, T.L., Martinez-Moreno, A., Ocampo-Garza, S.S. (2022). Microneedling plus topical … Continue reading
While serum DHT levels were not measured, there were no reports of sexual side effects from participants.
This is another positive (albeit preliminary) signal that topical dutasteride can produce results and reduce our risk of adverse events (and drug exposure) – especially when paired with microneedling. Just see these before-and-after photos from one study participant:

Figure 9: (a). Vertex area trichoscopy and clinical photograph of a patient with androgenetic alopecia (Hamilton-Norwood Scale III) at baseline visit. (b). Frontal area trichoscopy and clinical photograph showing marked improvement (HamiltonNorwood Scale II) at week 16 after 3 sessions with microneedling plus topical 0.01% solution of dutasteride in monotherapy.[17]Sanchez-Meza, E., Ocampo-Candiani, J., Gomez-Flores, M., Herz-Ruelas, M.E., Ocampo-Garza, J., Orizaga-y-Quiroga, T.L., Martinez-Moreno, A., Ocampo-Garza, S.S. (2022). Microneedling plus topical … Continue reading
Another encouraging component of this study is that the total dutasteride dosage was lower than the 2018 study, yet still produced results. Whereas the 2018 study used dosages as high as 0.4mg weekly (at least for the first 8 weeks), this 2022 study used dosages equating to 0.1mg once every four weeks. If we are to take the minimal serum DHT changes from the 2018 study at face-value, then it’s even more unlikely that the dutasteride volumes used in this 2022 study led to appreciable changes to serum DHT.
Another study published this year (2025) also gave some insight into low topical dosages of dutasteride in people with AGA.
The investigators randomized 135 men with AGA into five groups: 0.01%, 0.02%, or 0.05% topical dutasteride (1 mL once daily), 1 mg oral finasteride daily, or a topical placebo. Treatments were continued for 24 weeks, with the topical solutions applied to a marked vertex target area.[18]Panuganti, V.K., Madala, P.K., Grandhi, V.R., Alluri, C.V., Mohammad, J., KSSVV, S.R., Dundigalla, M.R. (2025). A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate … Continue reading
Baseline characteristics were balanced across groups. Efficacy was assessed via macrophotography and target area hair counts (TAHC), global photographic assessment, and patient satisfaction questionnaires.
At 24 weeks:

Figure 10: Representative images of hair growth in male-pattern androgenetic alopecia after treatment with 0.01% dutasteride topical solution at 12 week (b) and 24 week (c) vs baseline (a); 0.02% dutasteride topical solution at 12 week (e) and 24 week (f) vs baseline (d); 0.05% dutasteride topical solution at 12 week (h) and 24 week (i) vs baseline (g); oral finasteride 1 mg tablets at week 12 (k) and week 24 (l) vs baseline (j); placebo at week 12 (n) and week 24 (o) vs baseline (m).[19]Panuganti, V.K., Madala, P.K., Grandhi, V.R., Alluri, C.V., Mohammad, J., KSSVV, S.R., Dundigalla, M.R. (2025). A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate … Continue reading
Our Analysis
On the surface, the Panuganti trial is extremely attractive: it suggests that low-dose topical dutasteride (0.05%) can outperform 1 mg oral finasteride in hair regrowth while producing only minimal average changes in serum DHT. However, several issues with the design and reporting warrant caution, and in our view, the topline conclusion should not be taken at face value.
Sponsorship and authorship
The trial was sponsored by Shilpa Medicare Limited, and all authors were company employees. Industry sponsorship does not invalidate results, but it does increase the importance of methodological transparency and independent replication—especially when findings are strikingly positive and out of step with real-world experience.
Hair counts that don’t match typical scalp biology
The reported baseline hair counts (≈300–330 hairs/cm²) in men with Norwood III–V vertex thinning are difficult to reconcile with established data. In non-balding adults, typical terminal hair densities are ~100–250 hairs/cm², and they fall substantially with moderate-to-severe AGA. Yet the study presents baseline photos of visibly thinned vertex regions alongside hair counts that exceed even full-density scalps.
The most likely explanations are that:
Any of these will inflate absolute hair counts and complicate the interpretation of changes over time.
Questionable consistency of the hair count target area
Accurate hair counting depends on revisiting the exact same 1 cm² area at each time point, typically anchored to a tattoo or permanent scalp mark. In the figures provided, the circular “counting zones” appear to shift in position, shape, and size between baseline, week 12, and week 24 for the same participant.
Even a 1–2 mm shift in the center of a 1 cm² circle can change measured hair counts by 50% or more in patchy thinning regions. Since the study reports changes on the order of ~10–15%, small misalignments in the counting area could fully account for the apparent “regrowth,” particularly in groups with smaller gains.
Limited insight into systemic exposure
Serum DHT and testosterone were reported only as group mean percentage changes, with no measures of variability (e.g., standard deviations) or individual pharmacokinetic correlations. This means:
For a drug like dutasteride, where individual absorption and metabolism vary widely, this lack of granularity limits the conclusions we can draw about “safety” at the individual level.
Conflict with real-world data and dose–response expectations
Over several years, our community has tracked people using low-dose topical dutasteride (e.g., 0.01–0.02%, 1–2 mL daily, sometimes higher weekly exposure than in the 0.05% arm of this study). Broadly:
Taken together, this creates a tension: the study’s claim that 1 mL of 0.05% topical dutasteride daily can outperform 1 mg oral finasteride on average, without meaningful systemic effects, does not match what we see in practice or what we would expect based on dutasteride pharmacology.

Figure 11: Changes from baseline to week 24 in (a) testosterone levels and (b) DHT levels.[20]Panuganti, V.K., Madala, P.K., Grandhi, V.R., Alluri, C.V., Mohammad, J., KSSVV, S.R., Dundigalla, M.R. (2025). A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate … Continue reading
Overall, the Panuganti et al. trial supports that low-dose topical dutasteride (0.01–0.05%) has real biologic activity, can improve hair parameters versus placebo, and may keep average serum DHT changes relatively modest. However, issues with baseline hair counts, apparent inconsistencies in how target areas were measured, limited systemic exposure data, and a headline result that conflicts with prior studies and real-world experience mean we don’t think this study justifies expecting low-dose topical dutasteride to reliably outperform oral finasteride. For now, it’s more reasonable to view low-dose topical dutasteride (≤0.05% with limited weekly exposure) as a localized, hair-loss–stabilizing option with modest regrowth and relatively mild systemic impact, while higher-dose topical regimens are more likely to produce cosmetically meaningful gains but also to behave more like oral dutasteride in terms of systemic DHT suppression and potential side effects.
Yet another study came out in 2025, combining skin patting and iontophoresis (a medical procedure using a mild electrical current) with dutasteride gel in male and menopausal female AGA.
In this single-center pilot study, researchers enrolled 20 adults (10 men, 10 postmenopausal women) with AGA who had failed at least 12 months of standard therapy (topical minoxidil and/or oral finasteride).[21]Cedirian, S., Pampaloni, F., Quadrelli, F., Rapparini, L., Bruni, F., Martelli, G., Piraccini, B.M., Starace, M. (2025). Efficacy of Skin Patting and Iontophoresis with Dutasteride Gel in Male and … Continue reading Participants underwent monthly sessions of a compounded 6% dutasteride gel delivered using a device that combines skin patting (SPi), microneedling, iontophoresis, electrostimulation, and red LED light over a standardized frontal-vertex treatment field for four months.
Hair density and shaft diameter were assessed by trichoscopy at baseline and again 8 weeks after the final session (i.e., roughly 6 months from baseline), alongside a hair pull test and patient-reported satisfaction scores. By the end of follow-up, frontal and vertex hair density increased significantly (p<0.001), hair shaft diameter improved in both regions (vertex p<0.001; frontal p=0.046), and pull test counts nearly halved (p<0.001), pointing to both regrowth and reduced shedding.
Clinically, investigators rated mean global improvement at +1.9 on a 7-point scale, corresponding to moderate regrowth and less shedding. Subjective outcomes were similarly positive: about 70% of participants perceived the treatment as moderately to very effective, mean cosmetic satisfaction was 3.4/4, and 85% described the procedure as pleasant. No adverse events or tolerability concerns were reported during treatment or follow-up.
Our Analysis
On paper, this is an encouraging signal: the participants experienced measurable gains in density, diameter, and shedding. The high satisfaction scores and absence of side effects also support the idea that this approach is, at minimum, well-tolerated.
However, the design makes it difficult to isolate what’s actually driving the benefit. Because the protocol combines several modalities, we can’t separate the relative contribution of dutasteride from the other treatments. Outcome measures were also partly subjective and non-validated, and all assessments were unblinded, which opens the door to expectation and observer bias.
A second major limitation is the complete absence of systemic safety data. Unlike the other studies, a high dosage of topical dutasteride is used (6%), but we don’t know the effect of this on systemic/serum DHT levels.
While lab work is really the only way to get a grip on things, this study suggests that topical dosages as low as 1 mL x 0.01%, and as infrequently applied as once every four weeks, can still produce results for more than 50% of men with androgenic alopecia.
This begs the question: just how low can we go for dosing? While we don’t yet have the answer, studies on a different delivery vehicle for dutasteride – mesotherapy – suggest we can go even lower.
Mesotherapy dutasteride is also known as intradermal dutasteride. This is different from topical dutasteride.
Whereas topical dutasteride is applied directly to the scalp, mesotherapy dutasteride is when dutasteride is injected directly into the scalp skin – between the epidermis and dermis (i.e., 0.5-0.7mm deep into the scalp).
Whereas only 25% of topical dutasteride is absorbed into the scalp dermis over 12 hours, 100% of mesotherapy dutasteride is absorbed into the scalp dermis, and immediately upon injection. After all, the drug is injected directly into the scalp, leaving no material to evaporate or get wiped away by sweat or during a shower.
That means, across equal dosages, that mesotherapy dutasteride will better saturate the scalp skin, but also lead to more systemic absorption.
The question then becomes: how do the pharmacokinetics of mesotherapy dutasteride change the equation for how much (and how frequently) we should be exposing our scalps to this medication in order to maximize hair gains while minimizing systemic DHT reductions?
While we don’t yet have perfect answers, there are a few studies that suggest the dose is even lower than topical dutasteride.
A 2017 study by Corralo et al. investigated the effects of mesotherapy dutasteride on people with androgenic alopecia.[22]Saceda-Corralo, D., Rodrigues-Barata, A.R., Vano-Galvan, S., Jaen-Olasolo, P. (2017). Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia. International Journal of Trichology. … Continue reading The researchers selected six participants to receive 1 mL of 0.01% dutasteride (i.e., 0.1 mg of dutasteride) once every three months, totaling three injection sessions at months 0, 3, and 6.
The investigation group also took serum DHT measurements before starting treatment, and one month after the final mesotherapy injection (according to personal email correspondences with the authors).
Three months after the last mesotherapy injection, the investigators measured hair parameter improvements. Encouragingly, 1 mL of 0.01% mesotherapy dutasteride once every three months led to statistically significant hair improvements for all participants. Moreover, no changes to serum hormonal profiles were observed.
Here are the before-and-after photos of a featured patient:

Figure 13: Androgenetic alopecia in a 33-year-old man before (a) and after (b) treatment with dutasteride injections through 6 months with a one-session treatment every 3 months.[23]Saceda-Corralo, D., Rodrigues-Barata, A.R., Vano-Galvan, S., Jaen-Olasolo, P. (2017). Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia. International Journal of Trichology. … Continue reading
The sample size of this study is incredibly small. With that said, the results are impressive, and they add to a growing number of signals suggesting that mesotherapy dutasteride (and topical dutasteride) improve hair growth for men and women with androgenic alopecia.
Moreover, this study suggests that a dosing schedule as infrequent as 1 mL of 0.01% dutasteride (i.e., 0.1 mg) once every three months can appreciably improve hair parameters, and without altering systemic levels of hormones.
However, just as with the last study measuring serum DHT levels, this investigation group waited a full month after a mesotherapy dutasteride session to read serum levels of DHT. While the results showed no effect on serum hormones, the reality is that serum DHT levels could have dropped during the days and weeks following an injection, only to rebound to baseline by the time these investigators decided to test.
On the other hand, it’s also possible that mesotherapy dutasteride changes the pharmacokinetics of dutasteride itself – perhaps by increasing tissue saturation time and decreasing systemic leakage rates. While this may sound absurd, other studies have demonstrated mesotherapy to exhibit this behavioral shift with other drugs and compounds.[24]Mammucari, M., Maggiori, E., Russo, D., Giorgio, C., Ronconi, G., Ferrara, P.E., Cazona, F., Antonaci, L., Violo, B., Velluci, R., Mediati, D.R., Migliore, A., Massafra, U., Bifarini, B., Gori, F., … Continue reading Therefore, it’s not unreasonable to assume these effects may also carry over to mesotherapy dutasteride, and that for unknown reasons, the drug has longer staying power in the scalp when injected (and less systemic absorption).
Based on the results of these serum DHT tests, preliminary evidence points toward mesotherapy dutasteride perhaps lasting longer in the scalp and conferring slower systemic absorption. But be forewarned: there is likely an upper limit for how much mesotherapy dutasteride we can inject before serum DHT levels start to decline.
We once had a member test 2 mL of 0.05% dutasteride (i.e., 1.0 mg of dutasteride, or 10x the dosage used in the 2017 study) during his first mesotherapy session. He did a great job tracking serum DHT changes before treatment and 4 days, 4 weeks, and 8 weeks after the injections.
His results? Serum DHT decreases shortly after treatment, which continued to decline up through month one. At that point, the member started experiencing cognitive-related side effects. By the second month, serum DHT levels began to rebound and all side effects went away.
| Serum DHT | Reported side effects | |
| Pre-treatment | 51 ng/dL (reference: 30-90 ng/dl) | No |
| Post-treatment (4 days) | 35 ng/dL | No |
| Post-treatment (4 weeks) | 25 ng/dL | Yes |
| Post-treatment (8 weeks) | 31 ng/dL | No |
With that said, there are a few things worth noting about this member’s experience:
So, by following lower dosage guidelines, we’re confident you can avoid a similar experience. In fact, a 2013 study on mesotherapy dutasteride echoes the experience from our member and shows why mesotherapy dosages, volumes, and frequencies matter a lot.
In 2013, a research team in Egypt enrolled 90 men with androgenic alopecia to test mesotherapy dutasteride at varying dosages, with the higher dosage also containing other potential hair growth-promoting ingredients. They randomized the men into three groups, and then set them up with the following treatment:
Then, the investigators performed 9 mesotherapy sessions over a span of 19 weeks. The sessions were as follows:
Given this dosing schedule, here’s how much dutasteride each group was exposed to over 19 weeks:
Results
After 19 weeks, here were the changes to hair parameters and serum DHT levels:
The bottom line: stick to mesotherapy dutasteride dosages of 0.1-0.2 mg per month. That’s probably close to the “sweet spot” for maximizing hair gains while minimizing unwanted systemic hormonal effects.
Ultimately, a number of factors determine how much of a substance will be absorbed systemically and how much of that substance will remain saturated in a tissue to exert its maximal effect. These factors include:
The above factors are influenced by drug preservatives, carrier agents, temperatures, injection needle depths, aqueous secretions from sweat glands, and even apocrine secretions from sebaceous glands (just to name a few). We can tell you right now: none of the studies on mesotherapy dutasteride made an effort to standardize these factors, or even mention them in their methodologies. In fact, we couldn’t even find standards for just how deep the mesotherapy needles were injected for any study. These are all big limitations for data quality.
(Side note: we’re planning on investigating these factors in early 2023, so that we can develop a better protocol for mesotherapy dutasteride – one that is optimized based on human data across multiple injection frequencies, exposure volumes, carrier agents, and needle depths. Expect more details about this toward the end of 2022.)
Yes. However, they mostly repeat the results we’ve discussed above. Moreover, to our knowledge, none of the other studies measured serum DHT levels, so they don’t help us get closer to answering our core question: “What’s the best protocol for mesotherapy dutasteride to maximize hair gains while minimizing systemic hormonal effects?”
With that said, there is one final study that provides some nuanced insights – particularly related to mesotherapy dutasteride and its variability in hair regrowth, depending on whether someone has metabolic syndrome.
In this 2021 study, researchers sought to determine the effects of mesotherapy dutasteride on females with pattern hair loss (androgenic alopecia), and how hair growth outcomes changed depending on whether participants had metabolic syndrome.[26]Moftah, N., Mubarak, R., Abdelghani, R. (2021). Clinical, trichoscopic, and folliscopic identification of the impact of metabolic syndrome on the response to intradermal dutasteride 0.02% injection … Continue reading
The researchers identified 51 females with pattern hair loss. Then, they determined which women also had metabolic syndrome. For reference, the investigators defined metabolic syndrome as meeting at least three of the following criteria:
This left 26 and 25 females with and without metabolic syndrome, respectively.
Next, the investigators administered mesotherapy dutasteride to all participants. This included 1 mL of 0.02% mesotherapy dutasteride (i.e., 0.2 mg of dutasteride) per session, with eight sessions spanning a period of ~6 months. A few months later, hair parameters were assessed to gauge results.
Results
Surprisingly, females with metabolic syndrome experienced an initial improvement in hair growth at month one, followed by an acceleration of hair loss by month three. Contrastingly, females without metabolic syndrome saw their hair growth increasingly improve throughout each month of treatment.
These results were not only reflected in phototrichograms (i.e., hair counts, hair diameters, and anagen:telogen ratios) but also in global photographs.
Just see these before-and-after photos of two females without metabolic syndrome:

Figure 14: Before and after of woman one without metabolic syndrome.[27]Moftah, N., Mubarak, R., Abdelghani, R. (2019). Clinical, trichoscopic, and folliscopic identification of the impact of metabolic syndrome on the response to intradermal dutasteride 0.02% injection … Continue reading

Figure 15: Before and after of woman two without metabolic syndrome.[28]Moftah, N., Mubarak, R., Abdelghani, R. (2019). Clinical, trichoscopic, and folliscopic identification of the impact of metabolic syndrome on the response to intradermal dutasteride 0.02% injection … Continue reading
Now see this before-and-after photoset of a female with metabolic syndrome:

Figure 16: Before-and-after images of a woman with metabolic syndrome.[29]Moftah, N., Mubarak, R., Abdelghani, R. (2019). Clinical, trichoscopic, and folliscopic identification of the impact of metabolic syndrome on the response to intradermal dutasteride 0.02% injection … Continue reading
On a positive note, no females in either group reported any side effects – sexual or otherwise. But the discrepancy in regrowth between those affected and unaffected by metabolic syndrome was, to put it simply, puzzling.
The researchers did not have a definitive answer. However, some studies suggest an association between metabolic syndrome and androgenic alopecia, with mechanistic data suggesting that insulin insensitivity can enhance androgen production in certain tissues – like the ovaries in women and, perhaps, other organs like the skin.
Oral dutasteride is known to have a mildly negative effect on insulin sensitivity. For most healthy people, this isn’t problematic. But the data are less clear for people who are already afflicted with metabolic syndrome and then start taking dutasteride.
Here’s the rationale the authors used to explain their results:
“These findings could be explained by the study conducted by Upreti et al. [59] who confirmed that dual inhibition of 5α reductase I and II by dutasteride lead to modulation of insulin sensitivity in the peripheral tissues. Accordingly, dutasteride induced reduction of insulin sensitivity that is already impaired in both MetS [55, 60] and FPHL [61-63] could be a possible mechanism of deterioration in participants with MetS. This possibility was recently supported by Sadgrove [64] who suggested that insulin resistance could enhance microinflammation in androgenetic alopecia both directly and indirectly by increased microbial colonization. Moreover, an in vitro study carried out by Philpott et al. [39] revealed that removal of insulin from the culture medium of human hair follicles could lead to follicular transformation into catagen state.“
The bottom line: if you’re already insulin resistant, perhaps it is worth getting those levels within normal ranges before trying dutasteride altogether– including via mesotherapy delivery vehicles.
Here are a few resources.
Here are a few resources.
References[+]
| ↑1, ↑2 | Herz-Ruelas, M.E., Alvarez-Villalobos, N.A., Millan-Alanis, J.M., de Leon-Gutierrez, H., Ocampo-Garza, S.S., Grimalt, R. (2020). Efficacy of Intralesional and Oral Dutasteride in the Treatment of Androgenetic Alopecia: A Systematic Review. Skin Appendage Disorders. 6(6). 338-345. Available at: https://doi.org/10.1159/000510697 |
|---|---|
| ↑3, ↑4, ↑5, ↑6 | Zhou, Z., Song, S., Gao, Z., Wu, J., Ma, J., Cui, Y. (2019). The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clinical Interventions in Aging. 14. 399-406. Available at: PMID 30863034 |
| ↑7 | Hagberg, K.W., Divan, H.A., Fang, S.C., Nickel, J.C., Jick, S.S. (2017). Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clinical Epidemiology. 9. 83-91. Available at: https://doi.org/10.2147/CLEP.S124674 |
| ↑8 | Rahimi-Ardabili, B., Pourandarjani, R., Habibollahi, P., Mualeki, A. (2006). Finasteride induced depression: a prospective study. BMC Clinical Pharmacology. 6(7). Available at: https://doi.org/10.1186/1472-6904-6-7 |
| ↑9 | Wang, K., Fan, D-D., Jin, S., Xing, N-Z., Niu, Y-N. (2014). Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications. Asian Journal of Andrology. 16(2). 274-279. Available at: https://doi.org/10.4103/1008-682X.123664 |
| ↑10 | Gisleskog, P.O., Hermann, D., Hammarlund-Udenaes, M., Karlsson, M.O. (1999). The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. British Journal of Clinical Pharmacology. 47. 53-58. Available at: https://doi.org/10.1046/j.1365-2125.1999.00843.x |
| ↑11 | Nada, E.A., El-Dawla, R.E., El-Maged, W.M.A., Elmagd, M.A.A. (2018). Topical dutasteride with microneedling in treatment of male androgenetic alopecia. Sohag Medical Journal. 22(1). 387-401. Available at: https://smj.journals.ekb.eg/article_42083_24b61cbba4be9982db23c318414034c0.pdf (Accessed: Novemeber 2025) |
| ↑12, ↑13, ↑14 | Nada, E.A., El-Dawla, R.E., El-Maged, W.M.A., Elmagd, M.A.A. (2018). Topical dutasteride with microneedling in treatment of male androgenetic alopecia. Sohag Medical Journal. 22(1). 387-401. Available at: https://smj.journals.ekb.eg/article_42083_24b61cbba4be9982db23c318414034c0.pdf (Accessed: November 2025) |
| ↑15, ↑16, ↑17 | Sanchez-Meza, E., Ocampo-Candiani, J., Gomez-Flores, M., Herz-Ruelas, M.E., Ocampo-Garza, J., Orizaga-y-Quiroga, T.L., Martinez-Moreno, A., Ocampo-Garza, S.S. (2022). Microneedling plus topical dutasteride solution for androgenetic alopecia: a randomized placebo-controlled study. JEADV. 36. c806-c808. Available at: https://doi.org/10.1111/jdv.18285 |
| ↑18, ↑19, ↑20 | Panuganti, V.K., Madala, P.K., Grandhi, V.R., Alluri, C.V., Mohammad, J., KSSVV, S.R., Dundigalla, M.R. (2025). A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia. Cureus. 17(8). e89309. Available at: https://doi.org/10.7759/cureus.89309 |
| ↑21 | Cedirian, S., Pampaloni, F., Quadrelli, F., Rapparini, L., Bruni, F., Martelli, G., Piraccini, B.M., Starace, M. (2025). Efficacy of Skin Patting and Iontophoresis with Dutasteride Gel in Male and Menopausal Female Androgenetic Alopecia: A Pilot Study. Dermatologic Therapy. 15(11). 3419-3424. Available at: https://doi.org/10.1007/s13555-025-01532-w. |
| ↑22, ↑23 | Saceda-Corralo, D., Rodrigues-Barata, A.R., Vano-Galvan, S., Jaen-Olasolo, P. (2017). Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia. International Journal of Trichology. 9(3). 143-145. Available at: https://doi.org/10.4103/ijt.ijt_73_16 |
| ↑24 | Mammucari, M., Maggiori, E., Russo, D., Giorgio, C., Ronconi, G., Ferrara, P.E., Cazona, F., Antonaci, L., Violo, B., Velluci, R., Mediati, D.R., Migliore, A., Massafra, U., Bifarini, B., Gori, F., di Carlo, M., Brauneis, S., Paolucci, T., Rocchi, P., Cugutti, A., Di Marzo, R., Bomprezzi, A., Santini, S., Giardini, M., Catizzone, A.R., Troili, F., Dorato, D., Gallo, A., Guglielmo, C., Natoli, S. (2020). Mesotherapy: From Historical Notes to Scientific Evidence and Future Prospects. ScientificWorldJournal. 3542848. Available at: https://doi.org/10.1155/2020/3542848 |
| ↑25 | Souto, E.B., Fangueiro, J.F., Fernandes, A.R., Cano, A., Sanchez-Lopez, E., Garcia, M.L., Severino, P., Paganelli, M.O., Chaud, M.V., Silva, A.M. (2022). Physicochemical and biopharmaceutical aspects influencing skin permeation and role of SLN and NLC for skin drug delivery. Heliyon. 8(2). e08938. Available at: https://doi.org/10.1016/j.heliyon.2022.e08938 |
| ↑26 | Moftah, N., Mubarak, R., Abdelghani, R. (2021). Clinical, trichoscopic, and folliscopic identification of the impact of metabolic syndrome on the response to intradermal dutasteride 0.02% injection in patients with female pattern hair loss: a prospective cohort study. 32(7). 827-836. Available at: https://doi.org/10.1080/09546634.2019.1708849 |
| ↑27, ↑28, ↑29 | Moftah, N., Mubarak, R., Abdelghani, R. (2019). Clinical, trichoscopic, and folliscopic identification of the impact of metabolic syndrome on the response to intradermal dutasteride 0.02% injection in patients with female pattern hair loss: a prospective cohort study. Journal of Dermatological Treatment. 32(7). Available at: https://doi.org/10.1080/09546634.2019.1708849 |
Oral finasteride remains the most clinically validated medication for androgenic alopecia (AGA). Over 20 years of trials and follow-up data show consistent, predictable outcomes in slowing miniaturization and restoring density, particularly in the vertex and mid-scalp.
Yet, despite this wealth of data, online forums and “miracle” before-and-after photos often distort expectations. These transformations represent the upper end of the response curve, while most users experience more moderate, steady results that unfold over months to years.
This article explores what realistic regrowth looks like with oral finasteride, how to interpret finasteride before and after photos critically, and what to expect when used correctly and consistently.
Oral finasteride is a type II 5ɑ-reductase inhibitor that reduces the conversion of testosterone to dihydrotestosterone (DHT), the key androgen responsible for hair follicle miniaturization in AGA.
Originally approved by the FDA at a dose of 1 mg for male pattern hair loss, oral finasteride has since become widely known as the gold-standard treatment for hair loss. Its primary mechanism is systemic DHT suppression, lowering circulating levels by roughly 60-70% and scalp DHT by up to 65%.[1]Caserini, M., Radicioni, M., Leuratti, C., Terragni, E., Iorizzo, M., Palmieri, R. (2016). Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men … Continue reading
As mentioned above, finasteride is a competitive inhibitor of the 5ɑ-reductase enzyme, specifically targeting the type II (and to a lesser extent, type III) isoenzymes.[2]Zito, P.M., Bistas, K.G., Patel, P., Syed, K. (2024). Finasteride. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513329/
Treatment with finasteride leads to a significant decrease in both scalp and serum DHT concentrations. This effect is dose-dependent and has been observed as early as 28 days after starting treatment.[3]Dallob, A.L., Sadick, N.S., Unger, W., Lipert, S., Geissler, L.A., Gregoire, S.L., Nguyen, H.H., Moore, E.C., Tanaka, W.K. (1994). The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp … Continue reading Lower DHT levels in the scalp prevent androgen-dependent miniaturization of hair follicles, promoting the maintenance and improvement of hair follicle size and number in the anagen (growth) phase.
Unlike topical formulations, oral finasteride exerts a systemic effect. More comprehensive, but also more likely to cause side effects in sensitive individuals.
The most commonly reported adverse effects of oral finasteride are sexual in nature, including decreased libido, erectile dysfunction, and reduced ejaculatory volume. These occur in a range of users depending on the study and determination of what a side effect is (<1% to 25%).[4]Traish, A.M., Hassani, J., Guay, A.T., Zitzmann, M., Hansen, M.L. (2011). Adverse side effects of 5ɑ-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and … Continue reading
Other potential side effects include psychological and neuropsychiatric effects and post-finasteride syndrome (PFS). PFS refers to persistent sexual, neurological, and physical symptoms that continue after stopping finasteride. However, the existence and prevalence of PFS are debated, with some studies suggesting a possible genetic predisposition.[5]Gupta, A.K., Talukder, M., Keene, S.A., Bamimore, M.A. (2025). Is the safety of finasteride correlated with its route of administration: topical versus oral? A pharmacovigilance study with data from … Continue reading
You can read in more depth about the potential side effects in our oral finasteride ultimate guide.
Finasteride is powerful and predictable, but even the best data can get lost when you see incredible results online. Online before-and-after posts tend to showcase outliers, individuals who happen to respond at the extreme high end of the efficacy curve.
Meanwhile, clinical averages show that:
Unrealistic expectations can lead to disappointment, early discontinuation, or cycling through treatments unnecessarily. Grounding expectations in clinical probabilities rather than forum anecdotes helps users stay consistent long enough to see results.
While oral finasteride can produce impressive regrowth, most users experience gradual thickening and stabilization rather than dramatic restoration.
Treatment outcomes typically follow a distribution pattern:
Factors influencing response:
Unlike many newer (and even potentially stronger acting treatments), oral finasteride benefits from decades of standardized data, making outcomes highly predictable. A good example of this is comparing finasteride to dutasteride. Finasteride is extremely well-studied; therefore, we can usually predict the type of results we will see. Dutasteride, on the other hand, has studies showing it can outperform even the likes of finasteride in terms of hair regrowth. But the number of clinical studies is lacking, meaning that it is more difficult to predict a consistent outcome.

Figure 1: For dutasteride, a wide, shallow curve represents a much wider spread of outcomes. For finasteride, a narrow bell curve shows predictable outcomes.
This predictability helps clinicians set clear, realistic expectations and provides users with confidence that consistency will lead to steady results.
The examples below help see what’s possible and do not represent what every user should expect. They are purely anecdotal and not independently verified by us or any qualified third party.

Source: u/Prize-Leg2544 via r/tressless.
This 23-year-old male took oral finasteride 1 mg daily for 2 months before titrating down to 1 mg every other day due to side effects. He also applied topical minoxidil foam twice daily, initially to the whole scalp but later exclusively to the hairline. He noted an initial shedding phase and early side effects on finasteride in the first month of treatment. In the second month, he described visible thickening while still on 1 mg daily. By month 3, he reduced finasteride to every other day and continued with minoxidil to maintain the progress. He reported marked improvement in hairline and density over the 3 months.
The user also described early transient effects, including testicular ache (first week), watery semen, heightened libido, and less intense orgasm, which resolved after dialing the finasteride down to every other day.

Source: u/zacboring via r/malehairadvice.
This male Redditor started treatment at age 24 after severe crown thinning since he was about 18. His one-year course consisted of finasteride 1 mg daily (generic), topical liquid minoxidil 1–2/day, and dermarolling roughly monthly (post-shower, before nightly minoxidil). He supplemented with vitamin D and occasional biotin, and he regularly used argan oil after showers to limit flaking.
The patient noted a strong early response, but felt his results peaked roughly halfway into treatment. He stopped minoxidil for 1 month and missed some doses in the months leading up to the post. His photos indicated a significant improvement in density compared to baseline, particularly at the hairline and the top. He noted more coverage at the crown but felt it was still noticeably weaker than desired. The patient reported no sexual side effects or skin issues.

Source: u/LongjumpingDurian429 via r/tressless.
This 24-year-old male’s intervention consisted of oral finasteride 1 mg once daily and oral minoxidil 2.5 mg once daily. The user noted the emergence of small baby hairs at the hairline and temples at month 2 of treatment. By months 4-5, he reported noticeable thickening, with longer eyelashes and denser eyebrows. By month 6, the user showed clear improvement, as evidenced by his wet-hair photos and day-to-day density. He reported visible density gains at the hairline with better coverage under bright light, with his crown improved from baseline, though not fully closed. He reported no side effects, apart from brief mild erectile difficulty early on that resolved.

Source: u/Buchaill-Bo via r/tressless.
This 24-year-old male’s intervention was oral finasteride 1 mg daily for 3 months, oral minoxidil 2.5 mg daily (added 2 weeks before the 3-month update), ketoconazole shampoo (Nizoral) about three times weekly, and dermaroller 1.5 mm once weekly over the whole scalp.
The user described gradual thickening over the 3-month finasteride course, with minoxidil introduced at month 2.5. He reported a noticeable improvement in density at the hairline and mid-scalp compared with baseline. He described a possible mild libido reduction on finasteride and thinning of the eyebrows thinned on finasteride, which appeared fuller after starting minoxidil. He reported no other significant effects.

Source: u/Moonrocks321 via r/tressless.
This 38-year-old male started the current treatment with oral finasteride 1 mg daily and topical minoxidil (strength/frequency not specified). He added topical finasteride (concentration not specified) and weekly microneedling at 0.25 mm in month 5. The patient reported a slight but noticeable improvement vs. baseline at month 5 and, at month 7, likewise described his progress as modest. In the 7 months, he achieved stabilization with modest density improvement, most visible anteriorly, with the crown remaining limited. He reported no side effects from finasteride and minoxidil.

Source: u/DatBronzeGuy via r/tressless.
This 28-year-old male reported on his 10-year treatment progress on oral finasteride 1 mg daily, before adding oral minoxidil 2.5 mg twice daily 4-5 months before the progress report. He confirmed no dermarolling or topical agent application. The patient reported that, between the ages of 18 and 27, he was on finasteride monotherapy, achieving significant regrowth and strong maintenance. Towards the end of that period, he reported subtle renewed thinning, prompting him to add oral minoxidil. Within 4 months thereafter, his hair density and thickness nearly doubled.
He reported good tolerance to finasteride with no noticeable side effects. He added that oral minoxidil caused mild generalized hypertrichosis (slightly darker chest/back hair, fuller beard, higher cheek/temple hairs), but was otherwise tolerated.

Source: u/danish0001 via r/tressless.
This 28-year-old male’s intervention included oral finasteride 1 mg daily, weekly microneedling with dermastamp 1.0–1.5 mm, and supplementation with vitamin D3 + K2, zinc, folate, magnesium glycinate, and ketoconazole 2% shampoo. Additionally, he made lifestyle adjustments, including going to the gym 2x/week and starting a higher-protein diet.
He noted a mild shedding phase in the first month of treatment. By month 2, he described the first visible tiny regrowth after a buzz cut, by which point the shedding had reduced. Overall, the patient described early regrowth at the hairline and thinning zones. He reported no side effects on finasteride 1 mg daily, stating that libido and energy have remained unchanged or improved.

Source: u/AthleteAfraid7844 via r/tressless.
This male Redditor’s intervention over 3 years was oral finasteride 1 mg daily and topical minoxidil (strength not specified).
In the first year, he noted steady cosmetic improvement, followed by continued thickening and maintenance of gains over years 2-3. Overall, the user reported substantial density gain, with perceived improvement in the hairline and temples over time. He mentioned no significant side effects and confirmed his sex drive had remained unchanged throughout treatment. He noted that the minoxidil sometimes caused dandruff and that on finasteride, he required greater mental focus to push weight-lifting sets to failure.

Source: u/Ill-Foundation2637 via r/tressless.

Source: u/Dantheghost012 via r/tressless.
This 25-year-old South Asian male’s intervention was oral finasteride 1.25 mg daily (5 mg tablets quartered) and oral minoxidil, starting at 2.5 mg daily, titrated to 5 mg after 3 months. He described a substantial shedding phase, particularly in the first 3 weeks of month 3. The following month, he reported progressive thickening and density gains with improved coverage. As of month 5.5, he is still improving and continuing both agents unchanged. Overall, he reported a marked increase in density, with a thicker texture, and the crown and hairline both looked fuller than baseline. He reported no side effects on either dose level for finasteride or oral minoxidil.
Based on the available research (which you can take a look at with our research tables here), we have created a probable hair regrowth timeline.

Figure 2: Typical regrowth for oral finasteride 1 mg.
Months 0-3: Adjustment Phase
In the first three months, most users experience minimal visible change. Finasteride actively lowers scalp and serum DHT levels, initiating follicle recovery. Some users notice a temporary increase in shedding as older hairs are shed to make way for new growth, while others observe subtle stabilization of hair loss.
Months 3-6: Reduction in Shedding
By this stage, a clear reduction in hair shedding often becomes noticeable. Although visible thickening remains limited for many, the treatment is beginning to normalize hair cycling. Early responders may report small areas of improved density, particularly in the crown or vertex.
Months 6-12: Early Cosmetic Improvements
Between 6 and 12 months, most responders start to see visible regrowth. Hair density gradually improves, strands appear thicker, and areas of thinning begin to fill in. The crown region typically shows improvement sooner than the frontal hairline, which tends to respond more slowly. Continued adherence is essential during this phase to sustain progress.
Months 12-24: Peak Response Period
During the second year, responders generally achieve their maximum results. Hair density, coverage, and stabilization reach their highest levels, with further visible gains possible in some individuals. Those starting with more advanced thinning usually experience consolidation rather than full growth.
Months 24+: Maintenance and Long-Term Stability
After two years, most users reach a plateau in visible improvement. Continued daily use of finasteride is needed to preserve these gains, as stopping the medication often results in gradual hair loss returning to baseline within 6-12 months. Some people combine treatments at this point to achieve further outcomes.
For most users, oral finasteride provides progressive, steady improvements over time, with long-term commitment being the key to maintaining results.
It’s important to set realistic expectations when starting any treatment. Finasteride primarily stabilizes hair loss during the early months, with noticeable growth typically developing later in the treatment course. True cosmetic improvement usually unfolds gradually over 12 to 24 months rather than weeks, reflecting the natural pace of the hair growth cycle.
Clinical trials suggest that most men experience visible thickening and halting of progression rather than full restoration, effectively “turning back the clock” by two to five years in terms of density and coverage.[11]Kaufman, K.D., Olson, E.A., Whiting, D., Savin, R., DeVillez, R., Bergfeld, W., Price, V.H., Van Neste, D., Roberts, J.L., Hordinsky, M., Shapiro, J., Binkowitz, B., Gormley, G.J. (1998). Finasteride … Continue reading,[12]Price, V.H., Roberts, J.L., Hordinsky, M., Olsen, E.A., Savin, R., Bergfeld, W., Fiedler, V., Lucky, A., Whiting, D.A., Pappas, F., Culbertson, J., Kotey, P., Meehan, A., Waldstreicher, J. (2000). … Continue reading,[13]Rossi, A., Mari, E., Scarno, M., Garelli, V., Maxia, C., Scali, E., Iorio, A., Carlesimo, M. (2012). Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a … Continue reading
Consistent photographic tracking using identical lighting and angles can help visualize these incremental gains. Long-term adherence is crucial, as discontinuation typically leads to renewed miniaturization and hair loss within several months of stopping treatment.
Oral finasteride remains the most extensively studied and clinically validated treatment for androgenic alopecia, offering predictable outcomes for most users through gradual thickening, stabilization of shedding, and preservation of existing hair rather than dramatic restoration. While newer options like oral minoxidil are gaining popularity, they remain off-label despite growing supportive evidence and should be used under medical supervision.
The key to achieving and maintaining meaningful results lies in consistency, patience, and realistic expectations, recognizing that hair regrowth is a slow, cumulative process measured over months and years. By grounding expectations in clinical evidence rather than anecdotal extremes, patients can make informed, balanced decisions and stay committed to a long-term plan that maximizes both safety and effectiveness.
References[+]
| ↑1 | Caserini, M., Radicioni, M., Leuratti, C., Terragni, E., Iorizzo, M., Palmieri, R. (2016). Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. International Journal of Clinical Pharmacology and Therapeutics. 54(1). 19-27. Available at: https://doi.org/10.5414/CP202467 |
|---|---|
| ↑2 | Zito, P.M., Bistas, K.G., Patel, P., Syed, K. (2024). Finasteride. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513329/ |
| ↑3 | Dallob, A.L., Sadick, N.S., Unger, W., Lipert, S., Geissler, L.A., Gregoire, S.L., Nguyen, H.H., Moore, E.C., Tanaka, W.K. (1994). The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. Journal of Clinical Endocrinology and Metabolism. 79(3). 703-706. Available at: https://doi.org/10.1210/jcem.79.3.8077349 |
| ↑4 | Traish, A.M., Hassani, J., Guay, A.T., Zitzmann, M., Hansen, M.L. (2011). Adverse side effects of 5ɑ-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. The Journal of Sexual Medicine. 872-884. Available at: https://doi.org/10.1111/j.1743-6109.2010.02157.x |
| ↑5 | Gupta, A.K., Talukder, M., Keene, S.A., Bamimore, M.A. (2025). Is the safety of finasteride correlated with its route of administration: topical versus oral? A pharmacovigilance study with data from the United States Food and Drug Administration adverse event reporting system. International Journal of Dermatology. Available at: https://doi.org/10.1111/ijd.17957 |
| ↑6 | Dhurat, R., Mathapati, S. (2015). Response to Microneedling Treatment in Men with Androgenetic Alopecia Who Failed to Respond to Conventional Therapy. Indian Journal of Dermatology. 60(3). 260-263. Available at: https://doi.org/10.4103/0019-5154.156361 |
| ↑7 | Camacho, F.M., Garcia-Hernandez, M.J., Fernandez-Crehuet, J.L. (2008). Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old. British Journal of Dermatology. 158(5). 1121-1124. Available at: https://doi.org/10.1111/j.1365-2133.2008.08509.x. |
| ↑8 | Yoshitake, T., Takeda, A., Ohki, K., Inoue, Y., Yamawaki, T., Otsuka, S., Akimoto, M., Nemoto, M., Shimakura, Y., Sato, A. (2015). Five-year efficacy of finasteride in 801 Japanese men with androgenetic alopecia. The Journal of Dermatology. 42(7). 735-738. Available at: https://doi.org/10.1111/1346-8138.12890 |
| ↑9 | Hu, R., Xu, F., Sheng, Y., Qi, S., Han, Y., Miao, Y., Rui, W., Yang, Q. (2015). Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients. Dermatologic Therapy. 28(5). 303-308. Available at: https://doi.org/10.1111/dth.12246 |
| ↑10 | Keene, S., Goren A. (2011). Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy. 24(2). 296-300. Available at: https://doi.org/10.1111/j.1529-8019.2011.01407.x. |
| ↑11 | Kaufman, K.D., Olson, E.A., Whiting, D., Savin, R., DeVillez, R., Bergfeld, W., Price, V.H., Van Neste, D., Roberts, J.L., Hordinsky, M., Shapiro, J., Binkowitz, B., Gormley, G.J. (1998). Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. Journal of the American Academy of Dermatology. 39(4 Pt 1), 578-589. Available at: https://doi.org/10.1016/s0190-9622(98)70007-6 |
| ↑12 | Price, V.H., Roberts, J.L., Hordinsky, M., Olsen, E.A., Savin, R., Bergfeld, W., Fiedler, V., Lucky, A., Whiting, D.A., Pappas, F., Culbertson, J., Kotey, P., Meehan, A., Waldstreicher, J. (2000). Lack of efficacy of finasteride in postmenopausal women with androgentic alopecia. Journal of the American Academy of Dermatology. 43(5 Pt 1). 768-776. Available at: https://doi.org/10.1067/mjd.2000.107953 |
| ↑13 | Rossi, A., Mari, E., Scarno, M., Garelli, V., Maxia, C., Scali, E., Iorio, A., Carlesimo, M. (2012). Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. International Journal of Immunopathology and Pharmacology. 25(4). 1167-1173. Available at: https://doi.org/10.1177/039463201202500435 |
Oral finasteride has established itself as a highly effective treatment for androgenic alopecia (AGA) and is widely prescribed around the globe. Its success can be largely attributed to its proven ability to slow hair loss and stimulate regrowth by inhibiting the conversion of testosterone to DHT, the hormone chiefly responsible for follicular miniaturization.
However, despite its well-documented efficacy, oral finasteride has become equally notorious for its potentially systemic side effects. Some men experience adverse effects such as decreased libido, erectile dysfunction, mood changes, and even persistent symptoms after discontinuation, a phenomenon called post-finasteride syndrome.[1]Diviccaro, S., Melcangi, R.C., Giatti, S. (2019). Post-finasteride syndrome: an emerging clinical problem. Neurobiology of Stress. 12. 100209. Available at: https://doi.org/10.1016/j.ynstr.2019.100209 This reputation has prompted many to seek alternatives that are both effective and safer for long-term use.
Recently, topical finasteride formulations have garnered attention as a promising alternative. By delivering the medication directly to the scalp, topical finasteride aims to minimize systemic absorption and thereby reduce the likelihood of side effects while still providing the benefits of DHT inhibition where it matters most. This alternative approach has piqued the interest of both patients wary of systemic issues and clinicians seeking tailored treatments.
In this article, we will examine whether topical finasteride can serve as a viable alternative to its oral counterpart. The main focus will be on answering three questions:
Ulo offers finasteride options that range from low to high dose finasteride – allowing you to be flexible in your treatment choices.
Low-dose & full-strength finasteride available, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
Some research directly compares oral finasteride (1 mg daily) with various concentrations of topical finasteride, aiming to match hair regrowth efficacy while minimizing systemic side effects. Let’s take a look at a couple of examples:
Finasteride is a competitive inhibitor of 5α-reductase, primarily targeting the type II isoenzyme at therapeutic doses, which predominates in the hair follicles and prostate. As mentioned above, this enzyme catalyzes the conversion of testosterone to DHT.
At higher tissue concentrations, finasteride can also inhibit type I 5α-reductase, which is primarily found in the skin and sebaceous glands; however, its clinical significance for hair loss at standard doses is limited. By selectively inhibiting the type II enzyme, finasteride effectively lowers local and systemic DHT levels.[5]Finn, D.A., Beadles-Bohling, A., Beckley, E.H., Ford, M.M., Gililland, K.R., Gorin-Meyer, R.E., Wiren, K.M. (2006). 12(1). 53-76. A New Look at the 5α-reductase Inhibitor Finasteride. CNS Drug … Continue reading
Finasteride’s effect on DHT suppression is characterized by a logarithmic dose-response curve, meaning that even very low systemic levels can produce a marked reduction in both serum and scalp DHT. Most of the drug’s inhibitory action is achieved at low doses, with additional dosing yielding only marginal further effect.
As a result, even minimal “leakage” of topically applied finasteride into the bloodstream can decrease DHT levels elsewhere in the body.
Pharmacokinetic studies show that inhibition of type-II 5ɑ-reductase reaches saturation at typical clinical dosage, while type-1 enzyme inhibition requires much higher concentrations. This nonlinear pharmacodynamic profile explains both the strong efficacy and the wide safety margin of topical finasteride: a small amount achieves most of the desired effect, so careful formulation is crucial to maximize scalp delivery while minimizing unwanted systemic exposure.[6]Suzuki, R., Satoh, H., Ohtani, H., Hori, S., Sawada, Y. (2010). Saturable Binding of Finasteride to Steroid 5ɑ-reductase as Determinant of Nonlinear Pharmacokinetics. Drug Metabolism and … Continue reading
Topical finasteride has been studied across a 200-fold concentration range, from 0.005% solutions to 1% gels. Collectively, these trials demonstrate meaningful reductions in shedding and measurable regrowth; however, systemic exposure increases with dose and vehicle potency.
| Study | Concentration & Vehicle | Hair Growth-Outcomes | Systemic/Serum Findings |
| Mazzarella 1997, single-blind, 52 men/women, 16 months. | 0.005% hydro-alcoholic solution | 73% reported “high effectiveness”; wash-test hair counts improved; slowed shedding by month 6 | No significant change in plasma DHT or testosterone; absorption was negligible. |
| Tanglertsampan 2012 RCT, 33 men, 24 weeks. | 0.1% lotion + 3% minoxidil | The combination arm gained more hairs/cm2 and thicker shafts than minoxidil alone. | Local irritation mild; systemic parameters not monitored. |
| Datta 2021 double-blind trial, 35 participants completed, 6 months. | 0.1% lotion +5% minoxidil vs oral 1 mg. | The topical combination was non-inferior to oral minoxidil for reducing the Hamilton-Norwood stage. | Sexual adverse events only occurred in the oral group; topical was well-tolerated. |
| Caserini 2016 OK study, 50 men, 1 week; Piraccini 2022 phase III, 323 completers, 24 weeks. | 0.25% solution. | -70% scalp DHT after once-daily 1 mL; +20.2 hairs in 1 cm2 target area at 24 weeks – numerically equal to oral 1 mg. | 100-200 μL doses reduced serum DHT by only 24-26%; 400 μL treatment reduced levels by 44-48%; Cmax was more than 100 times lower than oral. |
| Rossi 2020 retrospective, 69 women, 12-18 months. | 0.5% lotion (postmenopausal women) | The Finasteride + minoxidil group scored higher on a 7-point global scale compared to the 17ɑ-estradiol + minoxidil group. | No androgenic side effects reported. |
| Hajheydari 2009 DB-RCT, 45 men, 6 months. | 1% gel | Increases in total and terminal hair counts matched those of oral 1 mg; the bald area remained unchanged. | Serum DHT not assayed; clinical side-effects minimal. |
Even a micro-dose of 0.005% twice daily (~0.1 mg/day) curbed shedding and improved density without measurable systemic suppression, making it an attractive option for highly risk-averse users.[7]Mazzarella, F., Loconsole, F., Cammisa, A., Mastrolonardo, M., Vena, G.A. (1997). Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. … Continue reading
Adding 0.1% finasteride to minoxidil amplifies regrowth compared to minoxidil alone, while standalone 0.25% sprays deliver oral-level scalp DHT blockade, maintaining serum exposure roughly one-tenth that of tablets. Dose and volume are critical.[8]Caserini, M., Radicioni, M., Leuratti, C., Terragni, E., Iorizzo, M., Palmieri, R. (2016). Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men … Continue reading
Topical finasteride options at 0.5% have been shown to extend benefits to female pattern hair loss with good tolerability.[9]Rossi, A., Magri, F., D’Arino, A., Pigliacelli, F., Muscianese, M., Leoncini, P., Caro, G., Federico, A., Fortuna, M.C., Carlesimo, M. (2020). Efficacy of Topical Finasteride 0.5% vs 17ɑ-Estradiol … Continue reading
While topical finasteride offers an option for minimizing systemic exposure, several key variables influence the amount that enters the bloodstream, and this can occur surprisingly quickly.
To achieve the best results and reduce the likelihood of side effects, there are several strategies you can employ:
Before starting topical finasteride, get a baseline measurement of your serum DHT levels through a blood test. This serves as a reference to assess the extent to which systemic DHT is affected by your treatment.
After one month of consistent topical use, repeat the serum DHT test under the same conditions (preferably in the morning, fasted, and at a similar time of day). This helps you gauge systemic absorption and adjust your regimen if your serum DHT levels drop excessively. Hormone levels fluctuate based on daily rhythms, food intake, and stress, so always test under similar circumstances: morning, fasted, and ideally before applying the day’s finasteride.
Avoid supplements that may directly affect DHT, such as those that increase DHT (e.g., creatine) or quercetin (which may lower it). This ensures your test results and progress are a direct reflection of the topical finasteride.[12]van der Merwe, J., Brooke, N.E., Myburgh, K.H. (2009). Three weeks of creatine monohydrate supplementation affects dihydrotestosterone to testosterone ratio in college-aged rugby players. Clinical … Continue reading,[13]Ma, Z., Nguyen, T.H., Huynh, T.H., Do, P.T., Huynh, H. (2004). Reduction of rat prostate weight by combined quercetin-finasteride treatment is associated with cell cycle deregulation. Journal of … Continue reading
Visible improvements often require 12-24 months. Don’t make hasty adjustments if you don’t see immediate changes; hair cycles are slow.
Use standardized, high-quality photo documentation, same angle, lighting, and distance each time, to objectively monitor changes in hair density and coverage.
Robust evidence supports the use of combination therapies for AGA, with multi-modal approaches consistently outperforming monotherapy in terms of efficacy and speed of regrowth.
Finasteride + Minoxidil: Studies show that pairing topical finasteride with 5% minoxidil yields superior hair density and patient satisfaction compared to either agent alone, particularly after 24 weeks of treatment.[14]Apoorva, V.B., Vibhu, M., Singh, R.H., Smita, T. (2023). Comparative Efficacy of Topical Finasteride (0.25%) in Combination with Minoxidil (5%) Against 5% Minoxidil or 0.25% Finasteride Alone in Male … Continue reading,[15]Rossi, A., Caro, G. (2023). Efficacy of the association of topical minoxidil and topical finasteride compared to their use in monotherapy in men with androgenetic alopecia: A prospective, randomized, … Continue reading,[16]Abeck, F., Hansen, I., Kott, J., Schroder, F., Garrahy, E., Veneroso, J., Runger, A., Torster, L., Schneider, S.W., von Buren, J. (2024). Patient-reported outcomes of topical finasteride/minoxidil … Continue reading This combination is effective for both new users and those who have experienced shedding after discontinuing oral finasteride.

Figure 1: Effect of combination minoxidil and finasteride or monotherapy treatment on global photographic assessment score at T3 (3 months) and T6 (six months).[17]Rossi, A., Caro, G. (2023). Efficacy of the association of topical minoxidil and topical finasteride compared to their use in monotherapy in men with androgenetic alopecia: A prospective, randomized, … Continue reading Image obtained in line with the Creative Commons License.
Finasteride + Microneedling: Adding microneedling to topical therapy can significantly enhance outcomes. Clinical trials demonstrated that combining microneedling with minoxidil and/or finasteride increased hair density and shaft diameter more than minoxidil alone, with effects noticeable within just 12 weeks.[18]Chang, Y., Zhang, W., Zhou, J., Lv, L., He, Q., Chen, Y., Wang, P., Zhai, Q. (2025). Clinical efficacy of microneedle combined with 5% Minoxidil solution and finasteride in the treatment of … Continue reading,[19]Adistri, K., Sirait, S.P., Rihatmadja, R., Legiawati, L., Indriatmi, W., Saldi, S.R.F. (2024). Effectiveness and safety of the combination therapy of micro-needling and minoxidil in androgenetic … Continue reading
Triple Topical Therapy: Preliminary studies on formulations that combine finasteride, dutasteride, and minoxidil show promising results, with visible regrowth as early as three months in some cases.[20]Rafi, A.W., Katz, R.M. (2011). Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of Atopy on AGA. ISRN Dermatology. 241953. Available at: … Continue reading
So, combination therapy appears to be more effective than monotherapy. Therefore, leveraging two or more topical therapies or adding microneedling can support hair regrowth outcomes.
Good Candidates:
Not Ideal For:
Topical finasteride is a legitimate option for hair regrowth. When formulated and used properly, it can rival oral finasteride’s effectiveness with a lower risk of systemic side effects. Success hinges on the right delivery method, correct dilution, and consistent application. While not flawless, it excels as part of a comprehensive regimen, especially when paired with therapies like minoxidil or microneedling.
For those hesitant about oral medication, topical finasteride offers a practical, lower-risk compromise, provided users carefully follow evidence-based protocols to optimize both safety and results. Used strategically, it is a potent addition to hair loss treatment plans.
References[+]
| ↑1 | Diviccaro, S., Melcangi, R.C., Giatti, S. (2019). Post-finasteride syndrome: an emerging clinical problem. Neurobiology of Stress. 12. 100209. Available at: https://doi.org/10.1016/j.ynstr.2019.100209 |
|---|---|
| ↑2 | Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., Falques, M., Otero, R., Tamarit, M.L., Galvan, J., Tebbs, V., Massana, E., Topical Finasteride Study Group. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III randomized, controlled clinical trial. JEADV. 36(2). 286-294. Available at: https://doi.org/10.1111/jdv.17738 |
| ↑3 | Bhura, M. (2013). Comparative Analysis of Topical and Oral Finasteride in Androgenetic Alopecia: Impact on Hair Growth, Systemic Absorption, and Adverse Effects. Indian Journal of Basic and Applied Medical Research. 3(1). 436-444 |
| ↑4 | Hajheydari, Z., Akbari, J., Saeedi, M., Shokoohi, L. (2009). Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian Journal of Dermatology, Venereology, and Leprology. 75(1). 47-51. Available at: https://doi.org/10.4103/0378-6323.45220 |
| ↑5 | Finn, D.A., Beadles-Bohling, A., Beckley, E.H., Ford, M.M., Gililland, K.R., Gorin-Meyer, R.E., Wiren, K.M. (2006). 12(1). 53-76. A New Look at the 5α-reductase Inhibitor Finasteride. CNS Drug Reviews. Available at: https://doi.org/10.1111/j.1529-3458.2006.00053.x |
| ↑6 | Suzuki, R., Satoh, H., Ohtani, H., Hori, S., Sawada, Y. (2010). Saturable Binding of Finasteride to Steroid 5ɑ-reductase as Determinant of Nonlinear Pharmacokinetics. Drug Metabolism and Pharmacokinetics. 25(2). 208-213. Available at: https://doi.org/10.2133/dmpk.25.208 |
| ↑7 | Mazzarella, F., Loconsole, F., Cammisa, A., Mastrolonardo, M., Vena, G.A. (1997). Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. Journal of Dermatological Treatment. 8. 189-192. |
| ↑8 | Caserini, M., Radicioni, M., Leuratti, C., Terragni, E., Iorizzo, M., Palmieri, R. (2016). Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. International Journal of Clinical Pharmacology and Therapeutics. 54(1). 19-27. Available at: https://doi.org/10.5414/CP202467 |
| ↑9 | Rossi, A., Magri, F., D’Arino, A., Pigliacelli, F., Muscianese, M., Leoncini, P., Caro, G., Federico, A., Fortuna, M.C., Carlesimo, M. (2020). Efficacy of Topical Finasteride 0.5% vs 17ɑ-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients. Dermatology Practical & Conceptual. 10(2). E2020039. Available at: https://doi.org/10.5826/dpc.1002a39 |
| ↑10 | Rao, Y., Zheng, F., Zhang, X., Gao, J., Liang, W. (2008). In Vitro Percutaneous Permeation and Skin Accumulation of Finasteride Using Vesicular Ethosomal Carriers. AAPS PharmSciTech. 9(3). 860-865. Available at: https://doi.org/10.1208/s12249-008-9124-y |
| ↑11 | Brito, S., Baek, M., Bin, B-H. (2024). Skin Structure, Physiology, and Pathology in Topical and Transdermal Drug Delivery. Pharmaceutics. 16(11). 1403. Available at: https://doi.org/10.3390/pharmaceutics16111403 |
| ↑12 | van der Merwe, J., Brooke, N.E., Myburgh, K.H. (2009). Three weeks of creatine monohydrate supplementation affects dihydrotestosterone to testosterone ratio in college-aged rugby players. Clinical Journal of Sports Medicine. 19(5). 399-404. Available at: https://doi.org/10.1097/JSM.0b013e3181b8b52f. |
| ↑13 | Ma, Z., Nguyen, T.H., Huynh, T.H., Do, P.T., Huynh, H. (2004). Reduction of rat prostate weight by combined quercetin-finasteride treatment is associated with cell cycle deregulation. Journal of Endocrinology. 181(3). 493-507. Available at: https://doi.org/10.1677/joe.0.1810493 |
| ↑14 | Apoorva, V.B., Vibhu, M., Singh, R.H., Smita, T. (2023). Comparative Efficacy of Topical Finasteride (0.25%) in Combination with Minoxidil (5%) Against 5% Minoxidil or 0.25% Finasteride Alone in Male Androgenetic Alopecia: A Pilot, Randomized, Open-Label Study. International Journal of Trichology. 15(2). 56-62. Available at: https://doi.org/10.4103/ijt_ijt_72_22 |
| ↑15 | Rossi, A., Caro, G. (2023). Efficacy of the association of topical minoxidil and topical finasteride compared to their use in monotherapy in men with androgenetic alopecia: A prospective, randomized, controlled, assessor-blinded, 3-arm, pilot trial. Journal of Cosmetic Dermatology. 23(2). 502-509. Available at: https://doi.org/10.1111/jocd.15953 |
| ↑16 | Abeck, F., Hansen, I., Kott, J., Schroder, F., Garrahy, E., Veneroso, J., Runger, A., Torster, L., Schneider, S.W., von Buren, J. (2024). Patient-reported outcomes of topical finasteride/minoxidil treatment for male androgenetic alopecia: A retrospective study using telemedical data. Journal of Cosmetic Dermatology. 23(9). 2956-2963. Available at: https://doi.org/10.1111/jocd.16360 |
| ↑17 | Rossi, A., Caro, G. (2023). Efficacy of the association of topical minoxidil and topical finasteride compared to their use in monotherapy in men with androgenetic alopecia: A prospective, randomized, controlled, assessor-blinded, 3-arm, pilot trial. Journal of Cosmetic Dermatology. 23(2). 502-509. Available at: https://doi.org/10.1111/jocd.15953 |
| ↑18 | Chang, Y., Zhang, W., Zhou, J., Lv, L., He, Q., Chen, Y., Wang, P., Zhai, Q. (2025). Clinical efficacy of microneedle combined with 5% Minoxidil solution and finasteride in the treatment of androgenetic alopecia in males. Archives of Dermatological Research. 317(428). Available at: https://doi.org/10.1007/s00403-025-03891-y |
| ↑19 | Adistri, K., Sirait, S.P., Rihatmadja, R., Legiawati, L., Indriatmi, W., Saldi, S.R.F. (2024). Effectiveness and safety of the combination therapy of micro-needling and minoxidil in androgenetic alopecia of Indonesian men: a randomized controlled trial. Dermatology Reports. 16(3). 9945. Available at: https://doi.org/10.4081/dr.2024.9945 |
| ↑20 | Rafi, A.W., Katz, R.M. (2011). Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of Atopy on AGA. ISRN Dermatology. 241953. Available at: https://doi.org/10.5402/2011/241953 |
Topical minoxidil is a first-line treatment for female pattern hair loss (FPHL) and other conditions such as telogen effluvium and traction alopecia. Many women of reproductive age use minoxidil and may wonder about its safety when trying to conceive or in early pregnancy.
While most reproductive safety discussions focus on oral or systemic medications, even topically applied drugs can raise questions about potential effects on fertility or early fetal development. Although systemic absorption from topical formulations is low, uncertainty persists regarding potential hormonal or embryonic effects.
This article examines available evidence to evaluate whether topical minoxidil poses any risk to female fertility or conception. By reviewing preclinical studies and clinical and pharmacological data, we aim to clarify whether there is any risk associated with topical minoxidil when trying to conceive.
High-strength topical minoxidil available, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
Minoxidil may promote hair growth through several complementary mechanisms. After topical application, the drug is enzymatically converted by sulfotransferase (SULT1A1) into minoxidil sulfate, its active form. This metabolite enhances potassium channel activity within follicular cells, promoting cell proliferation and prolonging the anagen (growth) phase of the hair cycle. Additionally, minoxidil increases vascularity around the follicle by stimulating vascular endothelial growth factor (VEGF), improving oxygen and nutrient delivery to support stronger, thicker hair growth.[1]Suchonwanit, P., Thammarucha, S., & Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy. 13. 2777-2786. Available at: … Continue reading
There are important pharmacological distinctions between topical and oral formulations. Topical minoxidil acts locally on the scalp with minimal systemic absorption, which significantly reduces the risk of adverse effects. In contrast, oral minoxidil can cause systemic side effects, such as fluid retention, weight gain, increased blood pressure (hypertension), and other cardiovascular changes.[2]StatPearls Editorial Team. (no date). Minoxidil. In: StatPearls [Internet]. StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK482378/ (Accessed: October 2025)
Female fertility relies on coordinated hormonal cycles, healthy egg development, and a receptive uterine environment. Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) regulate ovulation, while estrogen and progesterone prepare the uterus for implantation and support early pregnancy.[3]Thiyagarajan, D. K., Basit, H., & Jeanmonod, R. (2024 Jan 1). Physiology, menstrual cycle. In: StatPearls [Internet]. StatPearls Publishing. Available at: … Continue reading In addition to hormonal balance, healthy reproductive anatomy is important: clear fallopian tubes, a healthy uterus, and a cervix free of significant abnormalities are required for fertilization and embryo implantation.[4]Mayo Clinic Staff. (no date). Female infertility – Symptoms & causes. Available at: https://www.mayoclinic.org/diseases-conditions/female-infertility/symptoms-causes/syc-20354308/ (Accessed: … Continue reading
Of course, women, or individuals who are female at birth, looking to conceive also need to consider the impact of medications following conception. The safe use of medications is essential to support maternal health and healthy fetal development while minimizing risks of complications and birth defects (teratogenic effects).
Systemic medications can interfere with fertility and pregnancy by disrupting hormonal balance or exerting teratogenic effects. For example, antiandrogens such as spironolactone, cyproterone acetate, and finasteride, sometimes prescribed for female hair loss, are contraindicated when trying to conceive due to their potential impact on fetal development.[5]BinJadeed, H. F., & Alajlan, A. (2021). Pregnancy and neonatal outcome with maternal exposure to finasteride: a case series. Journal of Dermatology and Dermatologic Surgery. 25(2). 84-86. … Continue reading,[6]Wu, M., Yu, Q., & Li, Q. (2016). Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Oncotarget. 7(50). 82074-82084. … Continue reading Animal models suggest these agents interfere with androgen signaling, which is essential for normal sexual differentiation, particularly in male fetuses.[7]Conley, J. M., Lambright, C. S., Evans, N., Cardon, M., Furr, J., Wilson, V. S., & Gray Jr, L. E. (2018). Mixed “antiandrogenic” chemicals at low individual doses produce reproductive tract … Continue reading In contrast, nutritional supplements like iron, vitamin D, and biotin are generally safe and can support overall reproductive health.
Topical minoxidil is formulated to act locally on the scalp, with only a small proportion entering systemic circulation – typically around 1–2%.[8]Suchonwanit, P., Thammarucha, S., & Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy. 13. 2777-2786. Available at: … Continue reading Pharmacokinetic studies show that this absorption rate can vary depending on several factors, including formulation strength (2% vs. 5%), frequency of application, and the integrity of the scalp barrier. Plasma minoxidil levels in individuals using topical formulations generally remain well below those associated with systemic pharmacologic or reproductive effects observed in animal studies.[9]Singh, S., Patil, A., Kianfar, N., Waśkiel-Burnat, A., Rudnicka, L., Sinclair, R., & Goldust, M. (2022). Does topical minoxidil at concentrations higher than 5% provide additional clinical … Continue reading,[10]Hsu, C. L., Liu, J. S., Lin, A. C., Yang, C. H., Chung, W. H., & Wu, W. G. (2014). Minoxidil may suppress androgen receptor‐related functions. Oncotarget. 5(8). 2187-2197. Available at: … Continue reading
By contrast, oral minoxidil is almost completely absorbed, leading to significantly higher plasma concentrations and systemic exposure. This explains why oral therapy, though often more potent, also carries a greater risk of systemic side effects, including edema, tachycardia, and generalized hypertrichosis.[11]Randolph, M., & Tosti, A. (2021). Oral minoxidil treatment for hair loss: a review of efficacy and safety. Journal of the American Academy of Dermatology. 84(3). 737-746. Available at: … Continue reading
When considering the impact of medications on women’s fertility and ability to conceive, it is also essential to review the evidence regarding potential effects during pregnancy, as treatments will inevitably continue to be taken into early pregnancy, and systemic effects may be long-lasting. Here, we review preclinical and clinical evidence on whether topical minoxidil affects female fertility and pregnancy.
Minoxidil is classified as a non-hormonal treatment, suggesting it is unlikely to impact hormonal cycles that impact fertility. However, due to the relationship between hair growth and hormonal pathways, some preclinical research has focused on how minoxidil affects androgen pathways.
One cell-based study suggests that minoxidil can directly interact with and weaken androgen receptor signaling. However, this study used higher concentrations of minoxidil than would be used in hair loss treatment, and for practical purposes, topical minoxidil remains classified as a non-hormonal treatment.[12]Hsu, C. L., Liu, J. S., Lin, A. C., Yang, C. H., Chung, W. H., & Wu, W. G. (2014). Minoxidil may suppress androgen receptor‐related functions. Oncotarget. 5(8). 2187-2197. Available at: … Continue reading
However, in an animal model using golden Syrian hamsters, 5% topical minoxidil did not prevent the androgen-dependent growth of pigmented spots, suggesting that minoxidil does not have any effect on androgen response.[13]Nuck, B. A., Fogelson, S. L., & Lucky, A. W. (1987). Topical minoxidil does not act as an antiandrogen in the flank organ of the golden Syrian hamster. Archives of Dermatology. 123(1). 59-61. … Continue reading
There is a significant lack of research using preclinical animal models investigating the impact of topical minoxidil on female fertility and during pregnancy. However, one small-scale study did examine the effect of 5% topical minoxidil on embryonic mortality in rats. They found no impact of daily minoxidil application over the course of 20 days of pregnancy compared to the control group. However, the sample size was relatively small (20 rats in total), and no molecular or cellular analysis was performed to look for potential mechanisms that could cause embryonic lethality.[14]Turkina, V. A., Chemodurova, N. Y., Pryzyglei, H. V., & Kuzminov, Y. B. (2021). Potential embryotoxic effect study of minoxidil-containing lotion in experiment with female rats. Світ … Continue reading
Unfortunately, a lack of research into the impact of medications on women and fetuses during pregnancy is a systemic issue within medicine. Pregnant women are generally excluded from clinical trials due to safety concerns, as well as the confounding impact of widespread hormonal changes associated with pregnancy.[15]Stock, S. J., & Norman, J. E. (2019). Medicines in pregnancy. F1000Research. 8(F1000Faculty Rev):911. Available at: https://doi.org/10.12688/f1000research.17535.1 These issues extend to women trying to conceive, and most clinical trials have explicit protocols that remove individuals from clinical trials after they become pregnant.[16]Phelan, A. L., Kunselman, A. R., Chuang, C. H., Raja-Khan, N. T., & Legro, R. S. (2016). Exclusion of women of childbearing potential in clinical trials of type 2 diabetes medications: a review … Continue reading
The safety of medications for pregnant women and their children is typically established after drugs have come to market, through observational studies and pharmacovigilance, which looks for cases where problems have arisen. While such processes are good at spotting signals of high risk, these forms of evidence are less powerful than clinical trials and cannot detect less impactful effects.
As such, determining the safety of drugs for pregnant women is often done using scarce information. As a result, many medications are contraindicated (their use is advised against) for pregnant women due to a lack of evidence, not because of evidence.[17]Thomas, S. H., & Yates, L. M. (2012). Prescribing without evidence – pregnancy. British Journal of Clinical Pharmacology. 74(4). 691-697. Available at: … Continue reading
Multiple reviews of the safety of dermatological treatments in pregnant women advise against the use of monoxidil.[18]Koh, Y. P., Tian, E. A., & Oon, H. H. (2019). New changes in pregnancy and lactation labelling: Review of dermatologic drugs. International Journal of Women’s Dermatology. 5(4). 216-226. … Continue reading,[19]Truong, T. M., Yaghi, M., & Murase, J. (2023). Dermatologic Drug Safety in Pregnancy. Journal of Dermatology for Physician Assistants. 17(3). 1-12. Available at: … Continue reading,[20]Suchonwanit, P., Thammarucha, S., & Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy. 13. 2777–2786. Available at: … Continue reading However, this advice appears to be based on two case studies where topical minoxidil was theorized as the cause of the birth defects. Case studies present a single individual (or group of individuals) where an event or phenomenon has occurred. They are a weak form of evidence and are typically used as the basis for larger studies.
In one of these case studies, the pregnancy of a 28-year-old woman who was applying topical minoxidil was terminated due to the presence of fetal malformation. Topical minoxidil was suggested as a possible cause of teratogenesis.[21]Smorlesi, C., Caldarella, A., Caramelli, L., Di Lollo, S., & Moroni, F. (2003). Topically applied minoxidil may cause fetal malformation: a case report. Birth Defects Research Part A: Clinical … Continue reading The other study noted a case of a rare condition called caudal regression syndrome in a fetus where the mother had been using topical minoxidil, though other causes were also proposed.[22]Rojansky, N., Fasouliotis, S. J., Ariel, I., & Nadjari, M. (2002). Extreme caudal agenesis. Possible drug-related etiology?. Journal of the American Academy of Dermatology. 47(3). 241-245. … Continue reading These cases were published in 2002 and 2003, and both advised that further studies were warranted.
In a more systematic approach, one study analysed FDA Adverse Event Reporting System (FAERS) data, which collects evidence of adverse effects related to medications.[23]Wu, M., Yu, Q., & Li, Q. (2016). Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Oncotarget. 7(50). 82074-82084. … Continue reading The study used data collected between 2004 and 2014. Over the ten years analyzed, 2 cases of induced abortion and 2 cases of spontaneous abortion were reported in women using minoxidil. This represents around 2% of cases reported. For comparison, induced abortion represented around 18% of reported adverse effects related to finasteride, for which it was the most commonly reported issue. No cases related to sexual dysfunction or loss of libido were reported.

Figure 1: Comparison between adverse events reported by female alopecia areata patients exposed to finasteride and minoxidil. Adapted from Table 4.[24]Wu, M., Yu, Q., & Li, Q. (2016). Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Oncotarget. 7(50). 82074-82084. … Continue reading Image used in accordance with the PMC Creative Commons Licence.
It is due to the lack of evidence and the potential issues that these case studies raise that minoxidil is typically contraindicated for women who are trying to conceive or are pregnant. There is no evidence to suggest that minoxidil has any impact on female fertility. Larger observational and controlled studies would be required to make evidence-based conclusions regarding the safety of minoxidil for women trying to conceive.
There is no direct evidence linking topical minoxidil to reduced fertility. The use of topical minoxidil is advised against for women trying to conceive due to a small number of reported cases where topical minoxidil was associated with fetal abnormalities.
The Food and Drug Administration (FDA) classifies topical minoxidil as a pregnancy category C drug. This means studies have shown a risk to the fetus, but there are no adequate, controlled studies in pregnant women. Such drugs are generally only prescribed if there is a significant benefit to the mother that outweighs potential risks. As such, a review published by the American Academy of Dermatology in 2025 advises against using minoxidil while pregnant.[25]Olsen, E. A., Sinclair, R., Hordinsky, M., Mesinkovska, N. A., Sadick, N., Shapiro, J., & Bergfeld, W. (2025). Summation and recommendations for the safe and effective use of topical and oral … Continue reading In the UK, the National Institute for Health and Care Excellence (NICE) also advises against the use of topical minoxidil when pregnant or breastfeeding.[26]National Institute for Health and Care Excellence. (no date). Female-pattern hair loss (female androgenetic alopecia) — Prescribing information: Topical minoxidil. Available at: … Continue reading
There is no evidence to suggest that topical minoxidil can impact fertility in women. There are a very limited number of cases reported where minoxidil has been associated with impotence in men.[27]Rietschel, R. L., & Duncan, S. H. (1987). Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. Journal of the American Academy of Dermatology. 16(3). 677-685. … Continue reading
There is limited research into the effect of minoxidil on female hormones or ovulation. However, minoxidil is not a hormonal drug, and there is limited evidence to suggest that it interferes significantly with hormones at levels associated with topical treatment.
While there is no evidence that minoxidil can impact women’s ability to conceive, it is not advised to use the treatment while pregnant. Therefore, it is recommended to stop using minoxidil while trying to conceive.[28]Olsen, E. A., Sinclair, R., Hordinsky, M., Mesinkovska, N. A., Sadick, N., Shapiro, J., & Bergfeld, W. (2025). Summation and recommendations for the safe and effective use of topical and oral … Continue reading
There are limited case reports that associate topical minoxidil with birth defects and fetal malformation, leading to termination. These findings have not been expanded on by larger trials or observational studies.[29]Smorlesi, C., Caldarella, A., Caramelli, L., Di Lollo, S., & Moroni, F. (2003). Topically applied minoxidil may cause fetal malformation: a case report. Birth Defects Research Part A: Clinical … Continue reading,[30]Rojansky, N., Fasouliotis, S. J., Ariel, I., & Nadjari, M. (2002). Extreme caudal agenesis. Possible drug-related etiology?. Journal of the American Academy of Dermatology. 47(3). 241-245. … Continue reading
Different hair loss treatments have fundamentally different mechanisms. Finasteride and dutasteride are hormonally active and may impact male fertility and fetal development.[31]BinJadeed, H. F., & Alajlan, A. (2021). Pregnancy and neonatal outcome with maternal exposure to finasteride: a case series. Journal of Dermatology and Dermatologic Surgery. 25(2). 84-86. … Continue reading,[32]Wu, M., Yu, Q., & Li, Q. (2016). Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Oncotarget. 7(50). 82074-82084. … Continue reading Risks associated with minoxidil are significantly less well established, and adverse reproductive events have been shown to be significantly lower than finasteride.[33]Wu, M., Yu, Q., & Li, Q. (2016). Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Oncotarget. 7(50). 82074-82084. … Continue reading
There is a significant gap in our knowledge of whether minoxidil affects pregnancy and the mechanisms by which it might do so. Data from preclinical models has focused on hair cycle dynamics rather than reproductive parameters, with only limited research on its impact on androgenic hormonal pathways.
Both of the case studies that associated topical minoxidil with adverse pregnancy outcomes are over 20 years old, with no follow-up studies to better understand these reports. Clinical trials or observational studies would be necessary to make evidence-based assessments on the safety of minoxidil during pregnancy and its impact on female fertility.
Current evidence does not show that topical minoxidil impairs fertility or conception. However, because pregnancy safety data remain incomplete, discontinuation is recommended when planning conception – a precautionary measure rather than a proven necessity.
For women experiencing distressing hair loss, treatment decisions should balance cosmetic benefit with potential but unproven reproductive risk, ideally in consultation with a dermatologist or reproductive health specialist.
References[+]
| ↑1, ↑8 | Suchonwanit, P., Thammarucha, S., & Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy. 13. 2777-2786. Available at: https://doi.org/10.2147/DDDT.S214907 |
|---|---|
| ↑2 | StatPearls Editorial Team. (no date). Minoxidil. In: StatPearls [Internet]. StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK482378/ (Accessed: October 2025) |
| ↑3 | Thiyagarajan, D. K., Basit, H., & Jeanmonod, R. (2024 Jan 1). Physiology, menstrual cycle. In: StatPearls [Internet]. StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK500020/ (Accessed: October 2025) |
| ↑4 | Mayo Clinic Staff. (no date). Female infertility – Symptoms & causes. Available at: https://www.mayoclinic.org/diseases-conditions/female-infertility/symptoms-causes/syc-20354308/ (Accessed: October 2025) |
| ↑5, ↑31 | BinJadeed, H. F., & Alajlan, A. (2021). Pregnancy and neonatal outcome with maternal exposure to finasteride: a case series. Journal of Dermatology and Dermatologic Surgery. 25(2). 84-86. Available at: https://doi.org/10.4103/jdds.jdds_33_21 |
| ↑6, ↑23, ↑24, ↑33 | Wu, M., Yu, Q., & Li, Q. (2016). Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Oncotarget. 7(50). 82074-82084. Available at: https://doi.org/10.18632/oncotarget.12617 |
| ↑7 | Conley, J. M., Lambright, C. S., Evans, N., Cardon, M., Furr, J., Wilson, V. S., & Gray Jr, L. E. (2018). Mixed “antiandrogenic” chemicals at low individual doses produce reproductive tract malformations in the male rat. Toxicological Sciences. 164(1). 166-178. Available at: https://doi.org/10.1093/toxsci/kfy069 |
| ↑9 | Singh, S., Patil, A., Kianfar, N., Waśkiel-Burnat, A., Rudnicka, L., Sinclair, R., & Goldust, M. (2022). Does topical minoxidil at concentrations higher than 5% provide additional clinical benefit?. Clinical and Experimental Dermatology. 47(11). 1951-1955. Available at: https://doi.org/10.1111/ced.15338 |
| ↑10, ↑12 | Hsu, C. L., Liu, J. S., Lin, A. C., Yang, C. H., Chung, W. H., & Wu, W. G. (2014). Minoxidil may suppress androgen receptor‐related functions. Oncotarget. 5(8). 2187-2197. Available at: /https://doi.org/10.18632/oncotarget.1886 |
| ↑11 | Randolph, M., & Tosti, A. (2021). Oral minoxidil treatment for hair loss: a review of efficacy and safety. Journal of the American Academy of Dermatology. 84(3). 737-746. Available at: https://doi.org/10.1016/j.jaad.2020.06.1009 |
| ↑13 | Nuck, B. A., Fogelson, S. L., & Lucky, A. W. (1987). Topical minoxidil does not act as an antiandrogen in the flank organ of the golden Syrian hamster. Archives of Dermatology. 123(1). 59-61. Available at: https://doi.org/10.1001/archderm.1987.01660250065019 |
| ↑14 | Turkina, V. A., Chemodurova, N. Y., Pryzyglei, H. V., & Kuzminov, Y. B. (2021). Potential embryotoxic effect study of minoxidil-containing lotion in experiment with female rats. Світ медицини та біології. (2). 248-251. Available at: https://doi.org/10.26724/2079-8334-2021-2-76-248-251 |
| ↑15 | Stock, S. J., & Norman, J. E. (2019). Medicines in pregnancy. F1000Research. 8(F1000Faculty Rev):911. Available at: https://doi.org/10.12688/f1000research.17535.1 |
| ↑16 | Phelan, A. L., Kunselman, A. R., Chuang, C. H., Raja-Khan, N. T., & Legro, R. S. (2016). Exclusion of women of childbearing potential in clinical trials of type 2 diabetes medications: a review of protocol-based barriers to enrollment. Diabetes Care. 39(6). 1004-1009. Available at: https://doi.org/10.2337/dc15-2723 |
| ↑17 | Thomas, S. H., & Yates, L. M. (2012). Prescribing without evidence – pregnancy. British Journal of Clinical Pharmacology. 74(4). 691-697. Available at: https://doi.org/10.1111/j.1365-2125.2012.04332.x |
| ↑18 | Koh, Y. P., Tian, E. A., & Oon, H. H. (2019). New changes in pregnancy and lactation labelling: Review of dermatologic drugs. International Journal of Women’s Dermatology. 5(4). 216-226. Available at: https://doi.org/10.1016/j.ijwd.2019.05.002 |
| ↑19 | Truong, T. M., Yaghi, M., & Murase, J. (2023). Dermatologic Drug Safety in Pregnancy. Journal of Dermatology for Physician Assistants. 17(3). 1-12. Available at: https://doi.org/10.58744/001c.88954 |
| ↑20 | Suchonwanit, P., Thammarucha, S., & Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy. 13. 2777–2786. Available at: https://doi.org/10.2147/DDDT.S214907 |
| ↑21, ↑29 | Smorlesi, C., Caldarella, A., Caramelli, L., Di Lollo, S., & Moroni, F. (2003). Topically applied minoxidil may cause fetal malformation: a case report. Birth Defects Research Part A: Clinical and Molecular Teratology. 67(12). 997-1001. Available at: https://doi.org/10.1002/bdra.10095 |
| ↑22, ↑30 | Rojansky, N., Fasouliotis, S. J., Ariel, I., & Nadjari, M. (2002). Extreme caudal agenesis. Possible drug-related etiology?. Journal of the American Academy of Dermatology. 47(3). 241-245. Available at: https://pubmed.ncbi.nlm.nih.gov/11933692/ |
| ↑25, ↑28 | Olsen, E. A., Sinclair, R., Hordinsky, M., Mesinkovska, N. A., Sadick, N., Shapiro, J., & Bergfeld, W. (2025). Summation and recommendations for the safe and effective use of topical and oral minoxidil. Journal of the American Academy of Dermatology. 93(2). 457-465. Available at: https://doi.org/10.1016/j.jaad.2025.04.016 |
| ↑26 | National Institute for Health and Care Excellence. (no date). Female-pattern hair loss (female androgenetic alopecia) — Prescribing information: Topical minoxidil. Available at: https://cks.nice.org.uk/topics/female-pattern-hair-loss-female-androgenetic-alopecia/prescribing-information/topical-minoxidil/ (Accessed: October 2025) |
| ↑27 | Rietschel, R. L., & Duncan, S. H. (1987). Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. Journal of the American Academy of Dermatology. 16(3). 677-685. Available at: https://doi.org/10.1016/S0190-9622(87)70087-5 |
| ↑32 | Wu, M., Yu, Q., & Li, Q. (2016). Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Oncotarget. 7(50). 82074-82084. Available at: https://doi.org/10.18632/oncotarget.12617 |
Topical minoxidil is one of the most widely used treatments for androgenic alopecia (AGA) in both men and women. While its efficacy and safety as a hair growth stimulant are well established, some men express concern about whether continuing hair loss treatments is safe when trying to conceive. These concerns often stem from known reproductive warnings associated with other medications, particularly finasteride, which directly influences hormonal pathways. Minoxidil, however, works through entirely different mechanisms, enhancing blood flow, prolonging the hair growth phase, and stimulating follicular activity.
This article examines the available scientific evidence to determine whether topical minoxidil has any measurable effect on male fertility. By reviewing preclinical studies, clinical trials, and pharmacologic data, we aim to clarify whether there is any credible link between minoxidil use and changes in reproductive hormones, sperm quality, or conception outcomes.
High-strength topical minoxidil available, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
Topical minoxidil stimulates hair growth primarily by increasing blood flow and nutrient delivery to hair follicles. Once applied to the scalp, it’s converted by the enzyme sulfotransferase (SULT1A1) into its active metabolite, minoxidil sulfate, which promotes follicular cell proliferation and prolongs the anagen (growth) phase of the hair cycle. It also upregulates vascular endothelial growth factor (VEGF) and activates potassium channels, both of which create a more favorable microenvironment for hair growth.[1]Suchonwanit, P., Thammarucha, S., & Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy. 13. 2777-2786. Available at: … Continue reading
Many people choose topical minoxidil over oral formulations because it offers similar local benefits with minimal systemic absorption. This greatly reduces the risk of side effects such as water retention, hypertrichosis (excess body hair), or cardiovascular symptoms sometimes seen with oral minoxidil. As an over-the-counter option with a well-established safety profile, topical minoxidil remains the most accessible first-line treatment for AGA.
Male fertility is defined as the ability to produce viable sperm capable of fertilizing an egg, and is impacted by a wide range of factors. These include hormonal regulation of sperm production, urogenital abnormalities, genetic factors, and environmental factors such as diet, obesity, and cigarette smoking. Semen quality is the best single snapshot of male reproductive potential. Sperm count influences the statistical odds that enough sperm reach the egg; sperm motility determines whether sperm can traverse cervical mucus, the uterus, and the fallopian tube; and morphology reflects the proportion of intact sperm likely to bind and penetrate the egg. These parameters work together, so clinicians interpret them as a profile rather than in isolation.[2]StatPearls; Male Infertility. Available at: https://www.ncbi.nlm.nih.gov/books/NBK562258/ (Accessed: October 2025)
Importantly, medications or drugs can influence many aspects of sperm production and function. Certain prescription drugs, such as anabolic steroids, testosterone supplements, finasteride, spironolactone, and some antidepressants or antihypertensives, can suppress the hormonal pathways that regulate spermatogenesis, reducing sperm count or motility. Others may interfere with sperm maturation, DNA integrity, or seminal fluid composition, leading to poorer fertilization potential. Even topical or seemingly localized medications can, in rare cases, exert mild systemic effects that alter reproductive hormones or oxidative balance.[3]Semet, M., Paci, M., Saïas‐Magnan, J., Metzler‐Guillemain, C., Boissier, R., Lejeune, H., & Perrin, J. (2017). The impact of drugs on male fertility: a review. Andrology. 5(4). 640-663. … Continue reading
For this reason, men actively trying to conceive are often advised to review all current medications and supplements with a clinician to assess potential reproductive impacts and, if necessary, explore safer alternatives or temporary adjustments.
Topical minoxidil is designed to act locally on the scalp, with only a small fraction of the drug entering the bloodstream. Studies estimate that around 1-2% of applied minoxidil is systemically absorbed through intact skin, though this can vary depending on factors such as scalp condition, formulation type, and frequency of use.
For instance, alcohol-based liquid solutions may enhance penetration slightly more than foam preparations, while damaged or inflamed skin can increase absorption. The scalp’s stratum corneum serves as the main barrier, limiting systemic exposure and ensuring that most of the drug remains localized to hair follicles.[4]Gupta, A. K., Talukder, M., Venkataraman, M., & Bamimore, M. A. (2022). Minoxidil: a comprehensive review. Journal of Dermatological Treatment. 33(4). 1896-1906. Available at: … Continue reading
In contrast, oral minoxidil is fully absorbed into systemic circulation and metabolized in the liver, resulting in significantly higher plasma concentrations of active minoxidil sulfate. This explains why oral therapy, though often more potent, also carries a greater risk of systemic side effects, including edema, tachycardia, and generalized hypertrichosis.[5]Randolph, M., & Tosti, A. (2021). Oral minoxidil treatment for hair loss: a review of efficacy and safety. Journal of the American Academy of Dermatology. 84(3). 737-746. Available at: … Continue reading Topical use, by comparison, delivers similar follicular benefits with a much lower risk profile, making it the preferred option for those seeking targeted hair regrowth.
Topical minoxidil might raise concerns for men trying to conceive, as its activity and impact are related to hormonally sensitive pathways. To explore this question properly, we can look at the evidence from laboratory models, human studies, and systematic analyses to understand any potential risks.
Other hair loss treatments, such as finasteride, act on hormonal pathways to alter the activity of androgens like testosterone. They may therefore pose a risk to male fertility. As such, it’s important to establish the impact of minoxidil on hormonal factors such as androgen response.
Animal models, particularly those involving rodents and primates, have primarily examined hair cycle dynamics rather than reproductive parameters. These studies consistently show that minoxidil promotes the transition of hair follicles from the telogen (resting) to anagen (growth) phase, enlarges follicular structures, and increases local blood flow.
One study using golden Syrian hamsters showed that 5% topical minoxidil did not prevent the androgen-dependent growth of pigmented spots, suggesting that minoxidil does not have any effect on androgen response.[6]Nuck, B. A., Fogelson, S. L., & Lucky, A. W. (1987). Topical minoxidil does not act as an antiandrogen in the flank organ of the golden Syrian hamster. Archives of Dermatology. 123(1). 59-61. … Continue reading
In contrast, a more recent, small-scale study using rats investigated the impact of topical minoxidil on sperm health. They found that the experimental group, receiving 10% minoxidil, had a 12-13% decline in testicular weight compared to the controls, as well as increases in markers related to oxidative stress within the testicles.[7]Turkina, V., Chemodurova, N., Hrushka, O., & Pryzyhlei, H. (2020). Topical effect of minoxidil-containing lotion on morphofunctional indicators of male rats’ reproductive system. … Continue reading Unfortunately, the authors do not specify the volume of 10% minoxidil used, making it impossible to make a concrete comparison to normal dosing in humans. This makes the translatability of these toxicology studies more challenging.
Research using cell-based models, including human hair dermal papilla cells, suggests that minoxidil can directly interact with and weaken androgen receptor signaling. However, this study used higher concentrations of minoxidil than would be used in hair loss treatment, and for practical purposes, topical minoxidil remains classified as a non-hormonal treatment.[8]Hsu, C. L., Liu, J. S., Lin, A. C., Yang, C. H., Chung, W. H., & Wu, W. G. (2014). Minoxidil may suppress androgen receptor‐related functions. Oncotarget. 5(8). 2187-2197. Available at: … Continue reading

Figure 1: In vitro studies show a potential effect of minoxidil on androgen receptor activity. Adapted from:[9]Hsu, C. L., Liu, J. S., Lin, A. C., Yang, C. H., Chung, W. H., & Wu, W. G. (2014). Minoxidil may suppress androgen receptor‐related functions. Oncotarget. 5(8). 2187-2197. Available at: … Continue reading Image used in accordance with the Creative Commons Attribution Licence.
While preclinical studies can provide insights into minoxidil activity, evidence for its effect and potential risks should be derived primarily from studies in humans. In clinical settings, topical minoxidil has been studied extensively for AGA, with trials ranging from short-term safety assessments to large randomized controlled trials. Across numerous studies, using 2%, 3%, 5%, and even 10% topical concentrations, the most commonly reported adverse events have been mild scalp irritation, contact dermatitis, or unwanted hair growth on non-target areas.[10]Olsen, E. A., Dunlap, F. E., Funicella, T., Koperski, J. A., Swinehart, J. M., Tschen, E. H., & Trancik, R. J. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical … Continue reading,[11]Hasanzadeh, H., Nasrollahi, S. A., Halavati, N., Saberi, M., & Firooz, A. (2016). Efficacy and safety of 5% minoxidil topical foam in male pattern hair loss treatment and patient satisfaction. … Continue reading,[12]Ghonemy, S., Alarawi, A., & Bessar, H. (2021). Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a … Continue reading
One randomized trial of 149 subjects reported two cases of impotence during the study, which disappeared following discontinuation of minoxidil treatment.[13]Rietschel, R. L., & Duncan, S. H. (1987). Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. Journal of the American Academy of Dermatology. 16(3). 677-685. … Continue reading This was the only case of sexual side effects we could find, and it seems to represent a rare complaint. Notably, however, none of these trials have reported reproductive or hormonal disturbances.
One randomized, controlled study that compared the impact of topical minoxidil alone to a solution containing 0.25% finasteride and 3% minoxidil explicitly monitored sexual side effects. The trial assessed levels of dihydrotestosterone (DHT), a marker for androgen suppression that may be relevant to male fertility. The report found a modest decrease in DHT only in the group who also applied finasteride, suggesting that minoxidil did not impact androgen activity.[14]Suchonwanit, P., Srisuwanwattana, P., Chalermroj, N., & Khunkhet, S. (2018). A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride … Continue reading
The largest comparative analysis to date, using the FDA Adverse Event Reporting System (FAERS) data, reinforces these findings. Over ten years of reporting revealed that finasteride was associated with markedly higher rates of erectile dysfunction, decreased libido, and ejaculatory disorders. In contrast, minoxidil, both topical and oral, was not associated with reproductive toxicity in either men or women. Dermatologic reactions such as irritation or dermatitis were the only consistent signals. This post-marketing evidence, covering thousands of patients, supports the conclusion that minoxidil does not interfere with male sexual function or fertility.[15]Wu, M., Yu, Q., & Li, Q. (2016). Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Oncotarget. 7(50). 82074-82084. … Continue reading
It is worth noting that most clinical studies do not measure semen parameters, testosterone, or dihydrotestosterone (DHT) levels in participants, so while there is no evidence of harm, data on direct fertility endpoints remain limited. However, trials that have assessed hormonal changes indirectly, such as topical finasteride-minoxidil combinations, report only minimal and clinically insignificant reductions in DHT, well within physiologic ranges and unlikely to impact spermatogenesis. Collectively, this body of evidence supports that topical minoxidil, when used at therapeutic concentrations, exerts its effects locally on hair follicles without meaningful systemic hormonal consequences.
Compared with other medical treatments for hair loss, topical minoxidil has a distinctly favorable reproductive safety profile. Finasteride and dutasteride, both 5-α-reductase inhibitors, work by suppressing the conversion of testosterone to DHT, a potent androgen involved in follicular miniaturization. While effective, this mechanism directly influences sex hormone pathways and has been associated in some users with reduced libido, erectile dysfunction, decreased semen volume, and abnormal sperm morphology.[16]Gupta, A. K., Venkataraman, M., Talukder, M., & Bamimore, M. A. (2022). Finasteride for hair loss: a review. Journal of Dermatological Treatment. 33(4). 1938-1946. Available at: … Continue reading,[17]Estill, M. C., Ford, A., Omeira, R., & Rodman, M. (2023). Finasteride and dutasteride for the treatment of male androgenetic alopecia: a review of efficacy and reproductive adverse effects. … Continue reading
Topical minoxidil, in contrast, exerts no effect on androgen synthesis or receptor binding, acts locally, and is absorbed systemically at rates of roughly 1-2%. Clinical and pharmacologic studies have not detected significant changes in serum hormones, testicular function, or sperm parameters associated with its use. For men attempting to conceive, topical minoxidil is therefore considered the safer option when pharmacologic hair restoration is desired.
No systematic reviews or meta-analyses have found an association between topical minoxidil and male reproductive dysfunction. Across clinical trials and pharmacovigilance datasets (such as FAERS), the consensus remains that topical minoxidil poses minimal to no risk to male fertility. Its non-hormonal mechanism stands in contrast to antiandrogenic drugs like finasteride or dutasteride, which are known to suppress DHT levels and can cause sexual side effects in some users.
The absence of evidence of reproductive toxicity for topical minoxidil is notable given its widespread use over several decades. Still, it is important to acknowledge that the absence of evidence is not definitive proof of absence, and few studies have directly measured sperm quality or fertility outcomes, leaving a modest evidence gap for future research.
Professional society guidelines, including those from the American Academy of Dermatology (AAD), European Academy of Dermatology and Venereology (EADV), and National Institute for Health and Care Excellence (NICE), all recognize topical minoxidil as a first-line treatment for AGA. None include warnings about male fertility or recommend discontinuing treatment when trying to conceive. Recommendations against use in pregnancy and breastfeeding are directed exclusively at women due to potential fetal exposure, not paternal risk.[18]Olsen, E. A., Sinclair, R., Hordinsky, M., Mesinkovska, N. A., Sadick, N., Shapiro, J., & Bergfeld, W. (2025). Summation and recommendations for the safe and effective use of topical and oral … Continue reading
In clinical practice, dermatologists generally reassure male patients that topical minoxidil can be safely continued when planning conception. They may, however, emphasize good application hygiene, using the prescribed dose, applying only to the scalp, washing hands afterward, and allowing the product to dry fully before physical contact to prevent unintended transfer to partners or infants. Because systemic absorption is minimal, these precautions are primarily to avoid topical irritation rather than systemic effects.
Given the links between minoxidil activity and hormonally sensitive pathways related to hair loss, some men may have concerns about using the medication when trying to conceive. Let’s look at some of the potential misconceptions about topical minoxidil and fertility.
There is some limited evidence from animal studies suggesting that topical minoxidil may affect sperm quality.[19]Turkina, V., Chemodurova, N., Hrushka, O., & Pryzyhlei, H. (2020). Topical effect of minoxidil-containing lotion on morphofunctional indicators of male rats’ reproductive system. … Continue reading However, there is no evidence that topical minoxidil reduces sperm count, motility, or morphology. Clinical trials of 3%, 5%, and 10% minoxidil report vanishingly few reproductive or hormonal side effects. The drug acts locally on the scalp, with systemic absorption of only about 1–2%, far below levels that could influence reproductive physiology. Neither animal studies nor human trials have identified any fertility-related toxicity associated with topical minoxidil use.
Studies suggest that minoxidil does not interfere with androgen production, metabolism, or receptor binding at doses relevant for hair loss. It promotes hair growth through vascular and cellular mechanisms, such as increasing VEGF expression and opening potassium channels, not by modifying testosterone or dihydrotestosterone (DHT) pathways.
However, some research using cell-based models has suggested that minoxidil might impact androgen receptor activity at high concentrations.[20]Hsu, C. L., Liu, J. S., Lin, A. C., Yang, C. H., Chung, W. H., & Wu, W. G. (2014). Minoxidil may suppress androgen receptor‐related functions. Oncotarget. 5(8). 2187-2197. Available at: … Continue reading
Sexual side effects are very rarely reported in any major clinical trials or pharmacovigilance data concerning topical minoxidil, with only two cases of impotence associated with topical minoxidil reported in the literature. Erectile dysfunction, decreased libido, and ejaculatory changes are associated with oral 5-α-reductase inhibitors (such as finasteride), not with topical minoxidil.[21]Wu, M., Yu, Q., & Li, Q. (2016). Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Oncotarget. 7(50). 82074-82084. … Continue reading
Different hair loss treatments have fundamentally different mechanisms. Finasteride and dutasteride lower DHT and can influence sexual function and semen parameters in some users.[22]Estill, M. C., Ford, A., Omeira, R., & Rodman, M. (2023). Finasteride and dutasteride for the treatment of male androgenetic alopecia: a review of efficacy and reproductive adverse effects. … Continue reading Minoxidil, on the other hand, does not interact with the androgen pathway and has no known reproductive risks. Therefore, the fertility profile of topical minoxidil is significantly safer than that of antiandrogenic agents.
Topical minoxidil remains one of the safest and most accessible treatments for male pattern hair loss, with decades of research supporting its efficacy and tolerability. Unlike hormone-modulating therapies such as finasteride, minoxidil works through non-androgenic pathways and shows no evidence of affecting male fertility, hormone levels, or sexual function. While future studies could further clarify long-term reproductive outcomes, the current consensus is clear: topical minoxidil is a fertility-neutral, first-line option for men looking to manage hair loss safely.
References[+]
| ↑1 | Suchonwanit, P., Thammarucha, S., & Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy. 13. 2777-2786. Available at: https://doi.org/10.2147/DDDT.S214907 |
|---|---|
| ↑2 | StatPearls; Male Infertility. Available at: https://www.ncbi.nlm.nih.gov/books/NBK562258/ (Accessed: October 2025) |
| ↑3 | Semet, M., Paci, M., Saïas‐Magnan, J., Metzler‐Guillemain, C., Boissier, R., Lejeune, H., & Perrin, J. (2017). The impact of drugs on male fertility: a review. Andrology. 5(4). 640-663. Available at: https://doi.org/10.1111/andr.12366 |
| ↑4 | Gupta, A. K., Talukder, M., Venkataraman, M., & Bamimore, M. A. (2022). Minoxidil: a comprehensive review. Journal of Dermatological Treatment. 33(4). 1896-1906. Available at: https://doi.org/10.1080/09546634.2021.1945527 |
| ↑5 | Randolph, M., & Tosti, A. (2021). Oral minoxidil treatment for hair loss: a review of efficacy and safety. Journal of the American Academy of Dermatology. 84(3). 737-746. Available at: https://doi.org/10.1016/j.jaad.2020.06.1009 |
| ↑6 | Nuck, B. A., Fogelson, S. L., & Lucky, A. W. (1987). Topical minoxidil does not act as an antiandrogen in the flank organ of the golden Syrian hamster. Archives of Dermatology. 123(1). 59-61. Available at: https://doi.org/10.1001/archderm.1987.01660250065019 |
| ↑7, ↑19 | Turkina, V., Chemodurova, N., Hrushka, O., & Pryzyhlei, H. (2020). Topical effect of minoxidil-containing lotion on morphofunctional indicators of male rats’ reproductive system. Український журнал сучасних проблем токсикології. (2). 27-31. Available at: https://protox.medved.kiev.ua/index.php/en/issues/2020/2/item/633-topical-effect-of-minoxidil-containing-lotion-on-morphofunctional-indicators-of-male-rats-reproductive-system |
| ↑8 | Hsu, C. L., Liu, J. S., Lin, A. C., Yang, C. H., Chung, W. H., & Wu, W. G. (2014). Minoxidil may suppress androgen receptor‐related functions. Oncotarget. 5(8). 2187-2197. Available at: /https://doi.org/10.18632/oncotarget.1886 |
| ↑9, ↑20 | Hsu, C. L., Liu, J. S., Lin, A. C., Yang, C. H., Chung, W. H., & Wu, W. G. (2014). Minoxidil may suppress androgen receptor‐related functions. Oncotarget. 5(8). 2187-2197. Available at: /https://doi.org/10.18632/oncotarget.1886 |
| ↑10 | Olsen, E. A., Dunlap, F. E., Funicella, T., Koperski, J. A., Swinehart, J. M., Tschen, E. H., & Trancik, R. J. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology. 47(3). 377-385. Available at: https://doi.org/10.1067/mjd.2002.124088 |
| ↑11 | Hasanzadeh, H., Nasrollahi, S. A., Halavati, N., Saberi, M., & Firooz, A. (2016). Efficacy and safety of 5% minoxidil topical foam in male pattern hair loss treatment and patient satisfaction. Acta Dermatovenerol Alp Pannonica Adriat. 25(3). 41-44. Available at: https://doi.org/10.15570/actaapa.2016.12 |
| ↑12 | Ghonemy, S., Alarawi, A., & Bessar, H. (2021). Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. Journal of Dermatological Treatment. 32(2). 236-241. Available at: https://doi.org/10.1080/09546634.2019.1654070 |
| ↑13 | Rietschel, R. L., & Duncan, S. H. (1987). Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. Journal of the American Academy of Dermatology. 16(3). 677-685. Available at: https://doi.org/10.1016/S0190-9622(87)70087-5 |
| ↑14 | Suchonwanit, P., Srisuwanwattana, P., Chalermroj, N., & Khunkhet, S. (2018). A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology. 32(12). 2257-2263. Available at: https://doi.org/10.1111/jdv.15171 |
| ↑15, ↑21 | Wu, M., Yu, Q., & Li, Q. (2016). Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Oncotarget. 7(50). 82074-82084. Available at: https://doi.org/10.18632/oncotarget.12617 |
| ↑16 | Gupta, A. K., Venkataraman, M., Talukder, M., & Bamimore, M. A. (2022). Finasteride for hair loss: a review. Journal of Dermatological Treatment. 33(4). 1938-1946. Available at: https://doi.org/10.1080/09546634.2021.1959506 |
| ↑17 | Estill, M. C., Ford, A., Omeira, R., & Rodman, M. (2023). Finasteride and dutasteride for the treatment of male androgenetic alopecia: a review of efficacy and reproductive adverse effects. Georgetown Medical Review. 7(1). Available at: https://doi.org/10.52504/001c.88531 |
| ↑18 | Olsen, E. A., Sinclair, R., Hordinsky, M., Mesinkovska, N. A., Sadick, N., Shapiro, J., & Bergfeld, W. (2025). Summation and recommendations for the safe and effective use of topical and oral minoxidil. Journal of the American Academy of Dermatology. 93(2). 457-465. Available at: https://doi.org/10.1016/j.jaad.2025.04.016 |
| ↑22 | Estill, M. C., Ford, A., Omeira, R., & Rodman, M. (2023). Finasteride and dutasteride for the treatment of male androgenetic alopecia: a review of efficacy and reproductive adverse effects. Georgetown Medical Review. 7(1). Available at: https://doi.org/10.52504/001c.88531 |
Finasteride is widely used for androgenic alopecia (AGA) and benign prostate hyperplasia (BPH). It’s generally well tolerated, with most users experiencing no significant adverse effects. However, clinicians in eye clinics have reported occurrences of dry eye that could be related to the use of finasteride.[1]NZ Optics. (2022). Finasteride and dry eye disease. Available at: https://www.nzoptics.co.nz/live-articles/finasteride-and-dry-eye-disease/ (Accessed: October 2025)
Dry eye disease (DED) is a common eye disorder characterized by insufficient tear production or poor tear quality. This can cause inadequate lubrication of the eye’s surface, leading to discomfort, irritation, and potentially damage to the eye. The condition is multifactorial, meaning it can be caused by a number of different factors. One important cause is increased tear evaporation, leading to evaporative dry eye. The quality and structure of tears are regulated by hormonal pathways, meaning that the anti-androgenic activity of finasteride could drive the development of the condition.[2]Golden, M. I., Meyer, J. J., Zeppieri, M., & Patel, B. C. (2024). Dry Eye Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available at: … Continue reading
In this article, we will examine the research that links finasteride to dry eye disease and explore the potential mechanisms by which it may be contributing to the condition.
Oral finasteride & minoxidil available, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
Finasteride is a 5α-reductase inhibitor and works by reducing the conversion of testosterone to dihydrotestosterone (DHT). DHT drives the shrinking and weakening of hair follicles in AGA, meaning that finasteride activity can counteract these effects by decreasing the amount of DHT. Finasteride is typically administered orally, meaning it can have systemic effects on multiple parts of the body. This is particularly important in tissues that are sensitive to androgens like DHT.[3]Zito, P. M., Bistas, K. G., Patel, P., & Syed, K. (2024). Finasteride. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available at: … Continue reading

Figure 1. 5α-reductase converts testosterone into dihydrotestosterone. Finasteride is a 5α-reductase inhibitor, meaning it prevents or reduces this activity. Image adapted from Figure 1.[4]Azizi, A., Mumin, N. H., & Shafqat, N. (2021). Phytochemicals with anti 5-alpha-reductase activity: A prospective for prostate cancer treatment. F1000Research. 10. 221. Available at: … Continue reading Image used under Creative Commons License.
The meibomian glands are one such tissue. They are special sebaceous (oil-producing) glands located within the upper and lower eyelids, with each eye containing 20 – 40 of these glands. They produce meibum, a lipid-rich secretion that forms the outermost layer of the tear film and plays a critical role in maintaining ocular surface health. With every blink, meibum is expressed from the gland orifices, forming a thin, uniform layer over the eye. Meibum’s main function is to prevent evaporation of the tear film by creating a stable oil barrier, ensuring long-lasting lubrication of the eye’s surface.[5]Sabeti, S., Kheirkhah, A., Yin, J., & Dana, R. (2020). Management of meibomian gland dysfunction: a review. Survey of Ophthalmology. 65(2). 205-217. Available at: … Continue reading

Figure 2. The meibomian glands are arranged in parallel rows within the upper and lower eyelids. They produce meibum, which forms the lipid layer of the tear that coats the surface of the eye. Image adapted from Figure 3.[6]Dhamdhere, K., & Badawi, D. (2021). A blink-assisted, cornea-sparing wearable eyelid device for the effective penetration of therapeutic thermal energy into the meibomian glands for the treatment … Continue reading Image used under Creative Commons License.
Meibomian glands are directly regulated by androgens, via receptors present in their epithelial cells. Androgens, such as DHT, can bind to these receptors, directly influencing the synthesis of lipids essential for tear formation. Importantly, DHT is also synthesized in meibomian glands by 5α-reductase. This is where the connection to finasteride comes in: inhibition of 5α-reductase by the drug could stop DHT activity in the meibomian glands, stopping the production of lipids required to prevent tear evaporation. As such, while finasteride doesn’t target the eye, its impact on androgen pathways can have indirect effects.[7]Traish, A. M. (2020). Health risks associated with long-term finasteride and dutasteride use: it’s time to sound the alarm. The World Journal of Men’s Health. 38(3). 323-337. Available at: … Continue reading
Even partial androgen suppression, like oral finasteride for hair, could be enough to impact tear production, particularly in someone who has other risk factors associated with DED, such as older age, prolonged screen time, certain medications (antihistamines, antidepressants, diuretics, beta-blockers), autoimmune or connective tissue diseases, and environmental exposures such as wind, dry climates, or smoke.
A role for androgens in regulating meibomian gland function was proposed in a paper published in 2000.[8]Krenzer, K. L., Reza Dana, M., Ullman, M. D., Cermak, J. M., Tolls, D. B., Evans, J. E., & Sullivan, D. A. (2000). Effect of androgen deficiency on the human meibomian gland and ocular surface. … Continue reading Patients who were taking antiandrogen drugs for issues related to the prostate were assessed on symtpoms of DED and the contents of their meibomian gland secretions. They were compared to a control group that was on such medications. They found that antiandrogen therapy changes the composition of lipids in tears, while also decreasing the quality of tears and increasing participants’ susceptibility to light sensitivity, painful eyes, and blurred vision. This study laid the foundation for our current understanding of how DHT-lowering therapies might cause DED.
Animal models have been developed to understand the mechanisms that lead to DED, including a potential role for DHT-lowering therapies as suggested by these clinical findings. A 2014 study utilized a rat model to investigate the impact of finasteride on tear production.[9]Singh, S., Moksha, L., Sharma, N., Titiyal, J. S., Biswas, N. R., & Velpandian, T. (2014). Development and evaluation of animal models for sex steroid deficient dry eye. Journal of … Continue reading They found that oral administration of 1.6 mg/kg finasteride every day significantly decreased tear flow and increased the speed at which tears break up after 10 days in both male and female rats.
This study was supported by further research published in 2017, which used the same concentration of finasteride in rats for 40 days.[10]Li, K., Zhang, C., Yang, Z., Wang, Y., & Si, H. (2017). Evaluation of a novel dry eye model induced by oral administration of finasteride. Molecular Medicine Reports. 16(6). 8763-8770. Available … Continue reading They also found that tear production was reduced in finasteride-treated rats, and makers for tear break-up were increased. The impact of finasteride on tear production in rats is so reliable that it has been used to induce DED in models investigating potential treatments for the condition.[11]Zhang, C., Li, K., Yang, Z., Wang, Y., & Si, H. (2016). The effect of the aqueous extract of Bidens pilosa L. on androgen deficiency dry eye in rats. Cellular Physiology and Biochemistry. 39(1). … Continue reading

Figure 3. Finasteride treatment (Fin – right-hand group) increases fluorescein staining in the tears of rats, an indicator of tear break-up. Adapted from Figure 1.[12]Li, K., Zhang, C., Yang, Z., Wang, Y., & Si, H. (2017). Evaluation of a novel dry eye model induced by oral administration of finasteride. Molecular Medicine Reports. 16(6). 8763-8770. Available … Continue reading Image used under Creative Commons License.
Notably, these animal models use considerably higher concentrations of finasteride than would be recommended for hair loss – an equivalent dose for the average American man would be around 126 mg per day. In comparison, the standard regimen for AGA is only 1 mg per day. However, they do demonstrate the capacity for finasteride to impact tear production.
Preclinical data, as well as a deeper understanding of the androgen-associated causes of DED, led to some concern about the potential adverse effects of finasteride.[13]Traish, A. M. (2020). Health risks associated with long-term finasteride and dutasteride use: it’s time to sound the alarm. The World Journal of Men’s Health. 38(3). 323-337. Available at: … Continue reading
Recently, clinical researchers have further explored this link. A retrospective case series looked at 116 patients at an eye clinic with a history of DED who were taking finasteride.[14]Nguyen, B. J., Meer, E., Gupta, A. S., Jinpeng, G., Ying, G. S., Bunya, V. Y., Macchi, I., & Massaro-Giordano, M. (2022). The effect of finasteride on dry eye disease. Investigative Ophthalmology … Continue reading
They found that a significantly greater proportion of patients had MGD, conjunctival abnormalities, and corneal abnormalities during follow-up examinations compared to their initial assessment, a period of four and a half years on average.
They also found a trend toward increased disease severity in patients on a higher dose of finasteride, although these findings were not statistically significant. It is hard to draw any conclusions from this research, as it only looked at individuals who both took finasteride and had DED. A retrospective study or clinical trial that included individuals who did not take finasteride would provide significantly greater insights.
Anecdotal reports from an eye clinic in New Zealand have indicated that increasingly, patients presenting with DED are also taking finasteride.[15]NZ Optics. (2022). Finasteride and dry eye disease. Available at: https://www.nzoptics.co.nz/live-articles/finasteride-and-dry-eye-disease/ (Accessed: October 2025) Data on the impact of finasteride on DED is, therefore, lacking, and robust clinical studies are required to better understand the potential link.
Some conclusions can also be drawn from clinical studies investigating other antiandrogenic drugs. Such medications are often used against prostate cancer, which depends on androgens such as testosterone and DHT for its growth and survival. A retrospective study compared a group of 1791 patients with prostate cancer who were taking a range of androgen deprivation therapies with those who weren’t.[16]Chien, H. W., Lin, C. W., Lee, C. Y., Huang, J. Y., Yang, S. F., & Wang, K. (2022). The use of androgen deprivation therapy for prostate cancer and its effect on the subsequent dry eye disease: a … Continue reading They found no significant difference in the development of DED.
A similar study compared a smaller group of prostate cancer patients on antiandrogens (31 in total) to those not on such medications. However, it investigated tear formation in greater depth.[17]Kurna, S. A., Hacisalihoglu, A. O., Altun, A., Ozel, N. O., Uruc, F., Kanar, H. S., & Arsan, A. K. (2022). Effects of systemic anti-androgen drugs on the ocular surface. Journal Français … Continue reading
They found a significant increase in markers for tear break-up and complaints of dry eye. Importantly, neither of these studies distinguishes between forms of antiandrogen therapy, nor do they specifically investigate the role of finasteride.
Data from animal models provide a clear mechanism by which finasteride could impact tear production and cause MGD and DED. However, the limited availability of clinical data makes it challenging to draw evidence-based conclusions about the potential adverse effects of finasteride. Clinical studies using a wide range of antiandrogen therapies in a different cohort (prostate cancer patients) also provide conflicting information. It’s important to remember that the absence of evidence doesn’t mean definitive proof of absence, and you should still consider the potential effects on your eyes when taking finasteride.
Secondary effects – Inflammation and surface damage: Ongoing tear film instability can trigger inflammation, discomfort, and damage to the eye’s surface over time.
If you’re concerned about the risk of developing DED while taking finasteride, it’s important to consider other risk factors that could have an additive effect.[18]Britten-Jones, A. C., Wang, M. T., Samuels, I., Jennings, C., Stapleton, F., & Craig, J. P. (2024). Epidemiology and risk factors of dry eye disease: considerations for clinical management. … Continue reading Those at risk include:
Peri-and Post Menopausal Women – The hormonal changes of menopause lead to reduced secretion and quality in both lacrimal and meibomian glands, the core tear-producing tissues
Older People – The risk sharply increases after age 40, with prevalence rising further with each decade due to reduced tear production and gland function.
Contact Lens Wearers – Long-term use is linked to higher DED risk due to tear film disruption.
Screen Users – Reduced blink rate and incomplete blinks from device use elevate risk, especially in professional and urban populations.
Individuals on Certain Medications – Antihistamines, antidepressants, hormone therapies, and diuretics reduce tear secretion or alter tear composition.
People Exposed to Dry, Polluted, or Urban Environments – Low ambient humidity, air conditioning, pollution, and smoke contribute to increased evaporation and instability of the tear film.
Dry eye can often be managed through a combination of lifestyle changes, environmental adjustments, proper eye care, and medical support.[19]Donthineni, P. R., Shanbhag, S. S., & Basu, S. (2021). An evidence-based strategic approach to prevention and treatment of dry eye disease, a modern global epidemic. Healthcare. 9(1). 89. … Continue reading If you’re taking finasteride and notice eye discomfort or dryness, these steps may help minimize symptoms and protect long-term eye health.
Although preclinical and clinical evidence suggest a possible link between finasteride and DED, many questions remain unanswered. Animal models suggest a causal connection but cannot replicate human physiology, and typically administer much higher doses than those that would be administered in humans. Large, controlled trials investigating the use of finasteride at the 1 mg hair-loss dose are required to draw evidence-based conclusions about the role of finasteride in DED.
Finasteride is an effective, well-established, and typically well-tolerated treatment for hair. However, concerns about links to meibomian gland dysfunction and DED are rising. The eye is a hormonally responsive organ, and systemic medications can have subtle but meaningful effects on ocular health. While animal studies and hormonal mechanisms support a potential link to dry eye disease, human data remain limited and inconclusive, especially at the low doses used for androgenic alopecia. For now, users should monitor for symptoms like dryness or irritation and seek ophthalmologic advice if they occur.
References[+]
| ↑1, ↑15 | NZ Optics. (2022). Finasteride and dry eye disease. Available at: https://www.nzoptics.co.nz/live-articles/finasteride-and-dry-eye-disease/ (Accessed: October 2025) |
|---|---|
| ↑2 | Golden, M. I., Meyer, J. J., Zeppieri, M., & Patel, B. C. (2024). Dry Eye Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK470411/ (Accessed: October 2025) |
| ↑3 | Zito, P. M., Bistas, K. G., Patel, P., & Syed, K. (2024). Finasteride. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK513329/ (Accessed: October 2025) |
| ↑4 | Azizi, A., Mumin, N. H., & Shafqat, N. (2021). Phytochemicals with anti 5-alpha-reductase activity: A prospective for prostate cancer treatment. F1000Research. 10. 221. Available at: https://doi.org/10.12688/f1000research.51066.3 |
| ↑5 | Sabeti, S., Kheirkhah, A., Yin, J., & Dana, R. (2020). Management of meibomian gland dysfunction: a review. Survey of Ophthalmology. 65(2). 205-217. Available at: https://doi.org/10.1016/j.survophthal.2019.08.007 |
| ↑6 | Dhamdhere, K., & Badawi, D. (2021). A blink-assisted, cornea-sparing wearable eyelid device for the effective penetration of therapeutic thermal energy into the meibomian glands for the treatment of dry eye disease. Journal of Clinical & Experimental Ophthalmology. 12 (S12):003. Available at: https://www.longdom.org/open-access/a-blinkassisted-corneasparing-wearable-eyelid-device-for-the-effectivepenetration-of-therapeutic-thermal-energy-into-the.pdf (Accessed: October 2025) |
| ↑7, ↑13 | Traish, A. M. (2020). Health risks associated with long-term finasteride and dutasteride use: it’s time to sound the alarm. The World Journal of Men’s Health. 38(3). 323-337. Available at: https://doi.org/10.5534/wjmh.200012 |
| ↑8 | Krenzer, K. L., Reza Dana, M., Ullman, M. D., Cermak, J. M., Tolls, D. B., Evans, J. E., & Sullivan, D. A. (2000). Effect of androgen deficiency on the human meibomian gland and ocular surface. The Journal of Clinical Endocrinology & Metabolism. 85(12). 4874-4882. Available at: https://doi.org/10.1210/jcem.85.12.7072 |
| ↑9 | Singh, S., Moksha, L., Sharma, N., Titiyal, J. S., Biswas, N. R., & Velpandian, T. (2014). Development and evaluation of animal models for sex steroid deficient dry eye. Journal of Pharmacological and Toxicological Methods. 70(1). 29-34. Available at: https://doi.org/10.1016/j.vascn.2014.03.004 |
| ↑10 | Li, K., Zhang, C., Yang, Z., Wang, Y., & Si, H. (2017). Evaluation of a novel dry eye model induced by oral administration of finasteride. Molecular Medicine Reports. 16(6). 8763-8770. Available at: https://doi.org/10.3892/mmr.2017.7754 |
| ↑11 | Zhang, C., Li, K., Yang, Z., Wang, Y., & Si, H. (2016). The effect of the aqueous extract of Bidens pilosa L. on androgen deficiency dry eye in rats. Cellular Physiology and Biochemistry. 39(1). 266-277. Available at: https://doi.org/10.1159/000445622 |
| ↑12 | Li, K., Zhang, C., Yang, Z., Wang, Y., & Si, H. (2017). Evaluation of a novel dry eye model induced by oral administration of finasteride. Molecular Medicine Reports. 16(6). 8763-8770. Available at: https://doi.org/10.3892/mmr.2017.7754 |
| ↑14 | Nguyen, B. J., Meer, E., Gupta, A. S., Jinpeng, G., Ying, G. S., Bunya, V. Y., Macchi, I., & Massaro-Giordano, M. (2022). The effect of finasteride on dry eye disease. Investigative Ophthalmology & Visual Science. 63(7). 427. Available at: https://doi.org/10.1167/iovs.63.7.427 |
| ↑16 | Chien, H. W., Lin, C. W., Lee, C. Y., Huang, J. Y., Yang, S. F., & Wang, K. (2022). The use of androgen deprivation therapy for prostate cancer and its effect on the subsequent dry eye disease: a population-based cohort study. International Journal of Medical Sciences. 19(7). 1103-1109. Available at: https://doi.org/10.7150/ijms.73417 |
| ↑17 | Kurna, S. A., Hacisalihoglu, A. O., Altun, A., Ozel, N. O., Uruc, F., Kanar, H. S., & Arsan, A. K. (2022). Effects of systemic anti-androgen drugs on the ocular surface. Journal Français d’Ophtalmologie. 45(6). 619-627. Available at: https://doi.org/10.1016/j.jfo.2021.06.007 |
| ↑18 | Britten-Jones, A. C., Wang, M. T., Samuels, I., Jennings, C., Stapleton, F., & Craig, J. P. (2024). Epidemiology and risk factors of dry eye disease: considerations for clinical management. Medicina. 60(9). 1458. Available at: https://doi.org/10.3390/medicina60091458 |
| ↑19 | Donthineni, P. R., Shanbhag, S. S., & Basu, S. (2021). An evidence-based strategic approach to prevention and treatment of dry eye disease, a modern global epidemic. Healthcare. 9(1). 89. Available at: https://doi.org/10.3390/healthcare9010089 |
Testosterone replacement therapy (TRT) can be a life-changing treatment for many men, restoring healthy hormone levels and renewing vitality after declines associated with low testosterone. However, many encounter a harsh irony: the same treatment that revitalizes them may also lead to accelerated hair loss, known as androgenetic alopecia (AGA). This frustrating dilemma can compel some men to choose between their appearance and their health.
Why do TRT patients often experience hair thinning just months into treatment? The culprit is testosterone’s conversion to DHT, the hormone that drives male pattern hair loss. Fortunately, new developments in comprehensive care address the testosterone-to-hair-loss pathway, allowing men to enjoy both hormone optimization and healthy hair. These clinically rigorous, customizable, and medically supervised treatments eliminate the either-or paradox.
Perfect Hair Health’s PhD experts have teamed up with Ulo, a leader in men’s wellness and hair care, to share five evidence-based techniques for preserving hair while on TRT. With Ulo’s unique expertise at the intersection of hormone optimization and hair restoration, patients gain access to solutions that are both proven and personalized.
Read on to learn how Ulo can help you maintain both hormonal health and hair density.
Oral Dutasteride Hair gains bigger than finasteride? Dutasteride makes this possible, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
Before exploring solutions, we will briefly explain the science behind TRT and hair loss, including relevant medical research that supports prevention-based strategies for preserving hair during TRT.
To understand the link between TRT and hair loss, we turn to the molecular process that converts testosterone into dihydrotestosterone (DHT), the hormone that causes follicular degradation and balding. Two types of 5α-reductase enzymes are responsible for deriving DHT from testosterone: Type I (primarily located in the skin and sebaceous glands) and Type II (mainly located in the hair follicles of the crown and temporal regions).[1]Owecka, B., Tomaszewska, A., Dobrzeniecki, K., Owecki, M. (2024). The Hormonal Background of Hair Loss in Non-Scarring Alopecias. Biomedicines. 12(3). 513. Available at: … Continue reading
Androgenetic alopecia (AGA) can occur naturally in susceptible individuals, whose hair follicles have high concentrations of androgen receptors and 5α-reductase enzymes. However, adding exogenous T through TRT can expedite this process. TRT’s elevation of testosterone levels can raise DHT to two or three times higher than starting levels, depending on the dosage and mode of application. The conversion of T to DHT is especially prevalent in the crown and temporal areas of the scalp, where it causes hair thinning and loss.[2]Owecka, B., Tomaszewska, A., Dobrzeniecki, K., Owecki, M. (2024). The Hormonal Background of Hair Loss in Non-Scarring Alopecias. Biomedicines. 12(3). 513. Available at: … Continue reading,[3]Stocks, B., Asempa, O. (2025). Does testosterone replacement therapy cause hair loss? Baylor College of Medicine. Available at: … Continue reading
Genetic predisposition plays a significant role, as variations in androgen receptor genes determine individual sensitivity to DHT. This explains why patients on identical TRT regimens can experience varying levels of hair loss, with some experiencing dramatic loss and others experiencing little or no effect. In those with hereditary androgen sensitivity, the hair follicles respond poorly to even slight elevations in local DHT levels on the scalp.[4]Owecka, B., Tomaszewska, A., Dobrzeniecki, K., Owecki, M. (2024). The Hormonal Background of Hair Loss in Non-Scarring Alopecias. Biomedicines. 12(3). 513. Available at: … Continue reading
As previously noted, TRT increases testosterone and leads to higher levels of its derivative hormone, DHT, which binds to hair follicles and causes hair thinning and loss in genetically susceptible men. Spikes in DHT and associated hair loss can occur even with moderate TRT, as raising testosterone into the normal range can represent a significant increase from severe deficiency.[5]Borst, S.E., Shuster, J.J., Zou, B., Ye, F., Jia, H., Wokhlu, A., Yarrow, J.F. (2014). Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systemic review … Continue reading
Episodic TRT protocols like weekly injections can create testosterone peaks over 1,200 ng/dL for up to 48 hours after injection, leading to surges in scalp DHT production during these windows. Such DHT spikes can damage the follicles and contribute to rapid hair loss.[6]Stocks, B., Asempa, O. (2025). Does testosterone replacement therapy cause hair loss? Baylor College of Medicine. Available at: … Continue reading,[7]Shoskes, J.J., Wilson, M.K., Spinner, M.L. (2016). Pharmacology of testosterone replacement therapy preparations. Translational Andrology and Urology. 5(6). 834-843. Available at: … Continue reading
Disruption of hair follicle cycles can begin in the first 3-6 weeks of TRT. However, noticeable hair loss typically doesn’t emerge for several months, as early damage is concealed by hair growth cycles. Studies suggest higher TRT doses correlate with more rapid hair loss in susceptible patients.[8]Saad, F., Aversa, A., Isidori, A.M., Zafalon, L., Zitzmann, M., Gooren, L. (2011). Onset of effects of testosterone treatment and time span until maximum effects are achieved. European Journal of … Continue reading,[9]Fu, D., Huang, J., Li, K., Chen, Y., He, Y., Sun, Y., Guo, Y., Du, L., Qu, Q., Miao, Y., Hu, Z. (2021). Dihydrotestosterone-induced hair regrowth inhibition by activating androgen receptor in C57BL6 … Continue reading
Although DHT can harm the hair follicles, it plays a vital role in various biological processes, including sexual function, bone mineralization, and muscle development. Therefore, the aim of hair loss treatment during TRT is not to eliminate the hormone. Rather, the therapeutic goal is to lower DHT to a level that minimizes follicular damage while preserving systemic functions. Striking this balance in individuals often requires sophisticated strategies that exceed standardized DHT suppression protocols.[10]Owecka, B., Tomaszewska, A., Dobrzeniecki, K., Owecki, M. (2024). The Hormonal Background of Hair Loss in Non-Scarring Alopecias. Biomedicines. 12(3). 513. Available at: … Continue reading
While some patients may be tempted to terminate TRT to protect their hair, research findings support a more measured approach that takes TRT’s broader benefits into account. Patients who elect to stop taking testosterone for hair preservation may experience a return of detrimental symptoms: sexual dysfunction, depression, fatigue, muscle loss, and more. The psychological and physiological impacts of low T can outweigh cosmetic concerns.
Given these considerations, practitioners advise strategic early intervention over reactionary care, as hair restoration becomes much more challenging after considerable follicular shrinkage. Early discussion with healthcare providers about hair preservation strategies helps maintain hair health throughout the hormone optimization process.[11]Owecka, B., Tomaszewska, A., Dobrzeniecki, K., Owecki, M. (2024). The Hormonal Background of Hair Loss in Non-Scarring Alopecias. Biomedicines. 12(3). 513. Available at: … Continue reading
With the science behind TRT and hair loss clear, let’s look at the latest, evidence-based ways patients can protect their hair.
Hair loss associated with TRT often has distinct features, like episodic spikes in testosterone and DHT conversion rates. Although conventional hair loss interventions can be useful, protocols may benefit from personalization according to TRT regimens.
Ulo is a unique provider due to its innovative hair loss treatments and dual expertise in both hair restoration and hormone optimization. This combined clinical experience enables them to tailor treatments to individual patient needs, such as timing factors and treatment responses specific to TRT. All Ulo treatment protocols are physician-crafted and include close follow-up care to monitor for side effects and make adjustments as needed.
This overview outlines Ulo’s comprehensive strategy for hair loss intervention, from advanced prescription formulas to targeted nutritional support. All offerings are transparently priced with customizable features to account for TRT-related factors and individual patient considerations.
| Product Category | Mechanism of Action | Delivery Method | Formula Details | Price |
| Oral Medications | Systemic 5α-reductase inhibition and vasodilation | Oral capsule, tablet, or softgel | Finasteride, dutasteride, and minoxidil for systemic DHT blocking and growth stimulation | $24-65/month |
| Topical Finasteride | Localized Type II 5α-reductase inhibition with minimal systemic exposure | Solution | Concentration range (0.005%-0.2%); customizable adjuvants; irritant-free | $64+/month |
| Topical Dutasteride | Localized dual enzyme (Types I & II) inhibition for maximum scalp DHT suppression | Solution | Concentration range (0.02%-0.2%); customizable adjuvants; irritant-free | $84+/month |
| Growth Booster Topicals | Vasodilation, anti-inflammatory action without DHT manipulation | Solution | Customizable combinations of minoxidil, tretinoin, caffeine, melatonin, and cetirizine | $54/month |
| OTC Support Products | Nutritional optimization, scalp environment enhancement, and daily follicular support | Serum, supplements, shampoo, and conditioner | Evidence-based supplements targeting TRT-specific deficiencies; irritant-free hair care products | $29+/month |
This systemic approach provides several key advantages for men on testosterone therapy:
| Benefit: | Details: |
| ✓ Comprehensive treatment | Systemic DHT blocking plus vasodilation for growth stimulation |
| ✓ Maximum potency | Up to 93% DHT reduction with dutasteride |
| ✓ Convenience | Once-daily dosing |
| ✓ Customizable | Combination options with growth stimulators |
DHT blockers like finasteride and dutasteride treat hair loss by suppressing the 5α-reductase enzymes that metabolize testosterone into DHT. Oral preparations have systemic effects and therefore offer extensive treatment. They can be used in conjunction with oral growth stimulators, such as minoxidil, to minimize hair loss associated with TRT.
Finasteride inhibits the Type II 5α-reductase enzyme to reduce DHT levels by up to 70%. In contrast, dutasteride is a more potent intervention as a dual inhibitor of both Type I and Type II 5α-reductase enzymes, achieving up to 93% lower DHT levels. This thorough DHT suppression can make dutasteride useful for advanced hair loss cases as well as high-dose TRT patients who may not respond to topical treatments.[12]Arif, T., Dorjay, K., Adil, M., Sami, M. (2017). Dutasteride in Androgenetic Alopecia: An Update. Current Clinical Pharmacology. 12(1). 31-35. Available at: … Continue reading
Studies indicate that dutasteride’s therapeutic effects may continue to build beyond the 12 months at which many finasteride users experience a plateau, further establishing dutasteride as the most potent treatment option. While oral DHT blockers offer powerful treatment, their systemic effects contribute to a greater risk of serious side effects, so strict medical oversight is required.[13]Harcha, W.G., Martinez, J.B., Tsai, T-F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., Chetty, D. (2014). A randomized, active- and placebo-controlled study of the efficacy … Continue reading
Ulo’s oral treatments offer effective systemic intervention through various formulations designed for optimal bioavailability, featuring customizable options. Their oral Dutasteride Rx delivers a 0.5 mg dose of dual enzyme-blocking treatment in a softgel format designed to enhance absorption, overcoming the poor bioavailability of powder formulas touted by competitors.
Their gentler oral Finasteride Rx also offers systemic DHT suppression in a once-daily capsule, while an oral Minoxidil Rx (1.25 mg or 2.5 mg) tablet formula increases systemic circulation and upregulates hair growth factors to treat hair loss as an alternative to DHT-blocking medications.
Ulo also offers oral preparations that synergistically combine DHT blockers with minoxidil for effects that are shown to exceed those of monotherapies: Dutasteride + Minoxidil Rx and Finasteride + Minoxidil Rx, which come with optional adjuvants like vitamin D and folic acid to address deficiencies. Rather than combining oral dutasteride and minoxidil into a single capsule, as competitors do, Ulo maintains a separate soft gel and powder format for each, enabling proper absorption.
Key Takeaway: Oral medications such as finasteride, dutasteride, and minoxidil provide the strongest systemic protection against hair loss during TRT, but their broad effects mean they require careful medical supervision to manage potential side effects.
Topical finasteride offers these strategic benefits for TRT patients:
| Benefit: | Details: |
| ✓ Targeted action | Scalp-focused DHT reduction |
| ✓ Flexible dosing | Low-dose (0.005%) and full-strength (0.2%) options |
| ✓ Safer alternative to oral | Comparable efficacy to oral without systemic exposure side effects |
| ✓ Customizable | Optional minoxidil and adjuvant combinations |
Topical finasteride delivers targeted DHT suppression directly to the scalp, minimizing effects on the rest of the body. Studies show that topical finasteride can reduce scalp DHT to a therapeutic effect with little impact on serum DHT levels. In contrast, oral finasteride reduces DHT levels throughout the entire system. For men on TRT, maintaining systemic DHT is essential for bone, muscle, and sexual health; therefore, topical finasteride is typically the preferred option.[14]Kinter KJ, Amraei R, Anekar AA. Biochemistry, Dihydrotestosterone. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: … Continue reading,[15]Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., Falques, M., Otero, R., Tamarit, M.L., Galvan, J., Tebbs, V., Massana, E. (2021). Efficacy and safety of topical finasteride spray … Continue reading
Topical formulations also allow more precise dosing with flexible concentrations that can be tailored to patient needs and responses. Low-dose formulas (0.005%) may be more appropriate for early-stage or moderate TRT patients, while higher-strength options (0.2%) can offer more aggressive treatment for substantial hair loss or intensive TRT protocols. Topical solutions can easily incorporate elective adjuvants, such as absorption enhancers and anti-inflammatories, for synergistic benefits.[16]Kinter KJ, Amraei R, Anekar AA. Biochemistry, Dihydrotestosterone. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: … Continue reading
Ulo’s topical finasteride solution provides targeted scalp treatment with an optimized delivery base that is free from potential irritants, such as propylene glycol. Their fully customizable Finasteride + Minoxidil Plus Rx is available in finasteride doses of 0.005% for gentler therapy and 0.2% for stronger intervention.
The robust formulation includes a wide range of synergistic add-on choices that address multiple hair loss pathways: up to 7% minoxidil for growth stimulation, tretinoin for better absorption, and multiple antioxidants for comprehensive support. This adaptability enables treatment tailored to patient needs rather than fixed protocols. Physician-crafted and supervised topical protocols are considered safe and effective for prolonged use to complement TRT journeys.
Key Takeaway: Topical finasteride allows TRT patients to lower scalp DHT while preserving systemic androgen function, making it a preferred option for balancing hair health with hormonal benefits.
This powerful topical approach delivers distinct advantages:
| Benefit: | Details: |
| ✓ Dual enzyme blocking | Inhibits both Type I and Type II 5α-reductase |
| ✓ Max scalp DHT reduction | Superior enzyme inhibition for aggressive protocol |
| ✓ Safe and targeted treatment | Potent effects without systemic exposure |
| ✓ Concentration control | Low-dose (0.02%) to full-strength (0.2%) options |
| ✓ Personalized add-ons | Adjuvants can be tailored to individual needs |
Topical dutasteride leverages the dual enzyme inhibition and localized efficacy discussed in Methods 1 and 2 to powerfully suppress scalp DHT levels while maintaining systemic DHT. This approach can be beneficial for patients on intensive TRT protocols that don’t respond to single-enzyme-blocking treatments.
The superior targeted DHT suppression of topical dutasteride makes it an excellent choice for severe hair loss and TRT scenarios. It is the most potent topical DHT blocker available. Like topical finasteride, its concentration flexibility and easy incorporation of adjuvants enable more highly tailored and adaptable treatment compared to oral administration.[17]Arif, T., Dorjay, K., Adil, M., Sami, M. (2017). Dutasteride in Androgenetic Alopecia: An Update. Current Clinical Pharmacology. 12(1). 31-35. Available at: … Continue reading,[18]Harcha, W.G., Martinez, J.B., Tsai, T-F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., Chetty, D. (2014). A randomized, active- and placebo-controlled study of the efficacy … Continue reading,[19]Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between topical minoxidil 5% alone versus combined with dutasteride (topical 0.02% through microneedling or oral 0.5 mg) in … Continue reading
Ulo’s topical dutasteride offerings include both low-dose (0.02%) and full-strength (0.2%) versions of their Dutasteride + Minoxidil Plus Rx solution, delivering potent dual enzyme inhibition for precision scalp treatment. While the lower concentration may suit maintenance or preventative protocols, the highly concentrated formula may benefit severe hair loss patients and aggressive TRT regimens.
Like Ulo’s topical finasteride products, their dutasteride selections are fully customizable with synergistic add-ons that include minoxidil (up to 7%), caffeine, tretinoin, cetirizine, and melatonin. The clinically backed formulas are designed to deeply penetrate the scalp and follicles without the use of irritants, corticosteroids, or unproven ingredients seen in competing premium brands.
The platform’s Build Your Own Topical feature offers complete customization across the full range of topical electives, including a choice of finasteride or dutasteride with individualized adjuvant combinations.
Key Takeaway: Topical dutasteride delivers the most powerful scalp-targeted DHT reduction available and is well-suited for men with significant hair loss or intensive TRT regimens that do not respond to other approaches.
Non-hormonal growth stimulation provides these unique benefits:
| Benefit: | Details: |
| ✓ Hormone-free treatment | Growth stimulation without hormonal manipulation |
| ✓ Anti-inflammatory | Addresses scalp inflammation contributing to hair loss |
| ✓ High-strength formulas | 7% minoxidil with absorption enhancers |
| ✓ Versatile use | Standalone or in combination with DHT blockers |
Growth stimulators are useful for comprehensive hair restoration during TRT to address non-hormonal hair loss pathways outside of DHT’s purview. Minoxidil is one of the most commonly used medications, acting as a vasodilator to boost scalp circulation while upregulating growth factors to extend the anagen phase of each hair cycle.[20]Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between topical minoxidil 5% alone versus combined with dutasteride (topical 0.02% through microneedling or oral 0.5 mg) in … Continue reading,[21]Koralewicz, M.M., Szatkowska, O.A. (2024). Topical solutions for androgenetic alopecia: evaluating efficacy and safety. Forum Dermatologicum. 10(3). 71-78. Available at: … Continue reading
Calming agents like cetirizine, melatonin, and caffeine address scalp inflammation, another key contributor to follicular damage and hair loss. Caffeine also enhances follicular nutrient supply to act as a growth stimulant, while melatonin’s antioxidant protection reduces shedding.[22]Koralewicz, M.M., Szatkowska, O.A. (2024). Topical solutions for androgenetic alopecia: evaluating efficacy and safety. Forum Dermatologicum. 10(3). 71-78. Available at: … Continue reading
The powerful combination of growth stimulation with anti-inflammatory action can provide standalone benefits or be applied as a complementary therapy with DHT blockers. Studies show that minoxidil is effectively combined with DHT blockers, offering greater outcomes than single-agent therapies. Growth boosters are therefore vital to the success of TRT hair loss prevention protocols.[23]Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between topical minoxidil 5% alone versus combined with dutasteride (topical 0.02% through microneedling or oral 0.5 mg) in … Continue reading,[24]Koralewicz, M.M., Szatkowska, O.A. (2024). Topical solutions for androgenetic alopecia: evaluating efficacy and safety. Forum Dermatologicum. 10(3). 71-78. Available at: … Continue reading
Ulo offers two customizable growth stimulation topicals that can be used alone or in conjunction with DHT blockers, depending on the prescribed protocol. Their Minoxidil + Tretinoin Plus Rx solution features a high 7% minoxidil in combination with tretinoin for optimal absorption. Adjuvants like cetirizine, melatonin, and caffeine may be added for anti-inflammatory support, antioxidant protection, and enhanced microcirculation.
For patients interested in calming the scalp without actives like minoxidil, the Cetirizine Plus Rx solution delivers a proven dose of 1% cetirizine. This potent anti-inflammatory also has anti-histamine properties to support scalp health and hair growth. Caffeine and melatonin may be added for well-rounded, non-hormonal treatment.
Like all Ulo topicals, these selections offer superior scalp penetration without irritating carriers or excipients, making them ideal for extended daily use in patients with sensitive skin or long-term combination therapy needs.
Key Takeaway: Growth booster topicals like minoxidil, caffeine, and melatonin support follicle strength through circulation, inflammation control, and antioxidant activity, and they can be used alone or combined with DHT blockers for greater results.
Quality over-the-counter support offers these foundational advantages:
| Benefit: | Details: |
| ✓ Nutritional support | Addresses deficiencies contributing to hair loss |
| ✓ Scalp optimization | Creates an ideal environment for treatment absorption |
| ✓ Natural ingredients | Active botanicals and peptides |
| ✓ Complete system | Serum, supplements, shampoo, and conditioner |
High-quality, non-prescription products can also help target underlying hair health factors without hormonal suppression. These include nutritional support formulas that help address common deficiencies linked to hair loss. Such formulas may contain active botanical agents with anti-inflammatory or growth-promoting effects, providing gentle systemic support.[25]Koralewicz, M.M., Szatkowska, O.A. (2024). Topical solutions for androgenetic alopecia: evaluating efficacy and safety. Forum Dermatologicum. 10(3). 71-78. Available at: … Continue reading
Specialty hair care products, such as shampoos, conditioners, and serums, nourish and balance the scalp, providing an optimal environment for prescription medications to take hold and support overall treatment objectives. Non-prescription hair growth serums may contain botanical extracts and peptide-based therapeutics that soothe and strengthen the follicles as a complement to medical protocols.
Ulo’s four non-prescription haircare products support foundational hair health in synergy with the brand’s extensive prescription range. Their Hair Growth Serum contains three proprietary peptide blends that demonstrated comparable efficacy to minoxidil in a medically supervised study. Natural active ingredients such as saw palmetto, rosemary oil, and adenosine provide gentle DHT suppression, enhanced circulation, and growth stimulation, respectively.
The nutritional Hair Growth Supplement provides extensive hair and scalp nourishment with proven ingredients like vitamin D, biotin, hydrolyzed fish collagen, and saw palmetto. Antioxidants such as chlorophyll and astaxanthin combat oxidative stress from within.
Lastly, the Thickening Shampoo and Conditioner provide gentle daily scalp optimization with natural actives like caffeine to boost circulation, keratin to strengthen strands, and saw palmetto to suppress DHT levels. The PhD scientist-crafted formulas are free of known irritants and artificial fragrances, made instead with nourishing oils and amino acids that encourage natural hair growth and work to improve prescription treatment response.
Key Takeaway: Over-the-counter serums, supplements, and hair care products build the foundation for long-term hair preservation by supporting scalp health, addressing nutritional needs, and enhancing the effects of prescription treatments.
Managing hair health during TRT requires clinical expertise to address unique hormonal challenges that generic treatments often miss. Ulo’s multidisciplinary care, personalized protocols, advanced formulations, and high-quality standards make it a leader in TRT-focused hair restoration telehealth. Below is a summary of what sets Ulo apart.
Ulo partners exclusively with licensed and board-certified physicians to provide safe and effective care that meets the highest regulatory and safety standards. Full medical consultations and evaluations at onboarding enable Ulo’s qualified doctors to craft tailored treatment plans, while ongoing monitoring protocols establish positive outcomes.
Ulo operates as a leading telehealth provider with state-of-the-art services in both hair restoration and TRT, employing physicians with experience in both areas. The specialists at Ulo are uniquely qualified to address TRT-related hair loss with practical insights and actionable solutions.
While most competitors tout fixed, one-size-fits-all formulations, Ulo, in contrast, carries truly customizable treatment options with adjustable doses and elective add-ons to meet individual patient needs. This is an important feature for TRT patients, who may require medications that vary from standard formulas and can be adjusted to changing responses over time.
Ulo ensures product quality by sourcing all medications from certified domestic pharmacies. Formulations are designed for peak bioavailability with innovative delivery systems, free of harsh additives like propylene glycol, which can be found in many hair loss products.
Ulo’s fixed-rate monthly subscription pricing avoids the rising costs and hidden fees that are common among telemedicine competitors. This allows patients to budget for long-term integrated care. Subscriptions cover all essential services, including physician consultations, follow-ups, prescription deliveries, and more. The platform’s responsive customer service ensures uninterrupted treatment and full support throughout the process.
The chart below illustrates the main differences between Ulo’s expert model and standard telehealth hair loss providers, showcasing how Ulo is uniquely equipped to meet the hair restoration needs of TRT patients.
| Feature | Ulo | Standard Providers |
| Medical Oversight | Board-certified physicians with TRT and hair loss expertise | Generic telehealth consultations |
| Customization | True concentration flexibility (0.005%-0.2%); adjuvant options | Fixed formulations; limited options |
| Formulation Quality | Pharmaceutical-grade; soft gel dutasteride for optimal bioavailability | Standard compounding; limited bioavailability |
| Ingredient Safety | Irritant-free; no propylene glycol or corticosteroids | Often contains propylene glycol and harsh excipients |
| TRT Knowledge | Dual expertise in hormone optimization and hair restoration | Hair loss focus only; limited TRT understanding |
| Pricing Model | Transparent flat-rate monthly subscriptions | Hidden fees and escalating costs are common |
| Quality Assurance | Certificates of analysis; FDA-approved pharmacy sourcing | Limited transparency; variable quality standards |
| Combination Options | Extensive adjuvant library (tretinoin, caffeine, melatonin, cetirizine) | Basic combinations; limited synergistic ingredients |
| Follow-up Care | Unlimited physician access; regular monitoring protocols | Limited follow-up; basic customer service |
| Treatment Coordination | Can coordinate with existing TRT protocols | No hormone therapy coordination |
Hair restoration therapies, especially hormonal medications like DHT blockers, can interact with TRT and require strict medical oversight to monitor for adverse reactions. Among the different treatment methods discussed, safety profiles vary. Here is a brief overview of their safety findings. All medical concerns should ultimately be discussed with a qualified clinician.
Prescription treatments display differing safety profiles based on the delivery method, whether oral or topical. Oral DHT blockers have systemic exposure and therefore carry the risk of systemic side effects like sexual dysfunction, mood disorders, and gynecomastia; all of which require prompt medical evaluation. Oral minoxidil requires cardiovascular monitoring due to its circulatory effects.
Topical DHT blockers have limited systemic exposure and therefore milder associated side effects, often no more than minor localized scalp irritation that tends to resolve within 2-4 weeks. Regular follow-up exams are required every 3-6 months during the first year of prescribed hair loss treatment.
Over-the-counter products, such as shampoos and nutritional supplements, carry minimal risk; however, patients with allergies or sensitivities should carefully read the ingredients before use. OTC treatments can sometimes interact with medications or exacerbate underlying conditions, so it’s best to consult a healthcare professional for guidance.
Contraindications for prescription DHT blockers include severe cardiovascular conditions, active scalp infections, and liver disease. Women who are pregnant or plan to have a future pregnancy should avoid DHT blockers due to possible birth defects.
Consult your doctor for a complete list of all possible side effects, contraindications, and risk mitigation strategies.
Accelerated hair loss can be one of the most frustrating and disruptive elements of TRT, calling for sophisticated approaches that go beyond conventional hair loss treatment. TRT creates unique challenges that demand advanced intervention strategies.
Thanks to the wide-ranging methods discussed in this guide, men no longer have to choose between hair preservation and hormone optimization on TRT. With dual expertise, qualified medical oversight, and tailored formulations that meet leading quality standards, Ulo rises to meet the varied needs of TRT patients where generic providers fall short.
Don’t allow hair loss to interfere with your journey to hormonal health and restored vitality. Ulo’s scientific approach and clinical experience make them the clear choice for men seeking to maintain their hair while optimizing their hormone therapy. Consult with a licensed Ulo physician today to craft a personalized treatment plan.
Discover your unique hair preservation strategy with Ulo.
Does Ulo offer testosterone replacement therapy?
Yes, Ulo has testosterone replacement therapy offerings that include injections, topicals, and oral preparations. Like Ulo’s hair restoration services, their TRT program is medically rigorous and tailored to individual needs. Ulo’s multidisciplinary expertise gives them unique insight, enabling them to properly address both sides of the hormone equation when treating TRT-related hair loss.
Should I discuss hair loss concerns and treatment options with my doctor when starting TRT?
Yes, all hair concerns should be discussed with your clinician before starting TRT to enable proactive treatment planning and fully informed care decisions. Your doctor will assess your health profile and treatment goals to decide whether hair loss intervention is an appropriate choice and, if so, which method is best for you.
Which hair loss treatments require a prescription?
Prescriptions are required for DHT blockers like dutasteride and finasteride, growth stimulators like minoxidil, and some customized topicals. All require proper diagnostic and follow-up care protocols that meet clinical safety standards. Options that don’t require a prescription include over-the-counter nutritional supplements, serums, shampoos, and conditioners with unrestricted active ingredients like botanical extracts and peptides.
Can I combine hair loss treatment methods?
Yes, some hair loss treatments can be combined for synergistic effects. Popular combinations include minoxidil with DHT blockers (dutasteride or finasteride), alongside nutritional support. Treatments should only be combined under close medical supervision to avoid harmful interactions.
When do most hair loss treatments show results?
Although results differ depending on the patient and treatment type, most users experience initial effects within the first 3-6 months and more substantial benefits over 6-18 months. Consistent daily administration is required to successfully achieve and maintain hair loss treatment benefits.
What are common hair loss treatment side effects?
Potential side effects vary based on the type of treatment and are usually controllable with the right medical care. Topical treatments can produce mild and temporary irritation at the application site. Although rare, oral DHT-blocking medications can lead to systemic side effects like sexual dysfunction and mood disturbances requiring immediate medical attention. Thoroughly discuss all potential side effects and suitable monitoring protocols with your provider.
How much do Ulo’s hair loss treatments typically cost?
Ulo’s price points vary by treatment type and level of customization. Pricing reflects flat-rate monthly subscription fees that not only cover the cost of the medication but also include essential telehealth services like doctor consultations, follow-ups, and prescription deliveries. Their prescription oral treatments range from $24 to $65 per month, while topicals range from about $49 to $94 per month. OTC support products start at $29 per month.
What should I expect during my first consultation with Ulo?
The Ulo onboarding process starts with a thorough medical intake form that covers your health profile, treatment goals, and current medications. You will be partnered with one of Ulo’s licensed physicians, who, after reviewing your information, will collaborate with you to design a treatment plan tailored to your specific needs. During the initial consultation, your doctor will thoroughly discuss treatment options, realistic expectations, safety, and follow-up protocols to guarantee safe and effective care.
References[+]
| ↑1, ↑10, ↑11 | Owecka, B., Tomaszewska, A., Dobrzeniecki, K., Owecki, M. (2024). The Hormonal Background of Hair Loss in Non-Scarring Alopecias. Biomedicines. 12(3). 513. Available at: https://doi.org/10.3390/biomedicines12030513 |
|---|---|
| ↑2, ↑4 | Owecka, B., Tomaszewska, A., Dobrzeniecki, K., Owecki, M. (2024). The Hormonal Background of Hair Loss in Non-Scarring Alopecias. Biomedicines. 12(3). 513. Available at: https://doi.org/10.3390/biomedicines12030513 |
| ↑3, ↑6 | Stocks, B., Asempa, O. (2025). Does testosterone replacement therapy cause hair loss? Baylor College of Medicine. Available at: https://blogs.bcm.edu/2025/08/11/does-testosterone-replacement-therapy-cause-hair-loss/ (Accessed: November 2025) |
| ↑5 | Borst, S.E., Shuster, J.J., Zou, B., Ye, F., Jia, H., Wokhlu, A., Yarrow, J.F. (2014). Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systemic review and meta-analysis. BMC Medicine. 12. 211. Available at: https://doi.org/10.1186/s12916-014-0211-5 |
| ↑7 | Shoskes, J.J., Wilson, M.K., Spinner, M.L. (2016). Pharmacology of testosterone replacement therapy preparations. Translational Andrology and Urology. 5(6). 834-843. Available at: https://doi.org/10.21037/tau.2016.07.10 |
| ↑8 | Saad, F., Aversa, A., Isidori, A.M., Zafalon, L., Zitzmann, M., Gooren, L. (2011). Onset of effects of testosterone treatment and time span until maximum effects are achieved. European Journal of Endocrinology. 165(5). 675-685. Available at: https://doi.org/10.1530/EJE-11-0221 |
| ↑9 | Fu, D., Huang, J., Li, K., Chen, Y., He, Y., Sun, Y., Guo, Y., Du, L., Qu, Q., Miao, Y., Hu, Z. (2021). Dihydrotestosterone-induced hair regrowth inhibition by activating androgen receptor in C57BL6 mice simulates androgenetic alopecia. Biomedicine & Pharmacology. 137. 111247. Available at: https://doi.org/10.1016/j.biopha.2021.111247 |
| ↑12 | Arif, T., Dorjay, K., Adil, M., Sami, M. (2017). Dutasteride in Androgenetic Alopecia: An Update. Current Clinical Pharmacology. 12(1). 31-35. Available at: https://doi.org/10.2174/1574884712666170310111125 |
| ↑13 | Harcha, W.G., Martinez, J.B., Tsai, T-F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., Chetty, D. (2014). A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. Journal of the American Academy of Dermatology. 70(3). 489-498. Available at: https://doi.org/10.1016/j.jaad.2013.10.049 |
| ↑14, ↑16 | Kinter KJ, Amraei R, Anekar AA. Biochemistry, Dihydrotestosterone. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557634/ (Accessed: November 2025) |
| ↑15 | Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., Falques, M., Otero, R., Tamarit, M.L., Galvan, J., Tebbs, V., Massana, E. (2021). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology & Venereology. 36(2). Available at: https://doi.org/10.1111/jdv.17738 |
| ↑17 | Arif, T., Dorjay, K., Adil, M., Sami, M. (2017). Dutasteride in Androgenetic Alopecia: An Update. Current Clinical Pharmacology. 12(1). 31-35. Available at: https://doi.org/10.2174/1574884712666170310111125 |
| ↑18 | Harcha, W.G., Martinez, J.B., Tsai, T-F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., Chetty, D. (2014). A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. Journal of the American Academy of Dermatology. 70(3). 489-498. Available at: https://doi.org/10.1016/j.jaad.2013.10.049 |
| ↑19 | Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between topical minoxidil 5% alone versus combined with dutasteride (topical 0.02% through microneedling or oral 0.5 mg) in treatment of androgenetic alopecia. QJM: An International Journal of Medicine, 117(Supplement 1), hcae175.207. Available at: https://doi.org/10.1093/qjmed/hcae175.207 |
| ↑20, ↑23 | Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between topical minoxidil 5% alone versus combined with dutasteride (topical 0.02% through microneedling or oral 0.5 mg) in treatment of androgenetic alopecia. QJM: An International Journal of Medicine, 117(Supplement 1), hcae175.207. Available at: https://doi.org/10.1093/qjmed/hcae175.207 |
| ↑21, ↑22, ↑24, ↑25 | Koralewicz, M.M., Szatkowska, O.A. (2024). Topical solutions for androgenetic alopecia: evaluating efficacy and safety. Forum Dermatologicum. 10(3). 71-78. Available at: https://doi.org/10.5603/fd.101208 |
Millions worldwide experience hair loss, with androgenic alopecia (AGA) as the leading cause. Also known as male- or female-pattern hair loss, AGA becomes more prevalent with age. It affects a majority of men over the age of 50 and a substantial number of postmenopausal women. Hair thinning and balding due to AGA is not just a cosmetic concern but can significantly detract from self-esteem and overall quality of life.
Among popular hair restoration treatments, topical dutasteride is a breakthrough solution to the serious side effects and plateaued results many experience. This potent DHT blocker offers more targeted therapeutic benefits with minimal systemic exposure and reduced risk. However, not all topical dutasteride products meet quality standards, so specialized guidance is key to selecting the right formula.
The PhD-directed board of experts at Perfect Hair Health draws from the latest clinical data and verified customer feedback to deliver this comprehensive guide to the best topical dutasteride products available in 2025. Through our research collaboration with leading innovators in the field, including our partnership with Ulo, we provide unique insights into the most advanced hair restoration protocols.
Read on for our detailed analysis and evidence-based product recommendations.
Hair gains bigger than finasteride? Dutasteride makes this possible, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
Here’s a brief comparison of our most highly recommended topical dutasteride products. Continue reading for in-depth reviews.
| Product | Price | Dutasteride % | Delivery Method | Key Feature |
| Ulo | $84+/month | 0.02%-0.2% | Solution | PhD-developed extensive customization |
| XYON Health | $129+/month | 2% | Gel | Patented controlled-release technology |
| Strut Health | $69/month | Up to 0.1% | Gel | Alcohol-free and customizable |
| Blends | ~$45/month (90-day supply) | 0.3% | Gel | Proprietary hydrating formula |
| Happy Head | $59-89+/month | Up to 0.3% | Solution | Potency and customization |
| Maximus | $54.99 | 0.1% | Gel | Customizability, including the addition of antihistamines |
| Miiskin | $30-59 + Rx cost | Variable, custom | Solution | No subscription required |
| Musely | $33/month | 0.3% | Solution | Lowest cost option |
To begin, we will briefly explore the scientific background of topical dutasteride, including how it works to treat AGA and the distinct benefits of topical preparations.
Topical dutasteride is valued as a breakthrough treatment for AGA due to its powerful and targeted effects on the molecular levels of hair loss. The root cause of AGA is the testosterone-derived hormone dihydrotestosterone (DHT), which adheres to hair follicles and leads to follicular degeneration and hair loss over time. Dutasteride is classified as a DHT blocker, reducing DHT levels on the scalp to combat hair loss.[1]R. Cuevas-Díaz Durán., Martinez-Ledesma, E., Garcia-Garcia, M., Gauzin, D.B., Sarro-Ramirez, A., Gonzalez-Carrillo, C., Rodriguez-Sardin, D., Fuentes, A., Cardenas-Lopez, A. (2024) The Biology and … Continue reading,[2]Dhurat, R., Sharma, A., Rudnicka, L., Kroumpouzos, G., Kassir, M., Galadari, H., Wollina, U., Lotti, T., Golubović, M., Binic, I., Grabbe, S., & Goldust, M. (2020). 5‐Alpha reductase … Continue reading
Among DHT-blocking treatments, dutasteride is considered the most potent due to its dual enzyme activity. Testosterone is converted into DHT through two forms of 5α-reductase enzymes: Type I is located in the skin and sebaceous glands, and Type II is in the hair follicles. Finasteride inhibits only Type II for about 70% DHT reduction, while dutasteride inhibits both types to elicit greater DHT suppression (up to 93% in the skin and 99% in the follicles).[3]Arif, T., Dorjay, K., Adil, M., & Sami, M. (2017). Dutasteride in Androgenetic Alopecia: An Update.. Current clinical pharmacology, 12 1, 31-35. Available at: … Continue reading
Dutasteride’s powerful DHT inhibition leads to greater therapeutic outcomes in hair restoration. Clinical findings indicate dutasteride’s superior effects on hair count and mass in comparison to finasteride in terms of both quantitative and temporal metrics. While finasteride’s benefits tend to plateau after about 12 months of treatment, dutasteride demonstrates continued improvements up to 12 months and beyond.[4]Harcha, W., Martínez, J., Tsai, T., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study of the efficacy … Continue reading
Studies show that topical dutasteride is a safer option than oral with comparable and often better treatment outcomes. When applied locally to the scalp, dutasteride delivers targeted treatment with limited systemic exposure and a reduced risk of serious side effects. If present, adverse reactions to topical dutasteride tend to be transient and mild, in contrast to oral dutasteride’s potential systemic side effects like sexual dysfunction and mood disorders.[5]Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between Topical Minoxidil 5% Alone versus Combined with Dutasteride (Topical 0.02% through Microneedling or Oral 0.5 mg) in … Continue reading,[6]Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: … Continue reading
This and other clinically proposed advantages of topical dutasteride are briefly summarized as follows:
Plus, patients have a choice of different delivery methods (e.g., sprays, gels, solutions), which can offer greater convenience and adherence.
Combined, these factors locate topical dutasteride as a more effective and flexible hair restoration intervention with a greater safety profile than its oral counterpart.[7]Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between Topical Minoxidil 5% Alone versus Combined with Dutasteride (Topical 0.02% through Microneedling or Oral 0.5 mg) in … Continue reading,[8]Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: … Continue reading,[9]Radhakrishnan, P., Mariyappan, G., Karthi, J., & Jaisumi, K. (2024). Formulating, Optimizing and Evaluation of Dutasteride Loaded Insitu-Emulgel for Androgenetic Alopecia. International Journal … Continue reading
To help navigate the topical dutasteride market, we developed these quality benchmarks grounded in clinical expertise, scientific evidence, and patient feedback.
Quality dutasteride products demonstrate notable DHT reduction and improved hair growth within 3-6 months, with these effects continuing over 12 months or longer. The products recommended in this article were assessed based on documented DHT reductions, verified patient feedback, and peer-reviewed studies.
Given the prescription status of topical dutasteride, we verified each telehealth provider’s legitimacy in terms of physician supervision, adherence to legal requirements, and adherence to sound safety protocols. These include proper diagnostic procedures before prescribing, as well as close follow-up care to monitor for side effects and adjust the treatment as needed for optimal outcomes. Trustworthy providers exclusively partner with licensed physicians specialized in hair restoration.
When it comes to quality assurance, suppliers must partner only with authorized domestic pharmacies to source their compounded medications. Complete ingredient transparency and labeling of allergens establishes acceptable safety profiles.
Varied patient needs call for customizable treatments that exceed standard one-size-fits-all protocols. Outstanding brands provide a personalized approach through extensive customization options, including variable concentrations, adjuvant blends (e.g., minoxidil), and various delivery formats (e.g., solutions and controlled-release gels). These tailored therapies are physician-crafted to safely elicit the best results.
Prolonged, uninterrupted treatment is necessary to achieve positive results, highlighting the importance of user comfort and satisfaction. Practical considerations, such as application convenience, precise instructions, manageable dose routines, and excellent customer support, all influence treatment adherence.
Because treatment sustainability also depends on affordability, we also examined billing models and price transparency. Premium suppliers have honest and reasonable pricing that covers primary treatment costs (prescriptions, consultations, deliveries, and monitoring), free of hidden fees that are common among telehealth providers.
Begin by assessing your hair loss level and treatment objectives, determining whether moderate maintenance or intensive regrowth protocols are needed. Further considerations include application method preferences (gels, solutions, sprays, etc.), helpful adjuvants, and skin sensitivities. Budgetary limitations and your required level of physician involvement also come into play.
With these factors in mind, let’s dive into the following product reviews that highlight distinct approaches.
| Pros: | Cons: |
| ✓ PhD-scientist developed with thorough customization | ✗ USA-only service for prescription treatments |
| ✓ Customizable concentrations with adjuvant ingredients | |
| ✓ Board-certified physician oversight, monitoring, and tailored treatment protocols | |
| ✓ Verified quality and safety | |
| ✓ Full price transparency and free shipping |
The top position goes to Ulo, a leader in clinical rigor and precision hair loss medicine. Known for their highly individualized treatments, cutting-edge protocols, and PhD oversight, Ulo’s offerings are among the most comprehensive and patient-centered available. Their dual topical dutasteride solution with minoxidil delivers potent DHT suppression and new growth stimulation, proven to be more effective than either therapy alone.
Ulo’s topical systems feature customization across the spectrum, from dutasteride concentration (0.02% for lighter therapy to 0.2% for more aggressive intervention) to adjuvants like absorption enhancers, antioxidants, and vasodilators. Premium services include licensed dermatologist consultations, tailored treatment plans, and continued medical oversight, with a starting monthly subscription price of $84 and no added fees.
All Ulo safety and medication sourcing practices adhere to the highest regulatory standards, including partnerships with certified domestic pharmacies and strict follow-up protocols. Full ingredient transparency and irritant-free formulations establish excellent safety profiles. Patients enjoy free prescription deliveries and responsive support through Ulo’s sleek telehealth platform.
Our Verdict: Ulo’s advanced dual formula harnesses the power of customized topical dutasteride to deliver the gold standard of hair loss therapy. With PhD-developed formulas, genuine customization, and complete medical oversight, this platform offers proven benefits through a transparent monthly subscription that starts at $84. Their dedication to upholding the highest standards of safe and effective care positions Ulo as the best choice for your hair restoration needs.
| Pros: | Cons: |
| ✓ Proprietary SiloxysSystem™ Gel for timed release | ✗ Premium pricing at $129/month |
| ✓ Highest concentration (2% dutasteride) for aggressive protocols | ✗ Limited customization options |
| ✓ Physician oversight | ✗ Not recommended for sensitive skin |
| ✓ Service area includes the US and Canada |
XYON stands out for its innovative, technology-driven approach, exemplified by its proprietary SiloxysSystem Gel delivery base, which contains delayed-release topical dutasteride at a high concentration of 2%. This controlled-release method allows for a higher dutasteride concentration and more targeted treatment, protecting against systemic exposure and potentially serious side effects.
While this treatment is a strong option for advanced hair loss cases due to its potency, XYON emphasizes its advanced and proven delivery method over treatment customization features. Monotherapy involves a fixed dose of 2% dutasteride, which may be too strong for some patients. Excipients include ingredients like silicone that are not recommended for sensitive skin.
XYON’s premium price point reflects not only its forward-looking strategy but also its high medical standards, as the platform offers qualified physician support throughout the process.
Our Verdict: XYON’s topical dutasteride formulation delivers maximum treatment with minimal systemic risk through its unique delayed-release carrier gel. It is recommended for advanced hair loss patients who can tolerate higher doses and potential irritants, particularly those who don’t mind paying a premium for its advanced technology development.
| Pros: | Cons: |
|---|---|
| ✓ Good value at $69/month with full customization | ✗ Lower maximum dutasteride concentration (0.1%) |
| ✓ Alcohol-free, preservative-free options available | ✗ Moderate doses may be insufficient for advanced hair loss cases |
| ✓ Extensive customization of adjuvant ingredients | ✗ Occasional gaps in customer service are cited |
| ✓ Licensed medical oversight with hair loss specialization | ✗ Service area excludes Arkansas |
Strut Health is a solid mid-tier option that balances accessible pricing with medically guided customization, emphasizing cost-effectiveness over potency. The preservative- and alcohol-free dutasteride gel contains a moderate 0.1% dutasteride, with tailored add-on options including minoxidil, biotin, and tretinoin at varying concentrations. Capped at such a middling dose, this gentle gel formula is best for mild to moderate hair loss patients with sensitive or dry skin.
Fluocinolone, a corticosteroid, is also available as an adjuvant. While leading providers like Ulo avoid such ingredients due to potential safety concerns, Strut provides appropriate safety disclaimers and maintains an overall emphasis on ingredient transparency, backed by medical oversight.
Strut’s subscription fee of $69 per month for topical dutasteride treatment is a competitive offering, covering consultations, follow-ups, and prescription shipping. Patients cite flexible cancellation policies and rapid home deliveries as notable benefits. We detected some mixed reviews regarding delayed customer service responses and logistical issues.
Our Verdict: Strut Health offers a compelling value proposition with its topical dutasteride gel, priced at only $69 per month, and features that rival those of more expensive providers. The gentle formula with a limited 0.1% dutasteride concentration suits patients with moderate treatment needs who are seeking a budget-friendly option with flexible add-ons and legitimate medical oversight.
| Pros: | Cons: |
| ✓ Doctor-founded with hair restoration specialization | ✗ 90-day supply requirement may not suit all patients |
| ✓ Competitive pricing at ~$45/month (90-day supply) | ✗ Fixed formula despite “personalized” marketing claims |
| ✓ Preservative-free, alcohol-free formula with 5 active ingredients | ✗ Includes latanoprost with limited long-term safety data for scalp use |
| ✓ 0.3% dutasteride and 7.5% minoxidil offer powerful DHT inhibition | ✗ Lacks true customization compared to leading competitors |
| ✓ Proprietary hydrating gel base with advanced formulation |
Blends is a physician-founded company with a heavy focus on cutting-edge manufacturing methods and sophisticated formulations. Their small but specialized catalog includes this topical dutasteride treatment made with a proprietary gel base for timed medication release and scalp hydration. Free of alcohol and preservatives, the concentrated 0.3% dutasteride and 7.5% minoxidil formula offers powerful therapeutic effects.
Although Blends asserts the “personalized” and “customized” nature of its products, its Growth Pro Topical gel is actually a comprehensive fixed formula with three adjuvant ingredients in addition to dutasteride and minoxidil: tretinoin, latanoprost, and ketoconazole. Competitively priced at about $45/month (sold in 90-day batches), this offering stands out for its full ingredient transparency and high concentrations suited to aggressive treatment protocols.
However, the use of latanoprost poses concerns due to the lack of long-term studies confirming its safety and efficacy as a topical hair loss treatment. Despite marketing claims of customized protocols, Blends does not allow formulation adjustments to this fixed gel product. Although the monthly cost is lower than that of most leading brands of comparable quality, the minimum purchase requirement of a 90-day supply (~$135) may not suit all patients.
Our Verdict: This physician-crafted gel formula from Blends is competitively priced, featuring high concentrations of synergistic ingredients for advanced hair loss treatment. Its positioning as a mid-level selection rather than a top choice is due to its false personalization claims and unproven add-on ingredient.
| Pros: | Cons: |
| ✓ Dermatologist oversight with ongoing support | ✗ Limited dutasteride concentration options |
| ✓ 0.3% dutasteride and 8% minoxidil formula with customizable add-ons, including ketoconazole | ✗ Pricing increases after the initial months and can reach ~$109 |
| ✓ Established brand with a 6-month money-back guarantee | ✗ Some formulations contain potential irritants |
| ✓ User-friendly platform and free consultation | ✗ Shipping and customer service inconsistencies |
Happy Head represents a dependable option for targeted hair restoration, recognized for its dermatologist-backed and customizable treatments. This hybrid dutasteride-minoxidil solution offers a strong dose of 0.3% dutasteride with up to 8% minoxidil for effective DHT reduction. Elective adjuvants include retinoic acid and hydrocortisone. Anti-dandruff agent ketoconazole can be added for an additional fee.
While some clinicians warn against the use of topical corticosteroids like hydrocortisone, Happy Head seems to follow established medical safety protocols with appropriate disclaimers. Inactive ingredients like alcohol and propylene glycol can irritate and should be approached with caution. Highly concentrated DHT blockers with harsh excipients require close medical oversight, and patients with sensitive skin may want to seek other options.
Although transparent about costs, Happy Head’s variable pricing can grow quickly with treatment duration and formulation. Their topical dutasteride solution starts at $59 per month and shifts to $89 after the first six months. The anti-dandruff adjuvant can be added for $20, bringing the total to $109 per month, which exceeds the cost of some comparable providers. Mixed patient reviews cite issues with deliveries and logistical support.
Our Verdict: This combination treatment from Happy Head is a solid choice for patients in need of more aggressive treatment and concentrated formulas. Continued dermatologist oversight, personalization options, and potent formulations can help patients whose results may have stalled on other treatments. However, highly active ingredients and variable pricing may deter those seeking gentler therapies and fixed costs.
| Pros: | Cons: |
| ✓ High level of personalization with physician-driven telehealth oversight | ✗ Limited long-term safety data for some ingredient combinations |
| ✓ Competitive monthly pricing | ✗ Availability restricted to the U.S. |
| ✓ Physician-guided treatment plans and ongoing clinical support | ✗ No subscription flexibility (all via 90-day supply) |
| ✓ Proprietary gel base designed for scalp absorption and minimal mess | |
| ✓ Evidence-informed protocols supported by board-certified physicians |
Maximus Tribe’s Max-Absorb Gel is a highly customizable, prescription-only hair loss solution leveraging physician-driven telehealth and evidence-based formulation. At $54.99 for a 90-day supply, it offers a lot of value for those looking for efficacy and clinical support. The core formulation includes dutasteride (0.1%) with optional minoxidil, tretinoin, and fexofenadine, delivered in a proprietary gel base that is designed to minimize mess and maximize scalp coverage.
Maximus prioritizes convenience and targeted care: onboarding and ongoing support are managed by board-certified doctors, and the medication is shipped directly to the patient for easy home application. While ingredient customization and clinical guidance are strengths, choices remain limited in comparison to other telehealth options (like Ulo).
Our Verdict: Maximus offers a well-priced topical dutasteride gel that balances multi-ingredient efficacy with convenient home use and physician oversight.
| Pros: | Cons: |
| ✓ Direct board-certified dermatologist consultations | ✗ Total cost varies with third-party pharmacy fees |
| ✓ Custom-compounded formulations with up to 3 active ingredients | ✗ Basic compounding without advanced delivery systems |
| ✓ No automatic subscriptions—pay per order | ✗ Less specialized in hair loss compared to dedicated platforms |
| ✓ Legitimate medical oversight with prescription flexibility | |
| ✓ Serves both the USA and Mexico |
Miiskin differs from the subscription-based providers on this list, as it facilitates direct medical consultations between patients and qualified dermatologists. The pay-as-you-go model allows legitimate medical access without subscription requirements. Miiskin charges $59 for initial consultations and $30 for returning visits. Medication fees vary and are charged separately at the pharmacy where the medication is filled.
While the dermatologist-direct platform increases access to qualified care and prescription hair loss treatments, its simple compounded formulas lack the customization and specialization of leading brands. Ingredient disclosure is limited beyond general mentions of three-active-ingredient formulations and the listing of a combination of dutasteride and minoxidil therapy.
The model does not permit total cost calculation until third-party pharmacy checkout, separate from Miiskin’s billing process, which only covers prescribing dermatologist consultation fees.
Our Verdict: Although Miiskin offers medical legitimacy, the dermatology consultation platform lacks the treatment specialization and transparency of top dutasteride therapy sources. It may be a valuable tool for patients with hair loss to connect with qualified providers and access basic compounded formulas.
| Pros: | Cons: |
| ✓ Lowest cost option at $33/month | ✗ Minimal medical oversight compared to competitors |
| ✓ 0.3% dutasteride concentration in a customizable formula | ✗ Limited customization options |
| ✓ Aesthetic medicine platform with dermatologist involvement | ✗ Medical rigor lacking |
| ✓ Multi-ingredient formulations | ✗ Less specialized hair loss expertise |
| ✗ Some ingredients are not recommended for sensitive skin |
Musely’s topical dutasteride solution occupies the final slot on our list as the lowest-priced option at just $33 per month (plus a one-time $20 consultation fee at onboarding). The lower price point reflects less extensive offerings that are well-suited for patients who prefer a more self-directed approach. This tailored prescription formulation combines up to 0.3% dutasteride and 8% minoxidil with optional add-ons of ketoconazole to fight dandruff and hydrocortisone to reduce inflammation.
It is less customizable than other options, characteristic of Musely’s simplified strategy. Excipients like propylene glycol and alcohol may deter ingredient-conscious consumers due to irritant potential. While such potent formulas and highly active ingredients offer more powerful treatment, they also carry a greater risk of adverse reactions and call for qualified medical supervision.
However, unlike premium providers, Musely is not known for close medical oversight. In fact, the aesthetic medicine platform has a markedly superficial onboarding and assessment process that falls short of the thorough medical evaluations offered by top providers. Although clinicians are involved in the platform, follow-up care and specialized hair restoration knowledge are lacking, according to customer reviews.
Our Verdict: Musely is included as a purely budget-friendly option for cost-conscious patients who understand the importance of self-monitoring and supplement with appropriate medical consultation.
According to our thorough analysis, Ulo is the best choice for topical dutasteride therapy in 2025. This platform stands out for its rigorous scientific foundation, highly tailored treatments, and commitment to close medical oversight, outperforming the fixed protocols and misleading marketing claims of its peers.
Rather than standardized approaches, Ulo’s PhD-designed therapies with built-in customization features meet the individual needs of each patient, representing the pinnacle of evidence-based precision care in the rapidly evolving field of hair restoration medicine.
Clinical findings support the following timeline of expected treatment outcomes in topical dutasteride therapy. Familiarity with these will ground your therapy in a realistic outlook, encouraging patience and prolonged adherence.[10]Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between Topical Minoxidil 5% Alone versus Combined with Dutasteride (Topical 0.02% through Microneedling or Oral 0.5 mg) in … Continue reading,[11]Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: … Continue reading,[12]Radhakrishnan, P., Mariyappan, G., Karthi, J., & Jaisumi, K. (2024). Formulating, Optimizing and Evaluation of Dutasteride Loaded Insitu-Emulgel for Androgenetic Alopecia. International Journal … Continue reading
Topical dutasteride is considered a safe hair loss intervention, particularly when weighed against oral formulas that can carry substantial risk due to systemic exposure. Nonetheless, informed risk assessment and familiarity with safety protocols are recommended before beginning any new treatment. Here is a brief overview of medical data on the safety and side effects of topical dutasteride.[13]Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: … Continue reading
Adverse patient reactions to topical dutasteride are rare and typically limited to mild, localized scalp irritation that resolves in 2-4 weeks, occurring in only about 5-10% of new users. Depending on individual sensitivities and irritating formulation additives like alcohol, scalp dryness, flaking, and contact dermatitis are possible, though the latter is less common. Mild systemic side effects are extremely rare, documented in under 2% of patients.
Also rare are severe allergic reactions and pronounced systemic side effects, which can include sexual dysfunction, mood disorders, and gynecomastia. These all warrant prompt medical intervention. Topical dutasteride is not recommended in patients with active scalp infections and hormonal disorders.
Topical dutasteride is strongly contraindicated in pregnant or nursing women and in those planning future pregnancies due to the risk of birth defects. Patients with known hypersensitivity to DHT blockers should also avoid use.
Safety and optimal treatment outcomes depend on regular medical follow-up evaluations, typically at three-month intervals in the first year. This enables early identification of problems and treatment response evaluation.
Cutting-edge topical dutasteride formulations bridge the gap between pharmacological precision and patient satisfaction in hair restoration therapy. Available products represent a spectrum of targeted, proven treatments that are considered safer and more customizable than previous-generation modalities.
Our thorough review of the evolving market identified clear leaders, with Ulo setting itself apart as an exemplary provider of topical dutasteride. Its scientifically optimized protocols are tailored to meet the individual needs of each patient, with qualified medical supervision to ensure a safe and transformative treatment experience.
As hair restoration technology advances, leading topical dutasteride formulations, such as Ulo’s, are at the forefront, empowering users with convenient and clinically proven solutions that not only enhance appearance but also improve quality of life.
Explore Ulo’s advanced topical dutasteride treatments today.
Do I need a prescription for topical dutasteride? Yes, topical dutasteride is a prescription-only treatment in the United States. This ensures proper candidate screening and legitimate medical supervision throughout treatment.
When can I expect results? Initial DHT suppression on the scalp occurs within the first few days, but visible changes in hair growth typically emerge within 3-4 months. Benefits generally reach their peak after 12-18 months of consistent application.
How do I apply topical dutasteride? Use the product applicator to deposit the treatment directly onto clean, dry scalp areas where you are experiencing hair loss. Allow it to absorb fully before using other hair products. Following application, avoid wetting the hair for several hours and wash your hands thoroughly.
Can I combine topical dutasteride with other treatments? Yes, the benefits of topical dutasteride can be enhanced through combination therapies, such as minoxidil. Consult your prescribing doctor to learn about safe and effective hybrid treatments.
What will happen if I stop treatment? When treatment is halted, scalp DHT levels gradually return to starting levels, which typically leads to resumed hair loss after several months.
How much does topical dutasteride cost? Pricing varies from about $30 to $135+ for a monthly supply, depending on concentration, formulation, brand, and telehealth services included. Leading brands provide comprehensive medical oversight and customization, offering transparent and flat-rate monthly subscription fees.
References[+]
| ↑1 | R. Cuevas-Díaz Durán., Martinez-Ledesma, E., Garcia-Garcia, M., Gauzin, D.B., Sarro-Ramirez, A., Gonzalez-Carrillo, C., Rodriguez-Sardin, D., Fuentes, A., Cardenas-Lopez, A. (2024) The Biology and Genomics of Human Hair Follicles: A Focus on Androgenetic Alopecia. International Journal of Molecular Sciences, 25. Available at: https://doi.org/10.3390/ijms25052542. |
|---|---|
| ↑2 | Dhurat, R., Sharma, A., Rudnicka, L., Kroumpouzos, G., Kassir, M., Galadari, H., Wollina, U., Lotti, T., Golubović, M., Binic, I., Grabbe, S., & Goldust, M. (2020). 5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. Dermatologic Therapy, 33. Available at: https://doi.org/10.1111/dth.13379. |
| ↑3 | Arif, T., Dorjay, K., Adil, M., & Sami, M. (2017). Dutasteride in Androgenetic Alopecia: An Update.. Current clinical pharmacology, 12 1, 31-35. Available at: https://doi.org/10.2174/1574884712666170310111125. |
| ↑4 | Harcha, W., Martínez, J., Tsai, T., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. Journal of the American Academy of Dermatology, 70 3, 489-498.e3. Available at: https://doi.org/10.1016/j.jaad.2013.10.049. |
| ↑5, ↑7, ↑10 | Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between Topical Minoxidil 5% Alone versus Combined with Dutasteride (Topical 0.02% through Microneedling or Oral 0.5 mg) in Treatment of Androgenetic Alopecia. QJM: An International Journal of Medicine. Available at: https://doi.org/10.1093/qjmed/hcae175.207. |
| ↑6, ↑8, ↑11, ↑13 | Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: https://doi.org/10.1159/000541395. |
| ↑9, ↑12 | Radhakrishnan, P., Mariyappan, G., Karthi, J., & Jaisumi, K. (2024). Formulating, Optimizing and Evaluation of Dutasteride Loaded Insitu-Emulgel for Androgenetic Alopecia. International Journal of Pharmaceutical Research and Applications. Available at: https://doi.org/10.35629/4494-0906631659. |
Topical minoxidil is the most widely used treatment for female hair loss, but is it safe when trying to conceive? Here’s what current research says about fertility, pregnancy, and reproductive risks.